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SUMMARY 
Sustained protein homeostasis – proteostasis – is particularly important in the heart as 
cardiomyocytes are limited to self-renewal. The interaction between molecular 
chaperones and protein catabolic pathways, above all, the ubiquitin proteasome 
system (UPS) and (selective) autophagy, plays a critical role for protein turnover in 
the heart. Malfunctions of these processes due to increased stress caused by gene 
mutations, translational errors, or reduced efficiency result in accumulation of toxic 
protein aggregates and the progression of several cardiac diseases, such as dilated 
cardiomyopathy (DCM). This study identified the ubiquitin-specific peptidase USP5 
as a cell-type specific, critical deubiquitinating enzyme for polyubiquitin turnover and 
proteostasis in mice and human cardiomyocytes.  
Loss of USP5 in cardiomyocytes caused effects ranging from profound accumulation 
of polyubiquitin chains, defective polyubiquitin turnover, and strong suppression of 
proteolytic activity of the proteasome, irreversibly resulting in the formation of 
ubiquitin-conjugated protein aggregates. Impaired clearance of such aggregates by 
selective autophagy augmented the cytotoxic cellular stress response, progressively 
resulting in cardiac remodeling, severe DCM, and sudden death. Similar to the DCM 
phenotype observed in the USP5 mouse model, cardiomyocytes from human 
individuals with end-stage DCM displayed substantially reduced USP5 protein levels 
and accumulation of ubiquitinated protein aggregates lacking USP5. Interestingly, 
overexpression of USP5 in cardiomyocytes expressing a mutant form of titin, known 
to cause cardiomyopathy, abrogated formation of titin aggregates through elevated 
proteasomal activity. These findings might pave the way for a new innovative 
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therapeutic strategy by which USP5 may aid in reversing disease-related protein 
aggregation caused by truncated or missense mutations in structural genes.  
In summary, the findings of this study provide the first genetic evidence for the crucial 
role of USP5 in the regulation of UPS-dependent proteolysis and selective autophagy, 
two processes that are instrumental for protein quality control in the heart.  
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ZUSAMMENFASSUNG 
Ein konstantes Gleichgewicht an Proteinen – Proteostase – ist besonders im Herzen 
von Bedeutung, da Herzmuskelzellen aufgrund ihres postmitotischen Charakters nur 
über eine sehr begrenzte Teilungsfähigsfähigkeit verfügen. Die Interaktion zwischen 
Chaperonen und Proteinabbauwegen, allen voran das Ubiquitin-Proteasom-System 
(UPS) und (selektive) Autophagie, spielt eine grundlegende Rolle beim Proteinumsatz 
im Herzen. Fehlfunktionen dieser Prozesse, die häufig durch erhöhten zellulären 
Stress etwa infolge von Genmutationen, Translationsfehlern oder verminderter 
Effizienz der beiden Abbauwege verursacht werden, resultieren oftmals in der 
Ansammlung von toxischen Proteinaggregaten, die die Entstehung von 
Herzerkrankungen, wie dilatativer Kardiomyopathie (DCM), zu einem erheblichen 
Anteil fördern. In der hier vorgelegten Studie wurde USP5 als ein zelltyp-spezifisches 
deubiquitinierendes Enzym identifiziert, welches essentiell für die Regulierung des 
zellulären Umsatzes von Ubiquitin ist und bei der Aufrechterhaltung der Proteostase 
im Herzen von Mäusen und humanen Patienten eine wichtige Rolle einnimmt.  
Die Ergebnisse der Studie zeigen, dass der Verlust von USP5 in Herzmuskelzellen 
von Mäusen mit einer Ansammlung von freien Ubiquitinketten, einem gestörten 
Umsatz von Ubiquitin, sowie mit einer stark unterdrückten Aktivität des 20S 
Proteasoms einherging, was die Ansammlung ubiquitinierter Proteinaggregaten zur 
Folge hatte. Beeinträchtigungen im Abbau dieser Proteinaggregate durch selektive 
Autophagie führte zu einer verstärkten zytotoxischen Stressantwort, die progressiv zu 
Umbauprozessen im Herzen und der Entwicklung einer tödlich verlaufenden DCM 
führte. In Übereinstimmung mit den Daten aus dem USP5-Mausmodell zeigten 
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Herzmuskelzellen von Patienten mit DCM im Endstadium neben stark reduzierter 
Expression von USP5 eine verstärkte Ansammlung von Proteinaggregaten auf. Die 
Überexpression von USP5 in Herzmuskelzellen, die eine veränderte Variante des 
sarkomeren Proteins Titin exprimierten, trug maßgeblich zur verminderten Bildung 
von Aggregaten bei, die möglicherweise durch die gesteigerte proteasomale Aktivität 
zu erklären ist. 
Zusammenfassend zeigen die in dieser Studie erhobenen Daten, dass eine erhöhte 
Expression von USP5 die Bildung pathophysiologisch-relevanter Proteinaggregate 
eindämmen kann. In diesem Zusammenhang könnte der therapeutische Einsatz von 
USP5 die außer Kontrolle geratene Ansammlung toxischer Proteinaggregate, die 
größtenteils durch Mutationen essenzieller Strukturproteine hervorgerufen wird, 
minimieren. Des Weiteren liefern die Daten den ersten genetischen Beweis für die 
essentielle Rolle von USP5 bei der Regulierung zwei wichtiger Proteinabbauwege, die 
für die Proteinqualitätskontrolle im Herzen von überragender Bedeutung sind.  
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INTRODUCTION 
Proteostasis in Postmitotic Cells 
Postmitotic cells, such as neurons and cardiomyocytes, are terminally differentiated 
cells that exhibit a very limited self-renewal capacity [1]. In this respect, 
cardiomyocytes are particularly forced in maintaining equilibrated protein 
homeostasis – proteostasis – compared to other cells, which might handle ameliorated 
proteostasis caused by disturbed protein quality control (PQC) processes by self-
division. Even in the absence of pathological conditions, cardiomyocytes are 
continuously challenged to sustained proteostasis, as they are constantly subjected to 
diverse cellular challenges, due to several reasons [2]. First, as they are composed of 
highly specialized proteins, cardiomyocytes must maintain a stable proteome to 
conduct and contract properly, which is essential for both PQC surveillance and cell 
stability. Second, as cardiomyocytes are metabolically demanding cells, they have to 
continuously handle high rates of potentially proteotoxic agents, including reactive 
oxygen species [3] that arise from oxidative phosphorylation [4]. Third, their status as 
terminally differentiated, postmitotic cells restricts cardiomyocytes from self-renewal 
to bypass derailed PQC by cell division. As a result, cardiomyocytes can only 
neutralize aged- or stress-induced protein aggregates through balanced PQC and not 
by distribution of aggregates to one daughter cell, while keeping the other daughter 
cell free from proteotoxic stress [5]. In this respect, maintaining a healthy proteome 
through persistent PQC is critical for supporting a functional tissue and to keep the 
contractile property of the cardiac muscle intact and free of potentially toxic protein 
aggregates [6].   
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Proteostasis Network 
Proteins are complex macromolecules, which are required for most biological 
processes. In this respect, proper function of the approximately 20,000 to 25,000 
proteins encoded in the human genome relies on fine-tuning of cellular processes, 
collectively referred to as the proteostasis network. The proteostasis network (PN) is 
composed of a variety of components (Figure 1).  
 
Figure 1 Overview of the cellular proteostasis network.  
The proteostasis network (PN) in mammalian cells is composed of the translation machinery, molecular 
chaperones, the UPS, and (selective) autophagy. All these components are essential to maintain the overall 
flux of proteostasis (black arrows). Non-native protein conformations (red arrows), resulting from genetic 
mutations or environmental stress, are recognized by protein quality control processes to prevent 
accumulation of toxic protein aggregates in the cell. Misfolded, damaged, and aggregated proteins are 
either redirected to the folding machinery through disaggregation and refolding (blue arrows) or targeted 
to the two degradative systems if refolding is not an option (grey arrows). The UPS primarily degrades 
chaperone-presented, soluble misfolded, oxidized, mutant, or otherwise damaged proteins. As the UPS 
also removes proteins that are no longer needed, it provides temporal regulation of protein activity. 
Aggregated, insoluble proteins are degraded by lysosomal-dependent (selective) autophagy. Modified from 
[7]. 
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The mammalian PN comprises approximately 2,000 components that act in concert 
to maintain cellular homeostasis. Structurally, the PN can be divided into three 
branches depending on the particular function of individual factors: (a) protein 
biogenesis (~ 280 components), (b) folding of nascent proteins and conformational 
maintenance of the respective three-dimensional (3D) protein conformation, 
frequently coupled to transport, modification, and assembly (~ 330 components), and 
(c) irreversible proteolytic degradation of unfolded, misfolded, aged, and damaged 
proteins or protein aggregates to prevent deleterious effects of dysfunctional proteins. 
Protein degradation is carried out by either the ubiquitin-proteasome system (~ 850 
components) or (selective) autophagy (~ 530 components) (Figure 1) [8-10]. All PQC 
checkpoints dynamically act in concert to meet the requirements of the cell and to 
maintain organismal health. Thus, a healthy proteome determines the long-term cell 
viability of cells and organs. Nevertheless, the PN is challenged or rewired in many 
disorders, including neurodegenerative diseases, inflammation, or cancer, making it 
an attractive therapeutic target.  
Components of the Proteostasis Network in the Heart 
Chaperones  
Chaperones are the cells’ first frontline system to ensure correct folding of newly 
synthesized, nascent proteins into an active, stabilized, and persistent three-
dimensional (3D) conformation [11, 12]. Chaperones assist in this so called ‘de-novo’ 
protein folding process by recognition of generic structures, for instance hydrophobic 
amino acid residues, on the surface of nascent proteins. Binding to these residues 
promotes correct folding, implemented by changes in the kinetic partitioning via 
repetitive ATP- and co-chaperone-dependent binding and release cycles [13]. In 
addition to assist in correct folding of nascent proteins, chaperones prevent mutual 
interaction and subsequent formation of toxic protein aggregates, especially under 
cellular stress conditions, such as oxidative stress [9]. 
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Proteolytic degradation systems  
If chaperone activity becomes insufficient to guarantee proper folding of proteins or 
if the load of terminally un- and misfolded proteins exceeds the folding capacity of 
chaperones, chaperones keep proteins prone to aggregation in a soluble state to 
promote their proteolytic degradation by either the ubiquitin-proteasome system 
(UPS) or (selective) autophagy (Figure 1).  
The UPS is the most important cellular protein degradation (proteolytic) system that 
predominantly directs chaperone-presented, soluble proteins to the 26S proteasome 
for destruction [14, 15]. For this reason, chaperones and the UPS have to work in 
concert to degrade chaperone-resistant, potentially harmful proteins [16]. However, 
the UPS is also involved in the temporal regulation of protein activity by degrading 
normal proteins that after fulfilling their cellular function are no longer needed. To 
prevent accumulation of terminally un- or misfolded proteins whenever chaperone or 
UPS activity becomes compromised, autophagy functions as an extra branch of 
cellular PQC to guarantee clearance of polyubiquitin-conjugated protein aggregates 
by lysosome-dependent proteolysis. The autophagic machinery contains a large set of 
primarily hydrolytic enzymes, hence it also catabolizes proteolytic clearance of many 
macromolecules [17]. Nevertheless, only a cooperative work of both protein 
degradation systems assures cellular proteostasis by degrading potentially harmful or 
toxic protein aggregates. Depending on the physiological state and the respective cell 
type, the UPS is responsible for the proteolytic degradation of approximately 80-90 
% of all cellular proteins, while autophagy accounts for clearance of the remaining 10-
20 % of cellular proteins [18].  
The significance of the proteolytic degradation pathways has been acknowledged with 
two Nobel Prizes. In 2004, the Nobel Prize in Chemistry was awarded to Aaron 
Ciechanover, Avram Hershko, and Irwin Rose for the discovery of ubiquitin-
mediated protein degradation. In 2016, Yashinori Ohsumi was awarded with the 
Nobel Prize in Medicine and Physiology for his studies on the autophagy-lysosome 
pathway.  
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Cytoskeleton 
The cytoskeleton balances the communication between different constituents of the 
PQC machinery in contractile cells [19]. In addition to maintain proper proteostasis, 
the cytoskeleton further provides the fundamental contractile property of the cardiac 
muscle. The highly specialized network of the cytoskeleton, which comprises of a 
variety of filaments, including actin and myosin, but also intermediate filaments, and 
microtubules, interacts with various membrane-associated proteins, sarcomere 
proteins, or with proteins of the intercalated disc to ensure proper cardiac contraction 
(Figure 2).  
 
Figure 2 The cardiac cytoskeleton network.  
The cardiac cytoskeleton is a complex but rather dynamic network consisting of the filamentous 
proteins actin and myosin, as well as intermediate filaments, and microtubule s. The cytoskeleton 
substantially contributes to the transmission of mechanical and chemical stimuli within and between 
cardiomyocytes that is essential for contraction and sustained cardiac function. By anchoring 
various organelles, such as the nucleus, mitochondria, or the sarcomeric reticulum (SR), the 
cytoskeleton further acts as a stabilizing force that assists in cell stability. Adapted from [20]. 
  
INTRODUCTION 
6 
The cytoskeleton also interacts with numerous organelles, including the nucleus, the 
sarcomeric reticulum (SR), the endoplasmic reticulum (ER), lysosomes, or 
mitochondria. The synchronized interaction of the cytoskeleton with organelles is 
critical for the transmission of mechanical and chemical signals within and between 
cells and the transportation of ubiquitin-conjugated proteins along the PN [21, 22]. 
In this context, HDAC6-mediated acetylation of microtubules plays a central role for 
trafficking of proteins within cells. In contrast, acetylation is also fundamental to 
maintain contractile function as microtubules are in close contact with the SR, the ER 
and mitochondria to balance calcium homeostasis in various organelles. Impairment 
of the trafficking and/or contractile function of the cytoskeleton typically results in 
disturbed communication within the cardiac PN, loss of PQC, and severely impaired 
cardiac function [23, 24]. Hence, a functional cytoskeletal network protects against 
cardiac diseases.  
The Ubiquitin-Proteasome System 
The ubiquitin-proteasome system (UPS) is the key protein degradation system of the 
eukaryotic PN, taking care of unfolded, misfolded, damaged, oxidized, or mutated 
proteins, which failed to be properly refolded by chaperones. These mainly soluble 
proteins are marked by a polyubiquitin chain that is covalently attached to distinct 
lysine residues on the targeted protein and are subsequently degraded by proteolytic 
cleavage. In addition, the UPS is also crucial for the regulation of a stable protein pool 
as it removes short-lived proteins, which have fulfilled their respective function(s) 
[14]. 
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Ubiquitination 
Ubiquitination acts as a broker between cellular function and proteostasis. As free 
ubiquitin is the precious commodity, ubiquitination intersects and communicates at 
multiple points to balance homeostasis of diverse organelles and to coordinate cellular 
proteostasis. Additionally, deubiquitinating enzymes, as well as all four polyubiquitin 
precursor genes, are necessary to feed into a balanced ubiquitin pool by providing 
conjugation-competent ubiquitin.  
Posttranslational modifications of proteins, with the evolutionary highly conserved 
76-amino acid protein tag ubiquitin, are fundamental for eukaryotic cell functions. 
Ubiquitination helps to facilitate precise communication between and within cells by 
regulating a variety of cellular processes, including signal transduction, cell division, 
and cell differentiation, or in developing cells to become complex organisms. 
Eukaryotic cells encode four distinct ubiquitin precursors, UBB, UBC, UBA52, and 
UBA80/RPS27a, which are translated as polyubiquitin precursor proteins that need 
to be processed by individual deubiquitinating enzymes (DUBs) to generate active, 
conjugation-competent ubiquitin [25]. The two polyubiquitin precursor genes UBB 
and UBC are composed of ‘head-to-tail’ linked ubiquitin polymers, with UBB 
comprising 8-10 ubiquitin moieties and UBC 3-4 ubiquitin moieties fused in frame 
one to another. In contrast, the two ubiquitin-ribosomal precursor genes UBA52 and 
UBA80/RPS27a are translated as a single ubiquitin molecule that is fused at its 
carboxyl-terminus to a ribosomal protein [26, 27] (Figure 9).  
Proteins are labelled with ubiquitin through the cooperated, downwelling action of 
the following enzymes (Figure 3): E1 ubiquitin-activating, E2 ubiquitin-transferring, 
and E3 ubiquitin-ligating enzymes, in a cascade requiring ATP [28, 29].  
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Figure 3 Ubiquitination cascade.  
Scheme showing the ubiquitin cascade that is divided into three steps, each of which is catalyzed 
by a distinct class of enzymes. The first step, mediated by E1 – a ubiquitin-activating enzyme, uses 
the energy derived from hydrolysis of ATP to AMP and PPi to form a covalent thioester linkage 
with the carboxyl-terminus of ubiquitin. In a second reaction, ubiquitin is transferred to a cysteine 
residue within E2 – a ubiquitin-transferring enzyme. In the final step, E2 forms a complex with an 
E3 – a ubiquitin-ligating enzyme – which coordinates the transfer of ubiquitin, or already formed 
ubiquitin chains, onto the substrate. Reversal of the ubiquitination cascade is catalyzed by 
deubiquitinating enzymes (DUBs), which remove ubiquitin molecules or ubiquitin chains from a 
substrate. Ub, ubiquitin. Modified from [33]. 
The modification of proteins with ubiquitin can vary from the attachment of a single 
ubiquitin molecule (monoubiquitination), to the conjugation of several ubiquitin 
molecules, either attached as a single ubiquitin at multiple lysine residues (multi-
monoubiquitination), or of a ubiquitin chain (polyubiquitination) to any of its seven 
lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63), including the 
first methionine (M1). This so-called ubiquitin code determines the outcome of a 
ubiquitinated protein with respect to its cellular function (Figure 4, 5) [29-32]. 
INTRODUCTION 
9 
 
Figure 4 Variety of posttranslational modifications with ubiquitin.  
Scheme showing the different types of ubiquitin linkages on a substrate. Ubiquitin can be attached 
as a single molecule to a specific lysine residue on a substrate (monoubiquitination) or to various 
lysine residues (multi-monoubiquitination). Conjugation of a ubiquitin chain is nomenclature as 
polyubiquitination with the ubiquitin chain to be composed of either the same linkage specificity 
(homotypic polyubiquitination) or two or more different linkages in a single polymerization 
reaction (heterotypic polyubiquitination), generating a mixed polyubiquitin chain. The latter can be 
subdivided into non-branched polyubiquitin chains or branched polyubiquitin chains by which a 
single ubiquitin molecule is modified at two or more lysine residues. Modified from [18].  
 
Figure 5 The ubiquitin code and its biological role.  
Ubiquitin can be conjugated by another ubiquitin molecule through any of its seven lysine residues 
(Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63), or alternatively the first methionine (M1). 
The linkage specificity determines the outcome of the protein with respect to its cellular function. 
Modified from [37]. 
The 26S Proteasome 
The 26S proteasome is a large ~ 2.5-MDa complex, comprised of several subunits 
forming two major subcomplexes: the proteolytic core particle (20S proteasome) and 
the regulatory particle (19S proteasome) [33]. Since the proteasome is highly abundant 
both in the nucleus and cytoplasm, it ensures efficient degradation of short-lived 
proteins as well as unfolded, misfolded, mutated or otherwise damaged proteins. 
Therefore, the 26S proteasome governs central signaling processes in the cell. 
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The proteolytic core particle 
The core particle (CP) of the 26S proteasome, often referred to as 20S CP, is 
composed of 28 subunits. All subunits are uniquely assembled to form a barrel-shaped 
particle of ~730 kDa, with two outer α-rings and two inner β-rings axially stacked to 
build a hetero-heptameric ring. Each α-ring and β-ring comprises seven distinct but 
structurally related α and β subunits, named α1-α7 or β1-β7, respectively (Figure 6) 
[14]. The center of the α-ring forms a physical barrier, which controls the entrance of 
proteins into the proteolytically active cavity of the 20S proteasome that is formed by 
the β1, β2, and β5 subunits. Hereby, each catalytically active β subunit owns distinct 
peptidase cleavage specificity: the β1 subunit contains the caspase-like peptidase (also 
referred to as peptidyl–glutamyl–peptide bond hydrolyzing) activity that cleaves after 
acidic residues. The β2 subunit encodes the trypsin-like peptidase activity that cleaves 
after basic residues, whereas the β5 subunit, encoding the chymotrypsin-like peptidase 
activity, cleaves after large hydrophobic residues (Figure 6) [14]. 
 
Figure 6 The 20S core particle of the 26S proteasome.  
The proteolytically active 20S CP is comprised of two outer α- rings and two inner β-rings, forming the 
barrel-shaped core particle (CP). Each α- and β-ring is formed by seven distinct but structurally related 
subunits, with the subunits β1, β2, and β5 to harbor catalytically active peptidase activities. 
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Enzymatic peptidase activities of the 20S CP can be inhibited, either reversibly by 
peptidase aldehydes (e.g. MG132) and peptidase boronares (e.g. bortezominb), or 
irreversibly by β-lactone derivates (e.g. lactacystin) and epoxyketones (e.g. 
epoxymicin) [34]. It is possible to detect individual peptidase activities of the 20S 
proteasome via kinetic assays [35].  
The regulatory particle 
The regulatory particle (RP) of the 26S proteasome, often referred to as 19S RP, is 
the subunit of the proteasome that first gets in contact with ubiquitinated proteins 
destined for proteolytic cleavage. The 19S RP harbors 19 integral subunits, which 
form two subcomplexes: a lid and a base. The lid subcomplex, which sits on top of 
the base subcomplex, comprises nine non-ATPase subunits (Rpn3, Rpn5-9, Rpn11-
12), with Rpn11 exhibiting deubiquitinating enzyme activity that is instrumental for 
the degradation of ubiquitinated proteasomal substrates [36]. Rpn11 is located next 
to the substrate entry pore that is formed by the ATPase ring comprising the subunits 
Rpt1-Rpt6 [37]. By deubiquitinating the ubiquitin chain at a site proximal to the 
proteasomal substrate, Rnp11 releases the ubiquitin chain en bloc from the substrate, 
which must be further processed by other DUBs, presumably USP5, to generate free 
conjugation-competent ubiquitin. In contrast, the base subcomplex, which is located 
next to the 20S CP, comprises six homologous AAA-ATPase subunits (Rpt1-Rpt6), 
forming a hexameric ring, as well as the non-ATPase subunits Rpn1-Rpn2, Rpn10, 
and Rpn13 [14]. The ATPase ring essentially unfolds the now deubiquitinated 
proteasomal substrate, ensures the opening of the channel, and then translocates the 
substrate into the 20S CP for subsequent destruction by proteolytic cleavage. 
However, access of the substrate to the proteolytic core is only granted in an ATP 
bound state (Figure 7).  
The predominant role of the 19S RP is recognition, binding, and deubiquitination of 
polyubiquitinated proteins to recycle ubiquitin moieties. In addition, the ATP-
dependent 19S RP unfolds and translocates the now deubiquitinated substrate into 
the interior of the 20S CP for destruction through regulation of gate opening of the 
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20 CP α-rings. Collectively, the 19S RP regulates and coordinates all critical steps prior 
to proteolytic degradation of polyubiquitinated substrates. 
 
Figure 7 Proteolysis by the proteasome.  
The enzymatically active proteasome is capped on either or both ends of the 20S core particle 
(20S CP) by the 19S regulatory particle (19S RP), forming the 26S- or 30S proteasome, respectively. 
During proteolysis, the 19S RP captures and removes polyubiquitin chains on proteasomal 
substrates, unfolds the substrate, and opens the α ring to transfer the unfolded and deubiquitinated 
substrate into the 20S CP for its destruction.  
The 20S CP exists in a free, mainly inactive state, while its default status requires 
binding via the 19S RP, either as a single-capped 26S proteasome or a double-capped 
30S proteasome with two 19S RPs associated with both termini of the 20S CP in 
opposite directions (Figure 7) [38]. Binding to several proteasome activators, such as 
PA28 or PA200, opens the gate that is required for entering the catalytic cavity and 
proteasomal degradation of proteins [39]. However, the 19S RP represents the most 
potent proteasome activator that promotes ATP- and ubiquitin-dependent substrate 
turnover.  
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Impairment of the 26S proteasome 
Although proteasome activity is crucial for sustained cell viability, particularly in 
postmitotic cells such as cardiomyocytes and neurons, the abundance and capacity of 
proteasomes is rate-limiting. To cope with changing demands under challenging 
conditions, cells have evolved mechanisms to dynamically modify and adjust the 
composition and activity of the proteasome when necessary [40, 41]. For instance, 
increased ubiquitin stress, a condition caused by depletion of free ubiquitin, has been 
shown to provoke changes in proteasome composition as a result of elevated loading 
with the proteasomal assembly factor Ubp6 (human orthologue: USP14) [42]. Other 
studies have shown that the expression of genes encoding several other proteasomal 
subunits or assembly factors is altered in response to cellular stress. Furthermore, 
posttranslational modifications of several subunits of the proteasome can alter the 
composition of the 26S proteasome. Nonetheless, excessive external and internal 
stressors, e.g. inhibition of proteasome activity, oxidative stress, or aberrantly formed 
protein aggregates [43-45], results in compromised capacity of the 26S proteasome 
and extensive accumulation of potentially toxic proteins and protein aggregates, 
which continuously impede proteostasis [46]. Consequently, diminished proteasome 
activity and obstructed recycling of free ubiquitin and peptides disturb numerous 
cellular functions and thus play an important role in the pathology of multiple diseases 
[47, 48]. Cells respond to reduced proteasome activity, proteasome overload, and 
shortages of amino acids with efforts to adjust UPS activity via compensatory or 
regulatory actions of other key components of the PQC network [49]. Hereby, 
induction of (selective) autophagy eliminates the threat that results from damaged 
organelles or accumulation of potentially toxic protein aggregates [50, 51]. 
  
INTRODUCTION 
14 
Deubiquitinating enzymes  
Ubiquitination is a reversible process whereby specific proteases, collectively named 
deubiquitinating enzymes (DUBs), remove ubiquitin moieties of different topology 
and length from a substrate or within ubiquitin in a polyubiquitin chain [52]. The 
human genome encodes approximately 100 DUBs, which are classified into six 
individual families based on sequence and domain similarities (Figure 8): Ubiquitin-
specific peptidases (USPs, 56 active members), ovarian tumor proteases (OTUs, 16 
active members), JAB1/MPN/Mov34 family (JAMMs, 12 active members), 
Machado-Joseph disease proteases (MJDs, 4 active members), ubiquitin C-terminal 
hydrolases (UCHs, 4 active members), and the newly discovered MIU-containing 
novel DUB family proteases (MINDY, 4 active members) (Figure 8) [53]. JAMMs 
only comprise zinc metalloproteases, while the other five DUB families are cysteine 
proteases.  
 
Figure 8 Human deubiquitinating enzymes (DUBs).  
Human DUBs are categorized based on their homology in the catalytic domain into six families: 
ubiquitin specific peptidases (USPs), ovarian tumor proteases (OTUs), JAB1/MPN/Mov34 family 
(JAMMs), Machado-Joseph disease proteases (MJDs), ubiquitin C-terminal hydrolases (UCHs), and 
MIU-containing novel DUB family proteases (MINDY). All DUBs are cysteine proteases except for 
JAMMs, which only comprise zinc-dependent metalloproteases. Modified from [54]. 
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General functions of DUBs 
DUBs maintain cellular ubiquitin homeostasis by replenishing the pool of mono-
ubiquitin. In addition, many DUBs are important for processing, recycling, and 
remodeling of polyubiquitin chains on substrates to initiate and sustain ubiquitin-
dependent processes, and to release free ubiquitin moieties. In this respect, USP5, a 
family member of ubiquitin specific peptidases (USPs), maintains the pool of free 
ubiquitin as it preferentially releases free ubiquitin from unanchored polyubiquitin 
chains in vitro as well as in flies and yeast [55-58]. However, it remains speculative 
that USP5 fulfills this function in mammalian cells. Alternatively, there might be other 
USPs, which catalyze the breakdown of polyubiquitin chain in mammalian cells. In 
addition to recycling of free ubiquitin, three highly specific DUBs associated with the 
19S RP – PSMD14, USP14, and UCHL3 – modulate the fate of a substrate or the 
rate of substrate degradation by the proteasome by removing ubiquitin moieties, 
which impede entry of the substrate into the catalytically active 20S CP [59-62]. The 
19S RP subunit and metalloprotease PSMD14 (POH1/Rpn11) assists in ubiquitin-
dependent proteolysis by removing polyubiquitin chains en bloc prior to substrate 
degradation [63]. Hence, PSMD14 prevents undesired degradation of ubiquitin and 
releases free ubiquitin chains, which may be further processed by USP5. In contrast, 
the two transiently proteasome-associated DUBs USP14 and UCHL3 may aid in 
antagonizing proteolytic cleavage of a substrate by editing the ubiquitin chain, thereby 
decreasing the affinity of the substrate for the proteasome (Figure 9) [64, 65].  
Certain DUBs are further involved in processing of ubiquitin precursor genes to 
generate active monoubiquitin. Hereby, the two polyubiquitin precursor genes UBB 
and UBC are primarily modified by USP5 and Otulin, while UCHL3, USP9X, and 
USP7 catalyze trimming of the ubiquitin-ribosomal precursor genes UBA52 and 
UBA80 [25]. Moreover, DUBs counteract the ubiquitin cascade by either interfering 
with the formation of reactive E2- or E3-ubiquitin intermediates or by altering the 
stability or composition of an E3 complex (Figure 9).  
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Figure 9 Functions of DUBs.  
a. Ubiquitin, encoded by four genes (UBB, UBC, UBA52, and UBA80), is transcribed and translated 
as a linear fusion polypeptide consisting of multiple copies of ubiquitin with an extension of one or 
several amino acids at the carboxyl terminus (shown in orange) or ubiquitin fused to the amino 
terminus of either the 40S ribosomal protein L40 (L) or 60S ribosomal S27a (S), respectively 
(shown in green). DUBs assist in processing of these inactive ubiquitin precursors to generate 
conjugation-competent free ubiquitin. b. DUBs can further rescue a substrate from proteasomal 
degradation c. Deubiquitination removes a non-degradative ubiquitin signal from a substrate. d. 
DUBs are central for ubiquitin homeostasis by recycling of ubiquitin prior to degradation of the 
substrate by the 26S proteasome or autophagy. e. DUBs further assist in ubiquitin homeostasis by 
disassembly of ubiquitin chains generated by en bloc removal from a substrate prior to proteolysis. 
f. Some DUBs edit the length and topology of ubiquitin chains with the generated free ubiquitin to 
re-enter the pool of free ubiquitin. Modified from [60]. 
As a class of mainly cysteine peptidases that reverse ubiquitination, DUBs play 
important roles in the regulation of various cellular functions and biological processes, 
including cell cycle control, DNA damage response [66], gene expression [67], kinase 
activation [68], microbial pathogenesis [69], UPS-dependent proteolysis, autophagy 
[70], and many more.  
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Autophagy 
Autophagy, the second major intracellular catabolic system in mammalian cells, acts 
in lysosomal cleavage of cytosolic fractions, organelles, and macromolecules, to re-
supply cells with essential nutrients, which is fundamental for cellular protein 
homeostasis, cell differentiation, development, cell survival, and cell death. In contrast 
to UPS-dependent proteolytic processes, autophagy is mainly induced in response to 
intra- and extracellular stress conditions, including oxidative stress, nutrient 
deprivation, DNA damage, hypoxia or growth factor depletion. Defects in any step 
of the autophagic cargo elimination are causative for the development of various 
diseases, such as cancer, inflammation, neurodegenerative diseases [71, 72], or even 
cardiovascular disorders [73, 74].  
Non-selective autophagy 
Non-selective autophagy can be divided into three types: macroautophagy (mainly 
referred to as autophagy), microautophagy, and chaperone-mediated autophagy 
(Figure 10). The most common type of non-selective autophagy, macroautophagy, 
plays a key role for maintaining the energy balance of cells. During macroautophagy, 
large amounts of cytoplasmic constituents, organelles, and diverse macromolecules 
(lipids, proteins, carbohydrates, and nuclei acids), are engulfed in a double-membrane 
vesicle, called an autophagosome, and are transported to the lysosome. Fusion of the 
autophagosome with lysosomes, which contain diverse hydrolytic enzymes, causes 
degradation of both the sequestered material and the inner membrane of the 
autophagosome, and retrograde transport of amino acids across the lysosomal 
membrane (Figure 10).  
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Figure 10 Types of non-selective autophagy.  
Autophagy, the intracellular lysosomal-dependent degradation of cellular constituents, 
macromolecules, and organelles, can be divided into three subtypes according to the cargo delivery 
to the lysosome lumen: macroautophagy, microautophagy, and chaperone-mediated autophagy. 
During macroautophagy the cargo is transported inside a double-membrane vesicle, i.e. 
autophagosome, to fuse with the lysosome. In contrast, microautophagy is characterized by direct 
delivery of the cargo by local rearrangement of the lysosomal membrane. Chaperone-mediated 
autophagy requires binding of the cargo carrying a KFERQ motif to the HSC70 chaperone to 
translocate the cargo across the lysosome, which is mediated by the lysosome-associated 
membrane protein type 2A (LAMP-2A). Modified from [75]. 
In contrast, microautophagy and chaperone-mediated autophagy, both equally 
essential for the energy supply of cells, do not rely on de novo synthesis of 
autophagosomes to sequestrate cytosolic cargos. Microautophagy only requires the 
formation of lysosomal and endosomal membranes to deliver any cytoplasmic cargos 
into the lumen of the membranes for subsequent degradation by lysosomal hydrolysis. 
On the other hand, chaperone-mediated autophagy largely depends on HSC70 and 
HSC70-associated co-chaperones, which specifically recognize cytosolic cargos 
carrying the pentapeptide motif KFERQ. Once bound, the Hsc70 complex transports 
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the cargo with the aid of the lysosomal membrane protein type 2A (LAMP-2A) across 
the lysosomal membrane for consecutive degradation (Figure 10).  
Selective autophagy 
Selective autophagy, an alternative type of macroautophagy, evolved as a second 
major cellular PQC system, which eliminates misfolded and aggregated proteins that 
– based on their size, structure, and complexity – are excluded from UPS-dependent 
proteolysis by the 26S proteasome. Selective autophagy further assists in the 
degradation of specific pathogens and organelles, such as peroxisomes and 
mitochondria. In contrast to macroautophagy, selective autophagy depends on 
ubiquitination of the cargo as a common recognition signal. Once ubiquitinated, 
specific ubiquitin receptors, such as p62, OPTN, or NBR1, recognize and transport 
the cargo together with its ubiquitin tag, cargo adaptors, and other associated proteins 
to the autophagic machinery where it is hydrolyzed by lysosomes [76]. Importantly, 
these adaptors contain two domains: a ubiquitin-binding domain, essential for binding 
to ubiquitin degrons, and distinct LC3-binding domains, which promote the transport 
of ubiquitinated protein aggregates to the autophagic membrane (Figure 11) [76].  
In parallel, the deacetylase HDAC6 binds via its zinc-finger binding domain to 
ubiquitin chains on the cargo to induce the retrograde transport of the cargo along 
microtubule towards the nucleus where it becomes segregated into an aggresome [77]. 
HDAC6-dependent deacetylation of cortactin is crucial for the final steps of selective 
autophagy – remodeling of the actinomyosin network, engulfment of the aggresome 
in autophagosomes, and lysosomal degradation of the aggresome (Figure 11).  
In summary, selective clearance by macroautophagy and selective autophagy of 
potentially harmful cytoplasmic constituents and ubiquitinated proteins, which 
escaped degradation by the 26S proteasome, is important for PQC to guarantee 
sustained cellular homeostasis and to avoid cell damage or cell death arising from 
accumulation of toxic protein aggregates.  
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Figure 11 Selective autophagy. 
Terminally misfolded proteins, which escaped degradation by the 26S proteasome, tend to form 
small soluble aggregates, which are tagged with either a Lys48- or Lys63 linkage-specific ubiquitin 
chain. Binding of these ubiquitin-enriched aggregates by specific adapters of selective autophagy, 
carrying ubiquitin-binding (UBDs) and LC3-binding domains, e.g. p62, NBR, initiates formation of 
an autophagosome and autophagic clearance. Alternatively, the deacetylase HDAC6, which carries 
a zinc-finger binding UBD domain, binds to ubiquitin chains within soluble ubiquitin -conjugated 
aggregates to support their segregation into aggresomes and subsequent lysosomal degradation. 
Modified from [18]. 
Consequences of derailed cardiac protein quality control 
Ageing is often accompanied by derailment of proteostasis and concomitant failure 
of PQC, which not only attenuates protein degradation systems and the cellular stress 
response [78, 79] but rather favors the formation of protein aggregates. Studies in C. 
elegans have shown that protein synthesis progressively decelerates during aging [80]. 
While the expression of proteins important for maintaining UPS function, oxidative 
stress defense, and DNA replication is upregulated, levels of proteins important in 
mitochondrial and ribosomal PQC continuously decrease. In contrast, ageing in D. 
melanogaster is characterized by enhanced proteotoxicity and protein damage, which is 
caused by reduced protein synthesis, diminished demand on PQC processes to assist 
in folding, transport, and clearance of proteins, and failure in proteasome function. 
In contrast, aged human dermal fibroblasts exhibit reduced levels of chaperones as 
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well as proteasomal, mitochondrial, and ribosomal proteins. In-vivo studies on aged 
mice yielded similar results, showing mitochondrial proteins and proteins involved in 
counteracting stress response to be downregulated [81, 82].  
As protein functions decline with ageing and as life expectancy continuously 
increases, successive accumulation of damaged, unfolded, or terminally misfolded 
proteins along with concomitant failure of PQC processes account for the gradual 
progression of ageing and age-related diseases, including cancer, immunological and 
metabolic disorders, and neurodegenerative diseases with most of them still incurable 
[83, 84]. Numerous studies have shown that derailed proteostasis drives the 
progression of cardiac disorders, such as atrial fibrillation and cardiomyopathies [3, 
85]. Increased proteotoxicity in the heart can result from either loss-of-function or 
gain-of-function mutations of genes encoding cytoskeletal, sarcolemmal, or nuclear 
envelope proteins. Loss-of-function mutations impair the contractile and 
electrophysiological properties of cardiomyocytes due to constant cellular stress and 
excessive activation of protein catabolic processes [86]. In contrast, gain-of-function 
mutations favor the formation of amyloid-like protein aggregates causing enhanced 
proteotoxic stress [87]. Mutations in genes encoding sarcomere and cytoskeleton 
proteins, including desmin (Des), ß-myosin heavy chain (Myh7), cardiac troponin 
(Tnnt2), or titin (Ttn) are connected to the progression of inherited cardiomyopathies 
by which chaperone activity and protein catabolic processes are markedly elevated to 
initially ameliorate accumulation of harmful protein aggregates [88]. Nevertheless, 
enduring stress drains their capacity and causes degradation of sarcomeric structures, 
accompanied by cellular dysfunction and loss of functional cardiomyocytes, resulting 
in cardiac remodeling [89]. During the remodeling process, which mainly affects 
noncardiomyocytes, such as myofibroblasts, immune cells, and vascular cells, the 
cardiac muscle is exposed to an increased degree of inflammation and deposition of 
collagen, intended to maintain cardiac mass. In the end, increased stiffness and 
disturbed architecture of the myocardium results in cardiac failure [90]. Importantly, 
inherited cardiomyopathies remain an important cause of cardiac morbidity and 
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mortality worldwide and are a major cause of cardiac transplantation, since 
therapeutic strategies still remain limited [88].  
Besides cardiac remodeling due to enhanced fibrosis, the derailment of cardiac PQC 
results in the accumulation of protein aggregates interfering with the 26S proteasome 
function. Furthermore, protein aggregates impede cellular processes by binding to 
critical signaling and trafficking molecules, which may induce initiation of the cell 
death cascade [91, 92]. Protein aggregates have been identified in cardiomyocytes 
from patients with idiopathic, dilated and hypertrophic cardiomyopathy, but not in 
cardiomyocytes from healthy aged patients [93].  
Cardiomyopathy 
Cardiomyopathies are a heterogeneous class of myocardial diseases associated with 
structural and functional abnormalities, i.e. mechanical or electrical dysfunction, often 
in combination with inappropriate hypertrophy or dilation of either one or both 
ventricles. People affected by cardiomyopathies are at high risk for heart failure-
related disabilities with most patients dying due to sudden cardiac arrest [15]. The 
American Heart Association divides cardiomyopathies with regards to the etiology 
into two major groups: primary (intrinsic) and secondary (extrinsic) cardiomyopathies. 
Primary cardiomyopathies are myocardial disorders restricted to the cardiac muscle 
that are caused by either genetic or non-genetic alterations. In contrast, secondary 
cardiomyopathies are caused by myocardial damage as a result of systemic or multi-
organ disorders, such as myocardial ischemia, inflammation, infection, extensive 
alcohol abuse, or increased drug toxicity.  
Alternatively, cardiomyopathies are subdivided into four categories, based on their 
etiology as well as morphological and functional criteria, which include 
arrhythmogenic right ventricular cardiomyopathies, restrictive cardiomyopathies, 
hypertrophic cardiomyopathies, and dilated cardiomyopathies [94].  
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Arrhythmogenic right ventricular cardiomyopathy 
Arrhythmogenic right ventricular cardiomyopathy (ARCV), an inherited type of 
cardiomyopathy, is characterized by the loss of myocytes and replacement of mainly 
the right ventricular myocardium with fibrous and white adipose tissue that over time 
causes ventricular arrhythmias as a result of compromised ventricular inflow, outflow, 
and apex [94, 95]. The name is misleading, since ARCV is not restricted to the right 
ventricle. Up to 75 % of all identified patients do also show involvement of the left 
ventricle [96]. ARV is a very rare type of cardiomyopathy with an estimated prevalence 
of 1:5000, mainly affecting children, young adults, and athletes. 
Restrictive Cardiomyopathy  
Restrictive cardiomyopathy (RCM) is the least common form of cardiomyopathies 
with an unknown prevalence. RMC is mainly characterized by muscle stiffness due to 
impaired muscle relaxation accompanied by impaired ventricular filling, normal or 
reduced diastolic volume of the ventricles, and higher diastolic pressure [96]. In most 
cases, systolic volume remains normal or is slightly reduced while myocardial wall 
thickness is preserved. In response to restrictive filling with blood and high diastolic 
pressure, the myocardium is progressively replaced by interstitial fibrotic tissue and 
calcification, which further promotes muscle stiffness. Patients suffering from RCM 
often show symptoms of congestive heart failure, including peripheral edema, jugular 
vein distensions, and gallop rhythm. Other common symptoms of RCM include 
dyspnea, palpitations, syncope, fatigue, and limited exercise capacity [97].  
Hypertrophic cardiomyopathies 
Hypertrophic cardiomyopathy (HCM) represents the most common type of 
cardiomyopathy with a prevalence of 1:500 [98]. HCM is mostly inherited in an 
autosomal dominant manner and relies often on mutations in genes encoding any of 
the cardiac sarcomere proteins, although more than 100 genes are linked to the 
development of HCM with more and more genes being discovered [99]. 70-80 % of 
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all identified mutations occur in the genes that encode either the ß-myosin heavy chain 
(Myh7), cardiac myosin binding protein C (Mybpc), or cardiac troponin T (Tnnt2). 
Mutations in genes that encode cardiac troponin I (Tnni3) and α-tropomyosin (Tpm1) 
occur less frequently and account for 10 % of all cases [100].  
HCM is characterized by symmetrical or asymmetrical thickening of mainly the left 
ventricle, increased left ventricular mass, as well as hypertrophied, disorganized 
cardiomyocytes with enlarged nuclei. In many cases, cardiomyocytes are replaced with 
fibrotic tissue. Due to the thickness and stiffening of the ventricles, filling of the 
ventricles with blood becomes limited, which reduces the blood flow to the coronary 
arteries. Common symptoms of HCM include dyspnea at rest or during exercise, 
angina pectoris, palpitations, atrial fibrillation, dizziness, and presyncope or syncope. 
HCM patients, who do not get a heart transplantation in time, most likely die due to 
arrhythmias and sudden cardiac death [96, 101].  
Dilated cardiomyopathies 
Dilated cardiomyopathy (DCM) represents the second most common type of 
cardiomyopathies worldwide with a prevalence of 1:2500. DCM might be primarily 
caused by genetic and familial non-genetic factors, which account for 20-50 % of all 
cases, or secondary causes as a result of inflammation and autoimmune diseases. The 
majority of inherited causes are comprised of genetic mutations, which mainly affect 
structural proteins, such as the dystrophy-associated glycoprotein complex or 
components of the sarcomere in addition to cytoskeletal, sarcolemmal, and nuclear 
envelope proteins. In this regard, mutations in the gene that encodes the sarcomere 
protein titin (Ttn) account for up to 25 % of all identified forms of DCM [102, 103]. 
Many mutant genes that are linked to the development of DCM encode identical 
contractile components of the sarcomere, which are already associated with the 
progression of HCM, such as α-tropomyosin (TPM1), troponin T (TNNT2), ß-
myosin heavy chain (MYH7), or myosin-binding protein C (MYBPC3) [96]. Other 
inherited causes of DCM include mutations in the gene encoding the intermediate 
filament desmin [104] or in genes encoding heat shock proteins, ion channels, and 
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mitochondrial proteins [105]. Acquired causes of DCM include infections, e.g., 
myocarditis, endocrine or metabolic disorders, or progressive alcohol and drug abuse 
[15].  
DCM is characterized by dilation and enlargement of the left ventricle accompanied 
by persistent weakness, which results in systolic dysfunction in the absence of severe 
coronary artery disease [106, 107]. Permanent dilation of the left ventricle causes 
morphological changes and cardiac remodeling, by which the left ventricle becomes 
increasingly thin and thus acquires a more spherical, less elongated shape. Progressive 
cardiac remodeling leads to irreversible pathophysiological changes and deposition of 
interstitial or perivascular fibrotic tissues. Alterations in cardiac function, including 
decreased stroke volume, cardiac output, and ventricular filling, in combination with 
elevated end-diastolic pressure and cardiac preload and afterload are clinical 
characteristics of DCM. Collectively, all these alterations promote increased wall 
stress and elevated myocardial oxygen demand, which often result in myocyte damage 
and decline in myocardial performance. Progressive DCM results in congestive heart 
failure with elevated incidence of thromboembolic events, ventricular arrhythmias, 
and electromechanical dissociation of cardiomyocytes causing cardiac arrest in 
approximately 12 % of all DCM patients.  
Patients suffering from DCM show signs of tachycardia, excessive sweating, fluid 
retention, and ankle edema, accompanied by orthopnea and fatigue. Some patients 
also show symptoms like nausea, anorexia, or cachexia. However, DCM progresses 
exceptionally slowly until definite symptoms of congestive heart failure become 
evident. Nevertheless, with a prevalence rate of 25-30 % and a 1-year mortality rate 
of 50 % survival, DCM remains a most common indication for heart transplantation 
worldwide [15, 108, 109]. 
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AIM OF THE STUDY 
The present study was designed to examine the role of deubiquitinating enzymes 
(DUBs) in protein quality control (PQC) in the heart and to reveal its physiological 
function in the myocardium.  
To address this aspect, proximity-dependent biotinylation and affinity purification 
assay (BioID) was used to identify DUBs that interact with defined components of 
cellular PQC. Cardiac-specific conditional gain- and loss-of-function approaches in 
combination with diverse molecular and cell biology relevant techniques was applied 
to determine the function of these DUBs, predominantly with respect to their role in 
cardiac proteostasis both in-vitro and in-vivo.  
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MATERIAL AND METHODS 
Material 
Animal Nutrition 
Table 1 Animal nutrition 
Animal nutrition Company 
ssniff M-Z Extrudat ssniff Spezialdiäten GmbH 
Drugs 
Table 2 Drugs 
Drug Company Catalog no. 
4-Hydroxytamoxifen SIGMA-ALDRICH H7904-5MG 
Tamoxifen ≥ 99 % SIGMA-ALDRICH T5648-5G 
Enzymes 
Table 3 Enzymes 
Enzyme Company Catalog no. 
Proteinase K Carl Roth 7528.2 
SuperScript™ II Reverse 
Transcriptase including 5 x First 
strand buffer, 0.1 M DTT  
ThermoFisher SCIENTIFIC 18064014 
Taq Polymerase Homemade  
Trypsin EDTA ThermoFisher SCIENTIFIC R001100 
Trypsin SIGMA-ALDRICH T0303 
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Fluorogenic substrates 
Table 4 Fluorogenic substrates 
Fluorogenic substrate Company Catalog no. 
Boc-Leu-Arg-Arg-AMC Enzo  BML-BW8515 
Suc-Leu-Leu-Val-Tyr-AMC Enzo BML-P802 
Z-Leu-Leu-Glu-AMC Enzo BML-ZW9345 
Inhibitors 
Table 5 Inhibitors 
Inhibitor Company Catalog no. 
Aprotinin SIGMA-ALDRICH 10820 
Leupeptin SIGMA-ALDRICH L8511-5MG 
Sodium fluoride (NaF) SIGMA-ALDRICH S7920-100G 
Sodium orthovanadate (Na3Vo4) SIGMA-ALDRICH 450243 
MG132 In-solution Calbiochem 474791 
Phenylmethylsulfonyl fluoride 
(PMSF) 
SIGMA-ALDRICH P7626 
Chemicals and reagents 
Table 6 Chemicals and Reagents 
Chemical Company Catalog no. 
Acetonitrile Fluka 00687 
Agar 100 Resin Kit Agar Scientific Ltd AGR1031 
Agarose Carl Roth 2267 
Adenosine 5′-triphosphate disodium 
salt hydrate 
SIGMA-ALDRICH A-3377 
Ammonium persulfate Serva 3375 
Anti-V5 agarose conjugated beads SIGMA-ALDRICH A7345-1ML 
Biotin (≥99 %) SIGMA-ALDRICH B4501-100MG 
Bis-Tris AppliChem A1025,0500 
Bovine serum albumin (BSA) Fisher Scientific BP 1605 
Bovine serum albumin solution 
(BSA) 
SIGMA-ALDRICH A7284-500ML 
2,3-Butanedione monoxime (≥98 %) SIGMA-ALDRICH B0753-25G 
Calcium chloride x 2H2O Carl Roth 5239.2 
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Chloroquine SIGMA-ALDRICH C6628 
Creatinine hydrate SIGMA-ALDRICH C3630 
DAPI (4’, 6-diamidino-2-
phenylindole) 
ThermoFisher SCIENTIFIC D1306 
Deoxycholic acid Fluka 30970 
Dimethyl sulfoxide (DMSO) SIGMA-ALDRICH D-4540 
Disodium hydrogen phosphate 
(Na2HPO4) 
Merck 6580.0500 
Dynabeads® MyOne™ Streptavidin 
C1 
ThermoFisher SCIENTIFIC 65001 
1,4-Dithiothreit (DTT) Carl Roth 6908.2 
EDTA Carl Roth 8040.3 
EGTA SIGMA-ALDRICH E3889 
Entellan Merck 1079600500 
Ethanol (100 %) Carl Roth 9065.4 
Ethidium bromide solution (1 %) AppliChem A1152,0100 
FSC 22 Frozen Section Compound Leica 75806-668 
Fetal calf serum (FCS) SIGMA-ALDRICH F2442 
Formic acid Merck 1.00264.1000 
Gelatin from porcine skin SIGMA-ALDRICH G1890 
Glucose Carl Roth X997.2 
L-Glutamine-penicillin-streptomycin 
solution 
SIGMA-ALDRICH G6784-100ML 
Glutaraldehyde SIGMA-ALDRICH G5882 
Glycerin (87 %) Merck 1.04094.2500 
Glycine SIGMA-ALDRICH 15527 
HEPES Carl Roth 9105.3 
Hydrochloric acid (37 %) Carl Roth 4625.1 
InstantBlue Protein Stain Expedeon ISB1L 
Insulin-Transferrin-Sodium Selenite 
Media Supplement 
SIGMA-ALDRICH 11074547001 
Iodoacetamide SIGMA-ALDRICH I6125 
Isopropanol Carl Roth 6752.4 
L-Carnitine x HCl SIGMA-ALDRICH A6706 
Leupeptin ThermoFisher SCIENTIFIC 78435 
Liberase™ Roche 05401151001 
Lithium chloride Carl Roth P007.1 
Magnesium chloride x 6H2O Carl Roth 2189.1 
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Magnesium sulfate heptahydrate 
(MgSO4 x 7H2O) 
Merck 5886 
Methanol Carl Roth 4627.5 
Miglyol Caesar + Loretz 3274 
Nonidet P40 Fluka 74385 
4 x NuPAGE™ LDS Sample Buffer ThermoFisher SCIENTIFIC NP0008 
Oligo 15 primer Promega C110A 
Osmium tetroxide SIGMA-ALDRICH 75632-10ML 
Paraformaldehyde Carl Roth 0335.4 
Penicillin-Streptomycin           
(10,000 U/mL) 
ThermoFisher SCIENTIFIC 15140122 
Phenylmethylsulfonyl fluoride 
(PMSF) 
SIGMA-ALDRICH P7626 
Polybrene infection reagent SIGMA-ALDRICH TR-1003 
Potassium chloride (KCl) Carl Roth 6781.3 
Potassium bicarbonate (KHCO3) Merck 1.04854.0500 
Potassium dihydrogen phosphate 
(KH2PO4) 
Carl Roth P018.1 
Protein G Sepharose 4 Fast Flow 
beads 
GE Healthcare 17061801 
Red Alert™ 10x Merck 71078-3 
RNasin Plus Promega  
Rotiphorese® Gel 40 (29:1) Carl Roth A515.1 
Roti Quant  Carl Roth K015.2 
SDS Carl Roth 2326.3 
Skim milk Fluka 70166 
Sodium azide (NaN3) Carl Roth K305.1 
Sodium bicarbonate (NaHCO3) Merck 1.06329.0500 
Sodium chloride (NaCl) Carl Roth 3957.2 
Sodium deoxycholate Merck 1.06504.0100 
Sucrose Carl Roth 9097.1 
Taurine SIGMA-ALDRICH T0625 
TEMED Carl Roth 2367.1 
Tris Carl Roth 5429.2 
Triton-X 100 Carl Roth 6683.1 
TurboFect transfection reagent ThermoFisher SCIENTIFIC R0531 
Tween-20 Merck 822184.0500 
Xylol Carl Roth 9713.3 
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Buffers and solutions 
Table 7 Buffer Solutions 
Buffer Composition 
AbDil-Tx 1 x TBS; 0.1 % Triton X-100; 2 % BSA; 0.1 % NaN3 
10 % APS Dilute 10 g APS in 100 mL Aqua dest. 
BioID lysis buffer 50 mmol L-1 TrisCl; pH 7.4; 500 mmol L-1 NaCl; 0.2 % 
SDS; supplemented with protease inhibitors and PMSF 
BioID wash buffer 1 2 % SDS 
BioID wash buffer 2 0.1 % deoxycholic acid; 1 % Triton X-100; 1 mmol L-1 
EDTA, pH 8.0; 500 mmol L-1 NaCl; 50 mmol L-1 
HEPES, pH 7.5 
BioID wash buffer 3 0.5 % deoxycholic acid; 0.5 % NP-40; 1 mmol L-1 
EDTA, pH 8.0; 250 mmol L-1 LiCl; 10 mmol L-1 
TrisCl, pH 7.4 
5 % BSA Dilute 5 g APS in 100 mL 1 x TBS-T 
Cardiomyocyte isolation calcium-free 
buffer 
113 mmol L-1 NaCl; 4.7 mmol L-1 KCl; 0.6 mmol L-1 
KH2PO4; 0.6 mmol L-1 Na2HPO4; 1.2 mmol L-1 MgSO4 
x 7H2O; 12 mmol L-1 NaHCO3; 10 mmol L-1 KHCOS; 
10 mmol L-1 HEPES; 30 mmol L-1 taurine; 10 mmol L-1 
2,3-butanedionemonoxime; 5.5 mmol L-1 glucose 
Cardiomyocyte isolation enzyme 
buffer 
0.25 mg∙mL-1 Liberase™ DH; 0.14 mg∙mL-1 trypsin; 
12.5 µmol L-1 CaCl2 in calcium-free buffer 
Cardiomyocyte isolation stop    
buffer 1 
10% FCS; 12.5 µmol L-1 CaCl2 in enzyme buffer 
Cardiomyocyte isolation stop    
buffer 2 
5 % FCS; 12.5 µmol L-1 CaCl2 in enzyme buffer 
Cardiomyocyte cell culture medium M199 cell culture medium supplemented with 5 mmol 
L-1 creatinine x H2O; 2 mmol L-1 L-carnitine x HCl; 5 
mmol L-1 taurine; 25 mmol L-1 HEPES; 1 % 
penicillin/streptavidin; 10% fetal calf serum; 1% 
insulin-transferrin-sodium selenite media supplement, 
pH 7.3. 
Electron Microscopy fixation buffer 1.5 % glutaraldehyde; 1.5 % paraformaldehyde in 0.15 
mol L-1 HEPES 
Extraction buffer 100 mmol L-1 Tris-HCl, pH 8.0; 10 mmol L-1 EDTA; 
10% SDS 
Immunofluorescence blocking buffer 2 % FCS; 2 % BSA in 1x PBS 
Mass Spec Buffer A 0.1 % formic acid 
Mass Spec Buffer B 80 % acetonitrile; 0.1 % formic acid 
5 % Immunoblot blocking solution Dilute 5 g skim milk in 100 mL 1 x TBS-T 
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10 x PBS, pH 7.4 Dilute 80 g NaCl; 2 g KCl; 14.4 g Na2HPO4; 2.4 g 
KH2PO4 in 800 mL Aqua dest.; adjust pH to 7.4; refill 
to 1000 mL with Aqua dest. 
1 x PBS, pH 7.4 100 mL 10x PBS + 900 mL Aqua dest.; adjust pH to 
7.4 
2 x Proteasome assay buffer 50 mmol L-1 Tris, pH 8.0; 0.5 mmol L-1 EDTA, pH 8.0; 
40 µmol L-1 fluorogenic substrate; ± 40 µmol L-1 
proteasome inhibitor 
Proteasome lysis buffer 10 mmol L-1 Tris, pH 7.5; 1 mmol L-1 EDTA, pH 8.0;  
2 mmol L-1 ATP; 20% Glycerole; 4 mmol L-1 DTT 
RIPA lysis buffer, pH 8.0 50 mmol L-1 Tris, pH 7,4; 150 mmol L-1 NaCl; 1 % 
NP-40;       0.5 % sodium deoxycholate; 0.1 % SDS; 
protease inhibitors (2 mg mL-1 aprotinin, 2 mg mL-1 
leupeptin, 1 mol L-1 Na3VO4, 1 mol L-1 NaF, 0.2 mol L-
1 PSMF) 
10 % SDS Dilute 10 g SDS in 100 mL Aqua dest. 
50 x TAE Dilute 242 g Tris Base; 57.1 mL acetic acid; 100 mL 0.5       
mol L-1 EDTA, pH 8.0 in 1000 mL Aqua dest. 
10 x TBS, pH 7.6 0.2 mol L-1 Tris, 1.4 M NaCl 
1 x TBS 100 mL 10 x TBS + 900 mL Aqua dest. 
1 x TBS/T 100 mL 10 x TBS + 900 mL Aqua dest. + 0.1 % 
Tween®20 
TENS lysis buffer 1 mol L-1 Tris/HCl, pH 8.0; 0.5 mol L-1 EDAT, pH 
8.0; 4 mol L-1 NaCl; 20 % SDS 
10 x TE 100 mmol L-1 Tris-Cl; 10 mmol L-1 EDTA, pH 8.0 
1 x TE 100 mL 10 x TE + 900 mL Aqua dest. 
20 x Transfer buffer Dilute 163.2 g Bicine; 209.6 g Bis-Tris; 12 g EDTA in 
1000 mL Aqua dest. 
1 x Transfer buffer 250 mL 20 x transfer buffer; 1000 mL methanol; 3750 
mL Aqua dest. 
1 M Tris, pH 6.8 Dilute 12.1 g Tris in 80 mL Aqua dest.; adjust pH to 
6.8; refill to 100 mL with Aqua dest. 
1.5 M Tris, pH8.8 Dilute 18.17 g Tris in 80 mL Aqua dest.; adjust pH to 
8.8; refill to 100 mL with Aqua dest. 
Ubiquitin immunoblot blocking 
buffer 
0.5 % gelatin from porcine skin + 0.05 % Tween®20 in 
1 x PBS 
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Table 8 Ready-to-use Buffer Solutions 
Buffer Company Catalog no. 
NuPAGE™ MES SDS Running 
Buffer 
ThermoFisher SCIENTIFIC NP000202 
NuPAGE™ MOPS SDS Running 
Buffer 
ThermoFisher SCIENTIFIC NP000102 
TaqMan™ Gene Expression Master 
Mix 
Applied Biosystems™ 10525395 
Gel electrophoresis 
Table 9 Composition of a 9 % separating gel  
Reagent Add Final concentration 
Aqua dest 4.2 mL  
Acrylamide / Bisacrylamide (30 % / 0.8 %) 3.0 mL 9 % 
1.5 mM Tris (pH 8.8) 2.6 mL 0.39 mmol L-1 
10 % SDS 0.1 mL 0.1 % 
10 % APS 0.1 mL 0.1 % 
TEMED (> 99 %) 0.01 mL 0.04 % 
Table 10 Composition of a 5 % stacking gel 
Reagent Add Final concentration 
Aqua dest 2.975 mL  
Acrylamide / Bisacrylamide (30 % / 0.8 %) 0.67 mL 4 % 
0.5 mM Tris (pH 6.8) 1.25 mL 0.125 mmol L-1 
10 % SDS 0.05 mL 0.025 % 
10 % APS 0.05 mL 0.025 % 
TEMED (fertig, 99 %) 0.005 mL 0.00025 % 
Marker 
Table 11 Marker 
Marker Company / Composition 
Protein Marker VI (10 - 245) prestained BC PanReac AppliChem 
PUC Marker Homemade 
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Antibodies 
Primary antibodies 
Table 12 Primary antibodies for immunoblotting 
Primary antibody Dilution Catalog no. Company 
anti-Caspase-3 1:1000 9662 Cell Signaling Technology 
anti-Cleaved Caspase-3 
(Asp175) (5A1E) 
1:1000 9661 Cell Signaling Technology 
anti-GAPDH 1:1000 2118 Cell Signaling Technology 
anti-GFP 1:2000 ab6556 Abcam 
anti-HDAC6 1:500 PAB18362 Abnova 
Anti-HDAC6 1:2000 A301-342A Bethyl Laboratories 
anti-LC3A/B (D3U4C) 1:1000 12741 Cell Signaling Technology 
anti-PSMA4 1:1000 ab191403 Abcam 
anti-PSMC4 1:1000 TA332530 OriGene 
anti-PSMD4 1:1000 12441 Cell Signaling Technology 
anti-PSMD11 1:2000 NBP1-46192 Novus Biologicals 
anti-PSMD12 1:1000 orb214470 Biorbyt 
anti-PSMD14 1:1000 ab109123 Abcam 
anti-SQSTM1/p62 1:250 ab56416 abcam 
anti-α-tubulin 1:2000 T6074 Sigma-Aldrich 
anti-Ubiquitin (P4D1) 1:1000 3936 Cell Signaling Technology 
anti-Ubiquitin, Lys48-Specific, 
clone Apu2 
1:1000 05-1307 Millipore 
anti-Ubiquitin, Lys63-Specific, 
clone Apu3 
1:1000 05-1308 Millipore 
anti-Ubiquitin, Lys63-Specific, 
clone Apu3 
1:1000 ab179434 abcam 
anti-USP5 1:1000 A301-542A Bethyl Laboratories 
anti-V5 1:5000 ab9116 Abcam 
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Table 13 Primary antibodies for immunofluorescence staining 
Primary antibody Dilution Catalog no. Company 
anti- actin, α-smooth muscle 1:250 A2547 Sigma-Aldrich 
anti-ACTN1 1:250 ab68194 Abcam 
anti-Cleaved Caspase-3 
(Asp175) (5A1E) 
1:250 9661 Cell Signaling Technology 
anti-HDAC6 1:500 PAB18362 Abnova 
anti-Phalloidin-FITC 1:250 P5282 Sigma-Aldrich 
anti-Phalloidin-TRITC 1:300 P1951 Sigma-Aldrich 
anti-phospho Histone H3 
(Ser10) 
1:100 9701 Cell Signaling Technology 
anti-SQSTM1/p62 1:250 ab56416 Abcam 
anti-Ubiquitin (P4D1) 1:250 3936 Cell Signaling Technology 
anti-USP5 1:1000 A301-543A Bethyl Laboratories 
Secondary antibodies 
Table 14 Secondary antibodies for immunoblot analysis 
Secondary antibody Dilution Catalog no. Company 
goat-anti-mouse IgG, HRP 1:2000 31430 ThermoFisher 
SCIENTIFIC 
goat-anti-rabbit IgG, HRP 1:2000 31460 ThermoFisher 
SCIENTIFIC 
Table 15 Secondary antibodies for immunofluorescence staining 
Secondary antibody Dilution Catalog no. Company 
F(ab')2-Goat anti-Rabbit IgG 
(H+L) Cross-Adsorbed 
Secondary Antibody, Alexa 
Fluor 488 
1:1000 A-11070 ThermoFisher 
SCIENTIFIC 
Goat anti-Mouse IgG (H+L) 
Cross-Adsorbed Secondary 
Antibody, Alexa Fluor 488 
1:1000 A-11001 ThermoFisher 
SCIENTIFIC 
Goat anti-Mouse IgG (H+L) 
Cross-Adsorbed Secondary 
Antibody, Alexa Fluor 594 
1:1000 A-11005 ThermoFisher 
SCIENTIFIC 
Goat anti-Rabbit IgG (H+L) 
Cross-Adsorbed Secondary 
Antibody, Alexa Fluor 594 
1:1000 A-11012 ThermoFisher 
SCIENTIFIC 
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Primers 
Table 16 Primers for cloning 
Name Sequence 
Flag-HA-BigT-for 5’-GCT AGC AAT CGC CAC ACT ACA GAA CG-3’ 
Flag-HA-BigT-rev 5’-GCG GCC GCT TAC TAG GCG TAG TCG GG-3’ 
hsUSP5-isoform-for 5’-gat gac ttc tgg agc acg gcc ctg-3’ 
hUSP5-isoform-rev 5’-GCG GCC GCt tag ctg gcc act ctc tgg tag aag-3’ 
Psmd14-GFP-for 5’-aat aTT AAT TAA GCT AGC GCA TCG CCA TGA CCT CAA 
CCG GCC AGG ATT CC-3’ 
Psmd14-GFP-rev 5’-ata tGT CGA CGT GTG GGT GGG GCA TAT CCT CC-3’ 
Psmd14-V5-for 5’-aat aTT AAT TAA GCT AGC GCA TCG CCA TGA CCT CAA 
CCG GCC AGG ATT CC-3’ 
Psmd14-V5-rev 5’-atG GCG CGC GGC CGC GGA TCT ATC ACG TAG AAT CGA 
GAC CGA GGA GAG GGT TAG GGA TAG GCT TAC CTT TAA 
ATA CAA CAG TAT CCA ACA TTG CGG CC-3’ 
Hdac6-GFP-for 5’- aat aTT AAT TAA GCT AGC GCA TCG CCA TGG ACA GAC 
TTC TTA GAC TTG GAG G-3’ 
Hdac6-GFP-rev 5’- tat CTC GAG TTT AAA TAC AAC AGT ATC CAA CAT TGC 
GGC C-3’ 
hsUSP5-C-Fusion-for 5’-atc tcg TTA ATT AAG CAT CGC CAC CAT GGC GGA GCT 
GAG TGA GGA G-3’ 
hsUsp5-C-Fusion-rev 5’-ata tCT CGA GGC TGG CCA CTC TCT GGT AG-3’ 
hsUSP5-N-Fusion-for 5’-ata tCT CGA GAT GGC GGA GCT GAG TGA GGA G-3’ 
hsUSP5-N-Fusion-rev 5’-ata tGG CGC GCC taT TAG CTG GCC ACT CTC TGG TAG-3’ 
BirA-HA-for 5’-gcg cTT AAT TAA gat cga tcC TCG Aga agg aca ccg tgc ccc tg-3’ 
BirA-HA-rev 5’-tat GGC GCG Cct atg cgt aat ccg gta cat cg-3’ 
Myc-BirA-for 5’-atc tcg TTA ATT AAG CAT CGC CAC Cat gga aca aaa act cat ctc 
aga gga tct c-3’ 
Myc-BirA-rev 5’-ata tGG CGC GCC TTA AGC TTG GTA CCG AGC TCG G-3’ 
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qRT-PCR probes 
Table 17 TaqMan assay qRT-PCT probes 
Name Assay ID Species 
Acta1 Mm00808218_g1 mouse 
Fbxo32 Mm00499523_m1 mouse 
Klhl40 Mm01350720_m1 mouse 
Myc Mm00487804_m1 mouse 
Myh6 Mm00440359_m1 mouse 
Myh7 Mm00600555_m1 mouse 
Nppa Mm01255748_g1 mouse 
Psmd4 Mm01263490_m1 mouse 
Rps27a Mm01180369_g1 mouse 
Uba52 Mm02601856_g1 mouse 
Ubb Mm01622233_g1 mouse 
Ubc Mm02525934_g1 mouse 
Uch-l1 Mm00495900_m1 mouse 
Usp5 Mm00496734_g1 mouse 
Gapdh Mm99999915_g1 mouse 
Plasmids 
Table 18 Plasmids 
Plasmid Catalog no. Company 
Flag-HA-USP5 22590 Addgene (Wade Harper) 
Human ORFeome V8.1 Library OHS7588 Dharmacon™ 
pcDNA3.1 MCS-BirA*(R118G)-HA 36047 Addgene (Kyle Roux Lab) 
pcDNA3.1 mycBirA* 35700 Addgene (Kyle Roux Lab) 
Viruses 
Table 19 Viruses 
Virus Catalog no. Company 
Ad-Null 1240 VECTOR BIOLABS 
Ad-CVM-iCre 1045 VECTOR BIOLABS 
eGFP wildtype titin  Gift from Prof. M. Gautel 
eGFP p.C31712R titin  Gift from Prof. M. Gautel 
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Kits 
Table 20 Kits 
Kit Catalog no. Company 
Direct-zol™ RNA Kit R2052 Zymo Research 
ProteoStat® Aggresome Detection Kit ENZ-51035-K100 Enzo 
Super Signal West Pico 
Chemiluminescent Substrate kit 
PI34080 Thermo Fisher SCIENTIFIC 
Equipment 
Table 21 Equipment 
Equipment Company 
2K CCD camera  TRS, Tröndle 
Adhesive PCR Plate Seals ThermoFisher SCIENTIFIC 
Agarose gel electrophoresis chamber Peqlab 
Bio Doc analyzer Bio RAD 
Centrifuge Eppendorf 
Centrifuge Eppendorf 
ChemiDoc™ MP Imaging System BIO RAD 
Cold Plate for Tissue Embedding System Leica 
Cryostat Leica 
Eppendorftubes, 0.5 mL, 1.0 mL, 2.0 mL Eppendorf 
Filter tips (10 µL, 20 µL, 100 µL, 1000 µL) Fisher Scientific 
Flattening table Leica 
Fridge/Freezer Bosch 
Gelsystems (Mini, Maxi) VWR 
Greiner 96 well plates, polystyrene Thermo Fisher SCIENTIFIC 
Greiner centrifuge tubes, 15 mL Sigma-Aldrich 
Greiner centrifuge tubes, 50 mL Sigma-Aldrich 
Heating block IKA Labortechnik 
Tissue homogenizer POLYTRON 
Keyence Fluorescence Microscope Keyence 
Micro Centrifuge Carl Roth 
MicroAmp™ Fast Optical 96-Well Reaction Plate ThermoFisher SCIENTIFIC 
Microtome Leica 
Mini centrifuge Carl Roth 
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Multimode Microplate Reader BERTHOLD Technologies 
Nitrocellulose membranes Invitrogen 
Orbital platform shaker Heidolph 
PCR Cycler BIO RAD 
pH meter HANNA instruments 
Pipettes Rainin 
Power Supply Carl Roth, BIO RAD 
Scales / Precision Balances KERN, Sartorius 
Sonicator BANDELIN SONOPLUS 
StepOnePlus™ Real-Time PCR System ThermoFisher SCIENTIFIC 
SuperFrost Plus slides  Menzel-Glaeser 
Swing mill Retsch 
Thermomixer comfort Eppendorf 
ThermoMixer Eppendorf 
Tips (10 µL, 20 µL, 100 µL, 1000 µL) Greiner Bio-One 
Tissue cell culture plate VWR 
Transmission electron microscope  Zeiss 
Ultra-Turrax mit Netzgerät und 
Dispersionswerkzeug 
IKA Labortechnik 
Universal Oven Memmert 
UV Transilluminator INTAS 
Vacufuge™ Concentrator Eppendorf 
Vortex mixer Scientific Industries, Inc. 
Waterbath Leica 
XCell SureLock™ Mini-Cell and XCell II™ Blot 
Module 
ThermoFisher SCIENTIFIC 
Software 
Table 22 Software 
Software Company 
Gimp-2.8 GIMP 
Graph Pad Prism 7.0 Graph Pad Software 
Image J / Fiji NIH 
Image Lab Bio RAD 
MaxQuant (1.5.3.12) MPG 
Microsoft Office 2016 Microsoft Corporation® 
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Methods 
Animals  
Experiments involving animal health care and treatments were performed in 
agreement with institutional guidelines and the German animal welfare law. Each 
experiment was approved by the local governmental animal protection committee 
(Regierungspräsidium Darmstadt, B2/1136). All mice used in this study were housed 
in individually ventilated cages accompanied with environmental enrichment under 
specific pathogen-free conditions in the Animal House Facility of the Max Planck 
Institute for Heart and Lung Research, Bad Nauheim, Germany. Age-matched 
littermates were used for individual experiments. The number of mice used in each 
experiment is indicated in the figure legend. 
Engineering of genetically modified mice 
Conditional USP5 KO mice 
Transgenic mice harboring a tissue or cell-type specific deletion of Usp5 were 
generated in house. All animals were kept on a C57bl/6 genetic background.  
The Usp5 conditional knockout allele was engineered by electroporating the Targeted 
Knockout First construct Usp5tm1a(EUCOMM)Hmgu (EuMMCR), which contains an 
antibiotic neomycin resistance selection cassette, a lacZ cassette, and two loxP sites 
flanking exon 3-6, into V6.5 F1 hybrid embryonic stem ES cells (Figure 12). Targeted 
stem cell clones were selected by G418 treatment and screened by southern blotting 
with 5’ genotyping by SmaI digestion. Positive ES cell clones were injected into 
C57bl/6 (B6) blastocysts to generate chimeric mice (genotype: Usp5 flox neo/+). 
Chimeras were intercrossed to Flpe-recombinase expressing transgenic mice [110] to 
generate neomycin cassette deleted, heterozygous mice (genotype: Usp5 flox/+), 
which were backcrossed to C57bl/6 mice and bred to homozygosity (genotype: Usp5 
flox/flox).  
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Figure 12 Generation of transgenic mice to conditionally delete USP5 in a cell -type 
restricted manner.  
Schematic illustration of gene targeting strategy to generate a tissue- and cell-type specific Usp5 
mutant allele by which the exons 3 and 6, encoding the zinc-finger binding domain and the catalytic 
active site of Usp5, are flanked by a loxP site (red triangles). Cre recombinase mediated deletion 
resulted in a non-functional protein. E, exon; FRT, FLPe recognition target site; lacZ, ß-
galactosidase reporter; neo, neomycin resistance cassette; wt, wildtype.  
Conditional, cre-mediated recombination in the myocardium was implemented by 
crossbreeding Usp5 flox/flox mice with either XMLC2-cre [111] or MCK-cre [112] 
transgenic mice to facilitate deletion of Usp5 at embryonic (genotype: Usp5 
flox/flox//XMLC2-cre) or juvenile stage (genotype: Usp5 flox/flox//MCK-cre). For cre-
mediated recombination in adult stage, Usp5 flox/flox mice were crossbred with 
transgenic mice by which the Myh6 (αMHC) promoter directs expression of a 
tamoxifen-inducible MerCreMer recombinase [113] (Figure 12). Intraperitoneal (i.p.) 
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injection of 100 mg kg-1 tamoxifen to 8 weeks old mice for seven consecutive days 
resulted in deletion of Usp5 in mature cardiomyocytes (genotype: Usp5 
flox/flox//Myh6-MerCreMer). Cre-mediated deletion of Usp5 in mouse embryonic 
fibroblasts was achieved by crossbreeding Usp5 flox/flox mice with tamoxifen-
inducible Rosa26-CreERT2 transgenic mice [114] and subsequent administration of 1 
µmol L-1 4-Hydroxytamoxifen (4-OHT) to isolated mouse embryonic fibroblasts 
(MEFs) for 48 hours. Aged-matched littermates without cre-recombinase expression 
were used as an appropriate control cohort in all experiments.  
Conditional overexpression of human USP5 
Transgenic mice conditionally overexpressing human (hs) USP5 exon 15 long in the 
myocardium were generated in house, using a modified ROSA26 targeting locus by 
which the SA-site of pBigT was replaced by a synthetic CAG promoter [115]. The 
Flag-HA tagged plasmid of hsUSP5, encoding hsUSP5 exon 15 short, was PCR-
amplified (primers used: FlagHA-BigT-for and FlagHA-BigT-rev) to introduce NheI 
and NotI sites, and cloned into the pBigT-CAG vector. Human heart cDNA was then 
PCR-amplified (primers used: hsUSP5-isoform-for and hsUSP5-isoform-rev) to 
replace hsUSP5 exon 15 short with hsUSP5 exon 15 long by using SfiI and NotI 
cloning sites. The generated pBigT-CAG-Flag-HA-hsUSP5 exon 15 long cassette was 
subcloned in PacI and AscI site of the pRosa26-PA construct. The final construct 
was electroporated into V6.5 F1 hybrid ES cells and targeted stem cell clones were 
selected by G418 treatment and screened by Southern blotting with 5’ genotyping by 
EcoRV. Positive ES cell clones were injected into C57BL/6 (B6) blastocysts. The 
resultant chimeric mice were backcrossed to C57BL/6 mice to generate transgenic 
mice harboring a single mutant allele (genotype: hsUSP5 OE/+). Conditional cre-
mediated overexpression of hsUSP5 exon 15 long in the myocardium was achieved 
by crossbreeding hsUSP5 OE/+ mice with XMLC2-cre transgenic mice (genotype: 
hsUSP5 CO/+) (Figure 13). The hsUSP5 CO/+ alleles were kept heterozygous in all 
experimental studies. Aged-matched wildtype littermates with cre-recombinase 
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expression (genotype: hsUSP5 +/+//XMLC2-cre +/-) were used as appropriate 
control mice in all experiments.  
 
Figure 13 Generation of transgenic mice conditionally overexpressing human USP5 exon 15 
long in the myocardium.  
Schematic illustration of the gene targeting strategy for conditional overexpression of human (hs) USP5 
exon 15 long in cardiomyocytes. The modified pBigT backbone vector, which contains a CAG promotor, 
a flanked PGK-neo antibiotic selection cassette, and the cDNA encoding for FLAG-HA tagged hsUSP5 
exon 15 long, was inserted into the ROSA26 genomic locus by homologous recombination. XMLC2-Cre 
recombinase mediated deletion of the PGK-neo selection cassette resulted in specific overexpression of 
FLAG-HA tagged hsUSP5 exon 15 long in cardiomyocytes. tpA, transcriptional polyA stop sequence; bpA, 
bovine growth hormone polyadenylation site; MCS, multiple cloning site; DTA, subunit of the diphtheria 
toxin gene.  
Genotyping 
To perform genotyping of mice, tail biopsies were first digested in 500 µL tail lysis 
buffer, supplemented with 5 µL Proteinase K (20 mg mL-1), at 56 °C overnight. The 
next day, digested tail pieces were centrifuged at 14,000 rpm for 10 min and decanted 
into a new tube containing 500 µL isopropanol. Genomic DNA was precipitated by 
inverting the tubes. After centrifugation at 14,000 rpm for 20 min, supernatants were 
removed, and the genomic DNA-containing pellets washed in 500 µL 70 % ethanol, 
followed by centrifugation at 14,000 rpm for 5 min. Genomic DNA was air dried at 
RT for 1-2 h, resuspended in 300 µL 1x TE buffer, and dissolved by incubation at 56 
°C for 2-3 h. Genotyping PCRs were performed with self-designed primers, as 
indicated in Table 23 using appropriate cycling conditions (Table 24).  
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The master mix for one PCR reaction was prepared as followed: 
10x PCR buffer     2.5 µL 
MgCl2 (50 mmol L
-1)     1.0 µL 
dNTPs (10 mmol L-1)    0.5 µL 
Primer 1 (for)      0.5 µL 
Primer 2 (rev)     0.5 µL 
Primer 3 (wt)      0.5 µL 
Taq polymerase (5 U L-1)    0.2 µL 
ddH2O    18.5 µL 
Genomic DNA     1.0 µL 
PCR products were loaded on a 2 % agarose gel, supplemented with ready-to-use 
ethidium bromide solution, and ran for 30-45 min at 150-200 V, depending on the 
size of the gel. Double-stranded DNA was visualized under UV light and gels were 
imaged using a BioDoc analyzer (Figure 14). 
Table 23 Primers used for genotyping 
Primer Sequence 
Cre-for  5’-TAA ACT GGT CGA GCG ATG GAT TTC C-3’ 
Cre-rev 5’-CAT ATC TCG CGC GGC TCC GAC ACG G-3’ 
CreERT2 for 5’-AAG AAC CTG ATG GAC ATG TTC AGG G-3’ 
CreERT2 rev 5’-CCA GAC CAG GCC AGG TAT CTC T-3’ 
MCM-for 5’-CAA CAT GAA ATG CAA GAA CG-3’ 
MCM-rev 5’-GGA AAC CAT TTC CGG TTA TTC-3’ 
Rosa-CAGG-for 5’-CTT GCT CTC CCA AAG TCG CTC TGA G-3’ 
Rosa-CAGG-rev 5’-ACC GTA AGT TAT GTA ACG CGG AAC TCC-3’ 
Rosa-WT-rev 5’-CTT TAA GCC TGC CCA GAA GAC TCC C-3’ 
Usp5-3. loxP-for 5’-AGTCGCCATCTGCTCAGTCACTGTC-3’ 
Usp5-3. loxP-rev 5’-TGTGGTTGAGGATAGCCTTCACCTCC-3’ 
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Table 24 Genotyping protocols 
PCR Primer Program Fragment size 
Usp5 3. loxP Usp5-for 
Usp5-rev 
95°C 5:00 
95°C 0:30 
55°C 0:30 
72°C 0:30 
Go to 2, repeat 35x 
72°C 5:00 
12°C ∞ 
Wildtype 160 bp 
Transgene 196 bp 
XMLC2-cre 
MCK-cre 
Cre-for 
Cre-rev 
94°C 4:00 
94°C 0:30 
66°C 0:30 
72°C 0:45 
Go to 2, repeat 35x 
72°C 5:00 
12°C ∞ 
Transgene 244 bp 
Rosa26-CreERT2 CreERT2 for 
CreERT2 rev 
94°C 3:00 
94°C 0:30 
55°C 0:30 
72°C 0:40 
Go to 2, repeat 35x 
72°C 5:00 
12°C ∞ 
Transgene 791 bp 
MerCreMer MCM-for 
MCM-rev 
94°C 3:00 
94°C 0:30 
55°C 0:30 
72°C 0:40 
Go to 2, repeat 35x 
72°C 5:00 
12°C ∞ 
Transgene 400 bp 
ROSA-CAGG ROSA-CAGG-for 
ROSA-CAGG-rev 
ROSA-wt-rev 
94°C 3:00 
94°C 0:30 
57°C 0:30 
72°C 0:30 
Go to 2, repeat 35x 
72°C 5:00 
12°C ∞ 
Wildtype 249 bp 
Transgene 325 bp 
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Figure 14 Genotyping PCRs of transgenic mice used in this study.  
A. Genotyping of transgenic mice lacking USP5 in cardiomyocytes and MEFs was assessed by PCR 
analysis of tail-derived genomic DNA. PCRs were performed with primers specific for the 3. loxP 
site of Usp5 and the cre or Rosa26-creERT2 transgene. PCR products were separated by agarose gel 
electrophoresis and visualized using a BioDoc system. Lane 1, 3 show Usp5 flox/flox control mice 
(cre negative); lane 2, 4 show Usp5cKO (Usp5 flox/flox // Myh6-MerCreMer) or Usp5iKO (Usp5 
flox/flox // Rosa26-creERT2) mice (cre or Rosa26-creERT2 positive). B. Genotyping of transgenic mice 
overexpressing hsUSP5 exon 15 long in cardiomyocytes was assessed by PCR analysis of tail-
derived genomic DNA. PCR was performed with primers specific for the ROSA26 and cre 
recombinase transgene. PCR products were separated by agarose gel electrophoresis and 
visualized using a BioDoc system. Lane 2, 4 show hsUSP5 +/+ control mice (cre positive); lane 3,5 
show hsUSP5 CO/+ mice (cre positive). 
Isolation of adult cardiomyocytes 
Isolation of adult cardiomyocytes from 8 weeks old male mice only was performed as 
previously described by O’Connell et al [116]. In brief, dissected hearts were 
cannulated via the aorta and arrested by retrograde perfusion with calcium-free buffer. 
Cannulated hearts were enzymatically digested by perfusion with enzyme buffer 
solution and cut off from the cannula. Atria were separated, and ventricles were 
minced in stop buffer 1. After gentle pipetting, myocytes were at 500 rpm centrifuged 
for 1 min and cell pellets, containing the cardiomyocyte fraction, were re-suspended 
in stop buffer 2. The calcium content of the cell suspension was then stepwise 
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adjusted to 1 mmol L-1 and cardiomyocyte-containing cell pellets were re-suspended 
in M199 cell culture medium, supplemented with creatinine x H2O, L-carnitine x HCl, 
HEPES, penicillin/streptavidin, FCS, and insulin-transferrin-sodium selenite media 
supplement, and maintained at 37°C and 5 % CO2.  
Isolation of mouse embryonic fibroblasts 
Mouse embryonic fibroblasts (MEFs) were isolated from Usp5iKO mice (genotype: 
Usp5 flox/flox //CreERT2+/-) at E13.5 as described by Jozefczuk et al. [117]. Briefly, 
pregnant mice were sacrificed, embryos isolated and placed separately into a fresh 
petri dish containing ice-cold 1 x PBS. The umbilical cord and the hematopoietic 
tissue together with the tubular intestine were removed from each embryo and the 
bulk of the CNS was trimmed off by dissecting away the head above the level of the 
oral cavity. A small piece of the tail was saved for DNA extraction and genotyping. 
Each remaining embryo was transferred to a tissue culture hood, placed in a 100 mm 
dish containing 5 mL of 1 x trypsin, and minced with a sterile scalpel for 2 min. After 
incubation for 15 min at 37 °C, tissue bits containing MEFs were transferred into a 
15 mL canonical tube and pipetted several times to dissociate the tissue bits. After 
adding 5 mL of DMEM, supplemented with 10 % FCS and 1 % L-glutamine-
penicillin-streptomycin, MEFs were spin down at 1,000 rpm for 5 min, and the 
supernatant was carefully aspirated off. The cell pellets were re-suspended in 10 mL 
DMEM, supplemented with 10 % FCS and 1 % L-glutamine-penicillin-streptomycin, 
and plated to a new 100 mm dish. MEFs were maintained at 37°C and 5 % CO2.  
Adenoviral Infection 
Adenoviral infection of cardiomyocytes  
Isolated cardiomyocytes from hsUSP5 +/+ and hsUSP5 CO/+ mice were infected 
with an adenovirus expressing either an eGFP-tagged wildtype titin or disease-causing 
eGFP-tagged p.C31712R titin variant [118, 119] overnight. The day after, 
MATERIAL AND METHODS 
48 
cardiomyocytes were washed five times with 1 x PBS to remove remaining virus 
particles and cultured in fresh M199 medium for additional 48 h.  
Adenoviruses were a kind gift from Prof. Mathias Gautel, King’s College London, 
UK.  
Adenoviral Infection of MEFs 
Subconfluent MEFs were infected with a recombinant adenovirus expressing a codon 
improved cre-recombinase under the CMV promoter (Ad-CMV-iCre; 107 PFU mL-1) 
to induce site-specific recombination of genomic DNA between the two loxP sites 
flanking exon 3-6 of Usp5. An empty E1/E3 deletion, type 5 adenovirus (Ad-Null; 
107 PFU mL-1) was used as an appropriate mock control. Prior to virus infection, 
adenoviruses were incubated with polybrene to increase transduction efficacy. MEFs 
were incubated with the adenovirus mixture for 6 h and analyzed six days post-
transduction. 
Drug Treatment  
To study the effects of proteasome impairment in vitro, cardiomyocytes and MEFs 
were treated with the reversible proteasome inhibitor MG132 (10 µmol L-1) for 4 h. 
DMSO (0.2 %) treated cells served as an appropriate control cohort. 
To study the autophagic flux, cardiomyocytes were treated with chloroquine (20 µmol 
L-1) for 4 h. Chloroquine is a lysosomotropic agent that prevents endosomal 
acidification as it increases the lysosomal pH, thereby inhibiting the enzymatic activity 
of lysosomes. This results in impaired fusion of autophagosomes with lysosomes and 
lysosomal degradation of cell compartments, organelles, or protein aggregates. 
DMSO (0.2 %) treated cells served as an appropriate control cohort. 
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Proteasome activity assay 
Enzymatic peptidase activities of the 20S proteasome were analyzed as previously 
described [120] Cardiomyocytes and MEFs were lysed in ice-cold proteasome lysis 
buffer, sonicated for 20 secs at cycle 9, power 80 % and clarified by centrifugation at 
13,000 x g for 15 min at 4 °C. Sonication and centrifugation was repeated with the 
supernatants. 20 – 30 µL of cell lysates were transferred to a black 96 – well plate and 
mixed with proteasome assay buffer, supplemented with 40 µmol L-1 of specific 
activity-based fluorogenic (AMC-) peptide probes. Fluorescence intensity, which 
resulted from the release of the AMC, was monitored in 3-min intervals for a total 
time of 30 min at 37 °C using a multiplate reader with 380-nm excitation and 460-nm 
emission spectra. 
Fluorogenic peptide probes used to determine 20S proteasome activity included: Z-
Leu-Leu-Glu-AMC to measure peptidylglutamyl-peptide hydrolyzing (referred to as 
caspase-like) enzymatic activity, which is encoded by the ß1 subunit. Boc-Leu-Arg-Arg-
AMC was used to determine trypsin-like catalytic activity that is encoded by the ß2 
subunit. Suc-Leu-Leu-Val-Tyr-AMC was used to measure chymotrypsin-like catalytic 
activity, encoded by the ß5 subunit (Table 4). 
RNA isolation and quantitative RT-PCR 
RNA from cardiomyocytes and MEFs was extracted using the Direct-zol™ RNA Kit 
according to the manufacturer’s protocol and stored at – 80 °C until further usage. A 
total of 1 µg RNA was reverse transcribed to cDNA using the SuperScript™ II 
Reverse Transcriptase according to a protocol as followed: 
RNA sample (1 µg)     1.0 µg 
Oligo dT 15 primer     1.0 µL 
dNTPs      1.0 µL 
add ddH2O to   12.0 µL 
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The reaction mix was incubated for 5 minutes at 65 °C and cooled on ice. A synthesis 
mix, containing 
0.1 M DTT     2.0 µg 
5 x FS buffer     4.0 µL 
RNasin      1.0 µL  
was added and the reaction was incubated for 2 min at 42 °C. 1.0 µL of the 
SuperScript™ II Reverse Transcriptase was added to complete cDNA synthesis by 
incubation for 50 min at 42 °C followed by incubation for 15 min at 70 °C. Ready-
to-use cDNA was stored at – 80°C until further usage. 
TaqMan® Gene Expression Assays using specific TaqMan probes (Table 17) were 
used to perform quantitative RT-PCR (qRT-PCR) on a StepOnePlus Real-Time PCR 
System.  
The master mix for one qRT-PCR reaction was prepared as followed: 
TaqMan™ Gene expression master mix   5.0 µL 
TaqMan™ gene specific probe (FAM-dye)  0.5 µL 
TaqMan™ gapdh probe (VIC-dye)   0.5 µL 
cDNA (diluted 1:100)     4.0 µL 
Each sample was run in technical triplicates and repeated at least two times. Relative 
mRNA expression was calculated by the ∆∆Ct method and normalized to gapdh as an 
internal housekeeping control. 
Microarray analysis and GO term annotation  
Quality of extracted RNA of isolated cardiomyocytes was verified with the RNA 6000 
Nano Kit on an Agilent 2100 Bioanalyzer. RNA was labeled accordingly to the 
Affymetrix Whole Transcript Sense Target Labeling protocol and hybridized to 
Affymetrix Clariom™ D assays. Data were processed and analyzed by RMA 
algorithm using the Affymetrix Expression Console. Statistics were employed using 
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DNAStar Arraystar 11 to calculate FC values [121] in combination with students t-
test of log2-transformed data to identify significantly differentially expressed 
transcripts. 
Gene ontology annotations of identified gene sets were determined using the Gene 
Ontology enrichment analysis and visualization tool. GraphPad Prism 7 was used to 
generate heat maps and graph bars, and Venn diagrams were generated using the 
Bioinformatics & Evolutionary Genomics tool. 
Gorilla – available on http://cbl-gorilla.cs.technion.ac.il/ 
Bioinformatics & Evolutionary Genomics tool – available on 
http://bioinformatics.psb.ugent.be/webtools/Venn/ 
Protein extraction and immunoblot analysis 
Immunoblot analysis was performed accordingly to standard protocols. In brief, 
cardiomyocytes and MEFs were collected, lysed by homogenization in RIPA buffer, 
supplemented with protease inhibitor cocktail and PMSF, and sonicated for 20 sec at 
cycle 3, power 30 %. In contrast, human myocardial samples were homogenized in 
extraction buffer, supplemented with protease cocktail and PMSF, and sonicated for 
20 sec at cycle 3, power 30 %. After incubation on a rotating wheel at 4 °C for a 
minimum of 30 min, cell and tissue homogenates were clarified by centrifugation at 
14,000 rpm for 20 min at 4 °C. Supernatant, representing the cytoplasmic protein 
fraction, was collected and protein concentration was measured using Roti®Quant 
universal. 20 – 30 µg of proteins were separated by SDS-PAGE and blotted onto 
nitrocellulose membranes, followed by RedAlert™ staining to verify loading efficacy. 
Nitrocellulose membranes were blocked in 5 % skim milk / TBS-T for 30 min at RT 
and probed with specific primary antibodies overnight at 4 °C, followed by incubation 
with peroxidase-conjugated secondary antibodies for 2 hours at room temperature. 
Proteins were visualized by chemiluminescence using the Super Signal West Pico 
Chemiluminescent Substrate kit on a ChemiDoc™ MP Imaging System. 
Densitometric analysis of the chemiluminescence signals in Image J was performed 
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to quantify the relative protein expression. Absolute protein expressions were 
calculated by normalization to GAPDH. 
The protocol to detect ubiquitin levels in cell extracts of cardiomyocytes and MEFs 
was marginally modified. After SDS-PAGE and protein transfer, nitrocellulose 
membranes were boiled in ddH2O for 30 min and blocked in 0.5 % gelatin from 
porcine skin + 0.05 % Tween-20 in 1 x PBS. Membranes were probed with pan- and 
Lys48-linkage specific ubiquitin antibodies overnight at 4 °C or Lys63-linkage specific 
ubiquitin antibody for 2 hours at room temperature.  
All primary antibodies used in this study were diluted as indicated in Table 12 in 5 % 
BSA/TBS-T apart from ubiquitin antibodies, which were diluted in 5 % skim 
milk/TBS-T. All secondary antibodies were diluted in 5 % skim milk/TBS-T. 
Whole proteome analysis 
Whole proteome analysis was performed on cardiomyocytes only. Cells were lysed in 
ice-cold RIPA buffer, supplemented with protease inhibitors and PMSF, and 
cytoplasmic proteins were isolated as described in the previous section. 40 µg of 
protein was separated by SDS-PAGE and the gel was stained with InstantBlue Protein 
Stain to visualize robustness of protein separation. Thereafter, gel lanes were excised 
into evenly sized pieces, washed in ddH2O, and incubated with 50 mmol L-1 ABC / 
50 % EtOH for 20 min at RT. Gel pieces were dehydrated in absolute EtOH for 10 
min, dried in the Vagufuge™ Concentrator for 5 min, and further processed for in-
gel digestion [122]. Here, proteins were reduced in 100 mmol L-1 DTT, alkylated with 
550 mmol L-1 iodoacetamide, followed by washing and rehydrating steps with 50 
mmol L-1 ABC and absolute EtOH, respectively, each for 15 min. Afterwards, gel 
pieces were again dried in the Vagufuge™ Concentrator for 5 min and digested with 
12.5 ng µL-1 trypsin at 37 °C overnight. The next day, digested proteins were extracted 
with 70 % and 100 % acetonitrile, concentrated in in the Vagufuge™ Concentrator 
to a final volume of ~ 80 µL, mixed with 80 µL buffer C, and finally purified on C-
18 stop and go extraction stage tips made in-house [123]. Extracted peptides were 
separated on a linear 130 min gradient by a binary buffer gradient, consisting of buffer 
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A (0.1 % formic acid) and buffer B (80 % acetonitrile; 0.1 % formic acid), and analyzed 
by LC-MS/MS. MS spectra were acquired in the Orbitrap with a resolution of 70,000 
at 200 m∙z-1. Raw data were analyzed by MaxQuant [124] combined with 
implementation by the Andromeda search engine [125]. Protein assignment was 
performed by correlating identified spectra with the Uniprot murine database 
including a list of common contaminants. A minimal peptide length was defined as 
seven amino acids and the false discovery rate at protein and peptide level was set to 
1 %. P-values below 0.05 were considered as statistically significant. 
Human cardiac samples 
Human myocardial tissue samples were obtained from left ventricular biopsies of 
transplanted hearts from five individuals with late end-stage DCM, not showing any 
signs of myocardial infarction. Left ventricular myocardial samples, which were not 
used for heart transplantation, were obtained from two individuals with showing 
preserved cardiac function (EF > 60 %) and no symptoms of myocardial damage or 
ventricular dilation. These donor hearts (hereby referred to as non-failing) served as 
a control cohort. Immediately after tissue procurement, cardiac biopsies were shock 
frozen in liquid nitrogen and stored at – 80 °C until being processed for molecular 
analysis and immunohistochemistry. A small fraction of cardiac biopsies was fixed in 
buffered glutaraldehyde for electron microscopical analysis.  
All patients delivered a prospective written informed consent for research use of 
cardiac tissues to comply with the requirements of the Medical Council in Hesse, 
Germany, and the institutional ethics guidelines of the Kerckhoff Hospital, Bad 
Nauheim, Germany. The study was approved by the ethics committee of the Medical 
Council in Hesse, Germany. 
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Morphological analysis 
To perform cryosections, dissected mouse hearts were fixed in 4 % PFA / 1 x PBS 
overnight at 4 °C, immersed in 30 % sucrose / 1 x PBS for additional 24 hours at 4 
°C, embedded in FSC 22, frozen on dry ice, and stored at – 80 °C. Serial 6-µm thick 
cross sections were cut using a Leica CM 1950 cryostat, collected on SuperFrost Plus 
slides, and stored at – 20 °C until being processed for immunohistochemistry.  
Heart morphology was assessed by hematoxylin & eosin (H & E) staining following 
routine procedures. Briefly, frozen cryosections were air-dried and incubated in 
ddH2O for 2 min at RT, and stained with hematoxylin for 10 min. Staining solution 
was washed out in tepid running tap water and sections were counterstained with 
eosin for 7 min at RT. Afterwards, sections were dipped in increasing ethanol series 
(70 %, 80 %, 90 % ethanol), incubated in 100 % ethanol and Xylol for 5 min each, 
and embedded in Entellan.  
PROTEOSTAT® aggresome assay  
Protein aggregates and aggresomes in isolated cardiomyocytes and MEFs were 
visualized by the ProteoStat® Aggresome Detection Kit [126]. All components of the 
kit were prepared according to the manufacturer’s instructions.  
The kit provides a ready-to-use 488-nm excitable fluorescent molecular rotor dye that 
binds selectively to the hydrophobic surface of denatured protein cargos within 
aggresomes and aggresome-like inclusion bodies in fixed and permeabilized cells. 
Binding to the protein cargos induces a reaction in which protein aggregates become 
brightly fluorescent.  
Immunofluorescence staining of cells and tissues  
Cardiomyocytes and MEFs were fixed in 4 % PFA / 1 x PBS for 15 min, washed 3-
times in 1 x PBS, permeabilized in 0.1 % Triton X-100 / 1 x PBS for 10 min, and 
incubated in a blocking solution containing 2 % FCS, 2 % BSA in 1 x PBS for 30 min 
to reduce non-specific antibody binding. In contrast, cryosectioned tissue samples, 
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already pre-fixed in 4 % PFA / 1 x PBS, were only permeabilized in 0.1 % Triton X-
100 / 1 x PBS for 10 min followed by incubation in blocking buffer solution to reduce 
non-specific binding affinity towards antibodies. Afterwards, cells or tissue sections 
were incubated with primary antibodies, diluted in the blocking solution as indicated 
in Table 13, overnight at 4 °C. The day after, cells or tissue sections were washed 3-
times in 1x PBS and incubated with secondary antibodies conjugated with either Alexa 
Fluor™ 488 or Alexa Fluor™ 594, again diluted in the blocking solution, for 2 hours 
at RT. After three washing steps in 1 x PBS, nuclei were counterstained with 4’,6-
diamidino-2-phenylindole (DAPI), 1:1000 diluted in the blocking solution, for 15 min. 
Cells or tissue sections were again washed 3-times with 1 x PBS, mounted in Mowiol, 
and analyzed using a fluorescence microscope. 
Staining protocol to detect autophagosomes was solidly modified. Cardiomyocytes 
were first treated with 20 µmol L-1 chloroquine for 4 h to permit fusion of 
autophagosomes with lysosome. Afterwards, cardiomyocytes were fixed in ice-cold 
methanol for 5 min at RT, washed with 1 x PBS, incubated in an AbDil-Tx blocking 
buffer for 30 – 60 min at RT, followed by incubation with anti-LC3B (1:200 diluted 
in AbDil-Tx blocking buffer) overnight at 4 °C. The next day, cardiomyocytes were 
washed 3-times with 1 x PBS and incubated with appropriate secondary antibody 
conjugated with either Alexa Fluor™ 488 or Alexa Fluor™ 594 for 2 hours at RT.  
Electron microscopy 
Electron microscopy was used to analyze cardiomyocyte-restricted effects of loss of 
Usp5 on heart morphology. Animals were anesthetized, hearts were perfused with a 
fixative solution containing 1.5 % glutaraldehyde (v/v), 1.5 % paraformaldehyde (v/w) 
in 0.15 M HEPES (v/w), pH 8.0 and kept in fixative solution for at least 24 h until 
being processed for post-fixation in 1 % osmium tetroxide. Thereafter, samples were 
stained en bloc in 50 % saturated watery uranyl acetate, dehydrated by an ascending 
ethanol series, and embedded in Agar 100. Ultrathin sections were cut using an 
ultramicrotome at the Institute for Anatomy and Cell Biology, Justus-Liebig-
University Giessen, Germany, and image acquisition was performed with a 
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transmission electron microscope. All images were captured with a slow-scan 2K 
CCD camera.  
Plasmids 
All V5-tagged plasmids encoding human ubiquitin-specific peptidases (USPs) as well 
as the V5-tagged human HDAC6 plasmid were provided by the CCSB Human 
ORFeome V8.1 Library. In contrast, GFP- and V5-tagged plasmids encoding mouse 
PSMD14, human HDAC6, and human USP5, and the BioID fusion plasmids 
encoding human USP5 exon 15 long were generated by PCR amplification in house.  
Generation of PSMD14-GFP 
PCR amplification of the mouse Psmd14-GFP ORF was performed with the Psmd14-
GFP-for and Psmd14-GFP-rev primers. The final PSMD14-GFP vector was generated 
by 3-piece ligation of the Psmd14 amplicon (restriction sites: PacI and XhoI) and PCR 
amplified eGFP (restriction sites: XhoI and AscI) inserts into the modified pPyCAG-
IP backbone vector (restriction sites: PacI and AscI). 
Generation of PSMD14-V5 
V5-tagged PSMD14 was generated by PCR amplification of the mouse Psmd14-V5 
ORF with the Psmd14-V5-for and Psmd14-V5-rev primer. PCR amplified Psmd14-V5 
(restriction sites: PacI and XhoI) was inserted into the modified pPyCAG-IP 
backbone vector (restriction sites: PacI and AscI).  
Generation of HDAC6-GFP 
PCR amplification of the human Hdac6 ORF was performed using the Hdac6-GFP-
for and Hdac6-GFP-rev primers. The final HDAC6-GFP vector was generated by 3-
piece ligation of the PCR amplified Hdac6 (restriction sites: PacI and SalI) and eGFP 
(restrictions sites: XhoI and AscI) inserts into the modified pPyCAG-IP backbone 
vector (restriction sites: PacI and AscI).  
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Generation of USP5-GFP 
GFP-tagged USP5 was generated by PCR amplification of human USP5 ORF using 
the with USP5-N-fusion-for and USP5-N-Fusion-rev primer, followed by 3-piece ligation 
of the hsUSP5 amplicon (restriction sites: XhoI and AscI) together with eGFP 
(restriction sites: PacI and XhoI) into the modified pPyCAG-IP (restriction sites: PacI 
and AscI) backbone vector. 
Generation of USP5-BirA*(R118G)-HA 
The final hsUSP5-BirA(R118G)*-HA-tagged BioID fusion plasmid was generated by 
PCR amplification of the human USP5 ORF, encoding hsUSP5 exon 15 long, using 
the following primer combination hsUSP5-C-Fusion-for and hsUSP5-C-Fusion-rev. The 
BirA*(R118G)-HA fusion plasmid was PCR amplified by BirA-HA-for and BirA-HA-
rev using the pcDNA3.1 MCS-BirA*(R118G)-HA plasmid, which was provided by 
Addgene. A 3-piece ligation of the PCR amplified BirA*(R118G)-HA (restriction site: 
PacI and XhoI) and hsUSP5 (restriction site: XhoI and AscI) into the modified 
pPyCAG-IP backbone vector (restriction sites: PacI and AscI) resulted in generation 
of the final hsUSP5-BirA*(R118G)-HA vector.  
Generation of Myc-BirA(R118G)*-USP5 
The corresponding Myc-BirA*(R118G) tagged fusion plasmid was generated in a 
similar manner. First, human USP5 ORF was PCR amplified using hsUSP5-N-Fusion-
for and hsUSP5-N-Fusion-rev. The Myc-BirA*(R118G) fusion plasmid was PCR 
amplified by Myc-BirA-for and Myc-BirA-rev using pcDNA3.1 mycBirA* plasmid, 
which was provided by Addgene. The final Myc-BirA*(R118G)-hsUSP5 vector was 
generated by 3-piece ligation of PCR amplified Myc-BirA*(R118G) (restriction site: 
XhoI and AscI) and hsUSP5 (restriction site: PacI and XhoI) inserts into the modified 
pPyCAG-IP backbone vector (restriction sites: PacI and AscI). 
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Transfection and immunoprecipitation  
Subconfluent HEK293 cells, cultured in 100-mm cell culture dishes under humified 
atmosphere at 37 °C and 5 % CO2, were transiently transfected with 6 µg of individual 
plasmid DNA using TurboFect transfection reagent, as implemented by the 
manufacturer’s instructions. 24 h post-transfection, HEK293 cells were lysed in ice-
cold RIPA buffer, supplemented with protease inhibitors and PMSF, sonicated for 
20 secs at cycle 3, power 80 % and incubated on a rotating wheel for a minimum of 
30 min at 4 °C. Thereafter, homogenates were centrifuged at 14,000 rpm for 20 min 
at 4 °C, protein concentration was measured, and clarified cell lysates were further 
processed for immunoprecipitation.  
To precipitate V5-tagged USPs, a total amount of 1 mg mL-1 of the clarified cell lysates 
were incubated with 40 µg of anti-V5 agarose conjugated beads on a rotating wheel 
for 90 min at 4 °C. Beads were washed 4-times in 1 x PBS and immunoprecipitated 
V5-tagged USP protein complexes were eluted by boiling agarose beads in 2 x 
NuPAGE LDS sample buffer for 5 min at 100 °C. In contrast, precipitation of GFP-
tagged hsUSP5 variants was assessed by incubating 1 mg mL-1 of the clarified cell 
lysates with 5 µg of either anti-GFP or anti-IgG on a rotating wheel for 75 min at 4 
°C. Afterwards, cell lysates were supplemented with 40 µg protein g sepharose 4 fast 
flow beads and allowed to rotate for additional for 60 min 4 °C. Beads were washed 
3-times in ice-cold RIPA buffer, supplemented with protease inhibitors and PMSF, 
and immunoprecipitated GFP-tagged hUSP5 protein complexes were eluted by 
boiling beads in 2 x NuPAGE LDS sample buffer for 3 min at 95 °C. Precipitated 
protein complexes were subjected to SDS-PAGE and analyzed by immunoblotting. 
Bio-ID analysis 
HEK293 cells were transiently transfected with BioID fusion proteins using 
TurboFect transfection reagent according to manufacturer’s instruction. 24 h post-
transfection, HEK293 cells were supplemented with 50 µmol L-1 biotin for a 
maximum of 18 h and subjected to stringent lysis in BioID lysis buffer as described 
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[127]. Cell lysates were triturated with 20 % Triton X-100, twice sonicated for 30 secs 
at cycle 5, power 30 %, and mixed with pre-chilled TriCl. After another sonication 
step, cell lysates were cleared by centrifugation at 16,500 x g for 10 min at 4 °C. 
Proximity dependent biotin affinity capture was performed by incubating   1 mg∙mL-
1 of clarified cell lysates with 40 µL of magnetic beads coated with streptavidin on a 
rotating wheel overnight at 4 °C. Streptavidin coated beads were twice washed in wash 
buffer 1, twice washed in wash buffer 2, and once washed in wash buffer 3. 
Biotinylated proteins were eluted by boiling streptavidin coated beads in 1 x 
NuPAGE® LDS sample buffer for 10 min at 98 °C, followed by SDS-PAGE, and in-
gel digestion coupled to LC-MS/MS to identify protein interaction partners in close 
proximity to hsUSP5. BioID analysis was performed using technical triplicates for 
each condition. 
Image acquisition and processing 
Stained cardiomyocytes, MEFs, and cardiac cryosections were analyzed using the 
Keyence BZ-9000 fluorescence microscope. All settings for laser excitation were kept 
constant between the different groups to ensure robust comparison of the 
immunofluorescence signal. Images were processed using software as BZ-II Analyzer, 
ImageJ/Fiji [128], and GIMP (Version 2.8). 
Statistical analysis 
Statistical analysis was performed by using the following two-tailed tests: (a) for two 
groups, we used unpaired t-test with Welch’s correlation, or Wilcoxon-rank sum test 
(Mann-Whitney U-test) for nonparametric datasets or heterogeneous variance of the 
data; (b) for three or more groups, we used one-way ANOVA and subsequent Holm-
Sidak’s multiple comparison test, or Kruskal-Wallis test and subsequent Dunn’s or 
Tukey’s multiple comparisons in case of missing normal distribution or 
heterogeneous variance of the dataset. Survival curve analysis was performed using 
Kaplan-Meier log-rank (Mentel-Cox) test.  
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All data are expressed as mean ± standard error (s.e.m.) and P-values less than 0.05 
were considered statistically significant. No statistical method was used to 
predetermine samples size. All analyses were based on neither randomization or 
blinding. No animals were excluded from statistical analysis. GraphPad Prism 
Software, Version 7 was used for all statistical analyses. 
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RESULTS  
USP5 interacts with components of the cellular PQC machinery  
Efficient function of PQC processes, especially ubiquitin-dependent proteolysis and 
(selective) autophagy, relies on disassembly of ubiquitin conjugates from targeted 
proteins for reutilization of ubiquitin moieties. Previous studies highlighted the 
importance of a PSMD14-driven release of free ubiquitin chains to be essential for 
sustained proteostasis by stimulating HDAC6-dependent autophagic clearance of 
ubiquitinated protein aggregates and aggresomes in conditions of insufficient or 
impaired proteasome activity [129]. Initial binding of ubiquitin conjugates is catalyzed 
by three DUBs: PSMD14, USP14/Ubp6, and UCH37/UCHL5. PSDM14, as an 
integral subunit of 19S RP of the 26S proteasome, is essential for the release of 
ubiquitin chains en bloc from targeted proteins prior to proteasomal degradation. In 
contrast, the two DUBs USP14/Ubp6 and UCH37/UCHL5 reversibly associate with 
the 19S RP of the 26S proteasome to assist in deubiquitination of ubiquitinated 
proteins. To investigate the principal role of DUBs in PQC and to explore whether 
additional DUBs are involved in the regulation of PQC processes, an unbiased screen 
was utilized to identify newly, yet not described ubiquitin-specific peptidases (USPs) 
collaborating with PSMD14 to regulate turnover and reutilization of ubiquitin 
molecules (Figure 15 A). The screen revealed that 11 of 40 tested USPs were present 
in complexes containing PSMD14 (Figure 15 B-D), among them USP5 (Figure 15 B-
D).  
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Figure 15 Screen for complex formation of ubiquitin-specific peptidases (USPs) with 
PSMD14. 
A. Workflow for co-immunoprecipitation (co-IP) of GFP-tagged mouse PSMD14 with a V5-tagged library 
of ubiquitin-specific peptidases (USPs) in HEK293 cells. B-D. Immunoblot analysis of anti-V5 precipitated 
cell lysates probed with anti-GFP and anti-V5 antibody. Input and IP fractions are shown. * USPs interacting 
with PSMD14. 
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The interaction of USP5 with PSMD14 was a surprise, since USP5 has yet not been 
described as a stable interaction partner of PSMD14 nor of the 19S RP of the 26S 
proteasome. In fact, USP5 is predominantly linked to assist in disassembly of free, 
unattached ubiquitin chains in vitro [130]. In this context, complex formation of 
PSMD14 with USP5 makes sense as USP5 can disassemble unanchored ubiquitin 
chains, released by PSMD14-mediated deubiquitination, to assist in maintaining of a 
stable ubiquitin pool.  
To further characterize the function of USP5 in PQC processes, proximity-dependent 
biotinylation and affinity purification (BioID) was utilized, which complements and 
extends co-immunoprecipitation techniques [127]. For this purpose, HEK293 cells 
were transiently transfected with Bio-ID fusion plasmids encoding human (hs) USP5 
fused in frame to an amino-terminal Myc- or carboxyl-terminal HA-tagged mutated 
biotin ligase BirA*(R118G). 24 h post-transfection, cells were supplemented with 50 
µmol L-1 biotin for additional 18 h and biotinylated proteins in close vicinity to the 
hsUSP5 BioID fusion proteins were affinity purified and subsequently identified by 
liquid chromatography-mass spectroscopy (LC-MS/MS) (Figure 16 A). Immunoblot 
analysis confirmed robustness of the BioID approach as the hsUSP5 BioID protein 
was affinity purified along with biotinylated proteins (Figure 16 B). In all conditions, 
HEK293 cells transiently transfected with either Myc- or HA-tagged BirA*(R118G) 
served as an appropriate control to minimize identification of false-positive hsUSP5 
interaction partners, which may arise from unspecific complex formation (Figure 16 
C). Immunoblot analysis confirmed robustness of the BioID approach as the hsUSP5 
BioID protein was affinity purified along with biotinylated proteins (Figure 16 B). In 
all conditions, HEK293 cells transiently transfected with either Myc- or HA-tagged 
BirA*(R118G) served as an appropriate control to minimize identification of false-
positive hsUSP5 interaction partners, which may arise from unspecific complex 
formation (Figure 16 C).  
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Figure 16 Proximity dependent biotinylation and affinity purification approach (BioID) to 
identify the interactome of hsUSP5 exon 15 long.  
A. Workflow for BioID analysis in HEK293 cells transfected with either Myc- or HA-tagged BioID-USP5 
fusion plasmid. Biotinylated endogenous proteins in close proximity to the fusion protein were isolated 
by affinity capture on streptavidin coated beads and identified by LC-MS/MS. B, C. Coomassie stained SDS 
gels after streptavidin pulldown (left) and immunoblot of biotinylated proteins (right). Input and biotin-IP 
fraction are shown. *, expressed fusion proteins.  
Dependent on the position of the tag, mass spectroscopy detected 4-times more 
biotinylated endogenous proteins in cells transfected with hsUSP5-BirA*(R118G)-
HA in comparison to Myc-BirA*(R118G)-hsUSP5 transfected cells (Figure 17 A-E). 
The list of putative interaction partners of hsUSP5 identified by mass spectroscopy 
comprises numerous ubiquitin-related proteins, including ubiquitin ligases (E3s), 
DUBs, and subunits of the 26S proteasome, in addition to components of the 
(selective) autophagy pathway (Figure 17 F). Importantly, all detected proteins 
differed by a log2 ratio > 1.0 and a -log10 P-value > 1.3 to control experiments using 
BirA*(R118G) transfected cells, demonstrating the specificity of the BioID approach.  
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Figure 17 BioID analysis of amino- and carboxyl-terminal tagged hsUSP5 exon 15 long.  
A, C. Scatter plots showing biotinylated proteins identified in triplicate experiments using either HA (A)- 
or Myc-tagged (C) hsUSP5 fusion proteins. B, D. Volcano plots showing hsUSP5 interaction partners. 
Proteins biotinylated by hsUSP5-BirA*(R118G) are depicted in blue, proteins labelled by BirA*(R118G) 
are shown in orange. Adjusted P-values based on the -log10 ratio (y-axis) are plotted against chances based 
on the log2 ratio (x-axis). E. Venn diagram showing the overlap between proteins identified by different 
hsUSP5 fusion proteins. F. Heat map depicting proteins biotinylated by hsUSP5-BirA*(R118G).  
Next, all identified proteins were categorized based on cellular processes and their 
localization within the cell, whereas statistical significance was given by the –log10 P-
value. The majority of detected proteins was involved in the regulation of cellular 
protein catabolic processes, including proteolysis, protein polyubiquitination, and 
protein deubiquitination (Figure 18 A), in addition to an enrichment in proteins 
connected to either the ubiquitin ligase complex or the proteasome complex (Figure 
18 B).  
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Figure 18 Enrichment analysis of hsUSP5 exon 15 long interactome.  
A, B. Box plots showing enriched GO terms of proteins biotinylated by hsUSP5long-BirA*(R118G). GO 
terms referring to molecular function (A) and cellular component (B) are shown. Significance was 
calculated based on the -log10 P-value. 
Although the BioID approach validated the association of hsUSP5 with components 
of UPS-dependent protein catabolic processes and (selective) autophagy, PSMD14 
was not detected as a putative interaction partner, which might be due to technical 
reasons. Alternatively, it might indicate that complexes containing PSMD14 and 
USP5 only form transiently. Nevertheless, the data clearly demonstrate the overall 
importance of USP5 in the regulation of processes of the UPS, which is instrumental 
for cellular protein homeostasis.  
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Cardiomyocytes express a non-spliced variant of USP5 that is 
recruited to protein aggregates in response to proteasomal stress  
Izaguirre et al. showed USP5 to undergo a PTBP1-dependent differential splicing 
event at the genomic locus of exon 15 [131]. Splicing results in the formation of an 
exon 15 short isoform lacking 23 amino acids due to an alternative splice acceptor at 
the carboxyl-terminus of exon 15 (Figure 19 A, B). Exon 15 short isoform was 
reported to enhance cell growth and migration, while the exon 15 long isoform is 
associated with arrest of cell proliferation and migration in glioblastoma cells. As 
differential spliced variants of USP5 have solely been described in glioblastoma cells, 
the questions arose whether the two USP5 isoforms may also exist in other tissues 
and cells. 
 
Figure 19 Usp5 undergoes differential splicing at exon 15.  
A, B. Scheme depicting alternative spliced transcripts of mouse Usp5, encoding for an 858 amino acid long 
isoform (A), or an 835 amino acid short isoform (B), respectively. Alternative spliced part of exon 15 is 
depicted in a yellow box. ZnF-UBP, zinc-finger ubiquitin binding domain; UCH, ubiquitin carboxyl-terminal 
hydrolase domain; UBA, ubiquitin-binding associated domain; E15, exon 15; UBA, ubiquitin-associated 
domain. 
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To explore which USP5 isoform is present in a variety of mouse organs, semi-
quantitative reverse transcription PCR (sqRT-PCR) was performed with primers 
specifically detecting Usp5 exon 15 (Figure 20 A, B). sqRT-PCR detected the exon 15 
long isoform in organs containing large amounts of postmitotic cells prone to protein 
aggregation, such as the brain, heart, and skeletal muscles (e.g. Soleus, EDL), while 
the corresponding exon 15 short isoform was broadly expressed (Figure 20 C).  
 
Figure 20 Usp5 undergoes tissue-specific differential splicing.  
A, B. Scheme depicting alternative spliced transcripts of mouse Usp5 exon 15. Arrows indicate the location 
of primers used for semi-quantitative RT-PCR. Usp5 spliced transcripts differ by 69 bp (23 aa) at the C-
terminus of exon 15. (C) Splice variants of mouse Usp5 in different tissues assessed by semi-quantitative 
RT-PCR.  
To evaluate the splicing event in a more cell-type specific manner and with regards to 
postmitotic - versus proliferative cells, sqRT-PCR was performed with primary 
cardiomyocytes isolated at different developmental stages and mouse embryonic 
fibroblasts (MEFs) (Figure 21 A-D). Interestingly, adult cardiomyocytes, which lack 
self-renewal capacity, solely expressed the exon 15 long isoform, while primary 
cardiomyocytes isolated at E13.5 showed similar expression of both isoforms. Fetal 
cardiomyocytes isolated at juvenile stage generated both isoform with a shift towards 
expression of the exon 15 long isoform (Figure 21 A).   
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On the other hand, non-cardiomyocytes isolated from adult hearts and MEFs 
generated only the short isoform (Figure 21 B). Taken together, these findings 
indicate that alternative splicing of USP5 is restricted to proliferative cells as 
postmitotic cells lack the splicing event. 
 
Figure 21 Usp5 undergoes cell-type specific differential splicing. 
A. Splice variants of mouse Usp5 in isolated cardiomyocytes at different developmental stages and adult 
non-cardiomyocytes. B. Splice variants of mouse Usp5 in mouse embryonic fibroblasts (MEFs).  
Reciprocal co-immunoprecipitations (co-IPs) were performed to investigate exon 15 
isoform-specific differences of USP5 regarding protein complex formation with 
PSMD14 (Figure 22 A). I found that alternative splicing of USP5 had no impact on 
binding affinity towards PSMD14 (Figure 22 B, C). These results corroborate the 
previous results that USP5 and PSMD14 are part of the same protein complex. In 
addition, both exon 15 isoforms were able to interact with the deacetylase HDAC6 
(Figure 23 A-C), which is another crucial component of PQC, especially under stress 
conditions. HDAC6-restricted binding to free ubiquitin chains that are released en bloc 
by PSMD14-mediated deubiquitination promotes concentration and selective 
autophagy-dependent clearance of protein aggregates in cells with compromised 
proteasome activity [71, 129, 132].  
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Figure 22 USP5 co-immunoprecipitates with components of cellular PQC – PSMD14.  
A. Workflow for co-immunoprecipitation (co-IP) of GFP-tagged human isoforms of USP5 with V5-tagged 
mouse PSMD14 in HEK293 cells. B. Immunoblot analysis of anti-GFP precipitated cell lysates probed with 
anti-V5 and anti-GFP antibody. Input and IP fractions are shown. C. Immunoblot analysis of anti-GFP and 
IgG precipitated cell lysates probed with anti-V5 and anti-USP5 antibody. Input and IP fractions are shown. 
 
Figure 23 USP5 co-immunoprecipitates with components of cellular PQC – HDAC6.  
A. Workflow for co-immunoprecipitation of GFP-tagged human isoforms of USP5 with V5-tagged human 
HDAC6 in HEK293 cells. B. Immunoblot analysis of anti-GFP precipitated cell lysates probed with anti-V5 
and anti-GFP antibody. Input and IP fractions are shown. C. Immunoblot analysis of anti-GFP and IgG 
precipitated cell lysates probed with anti-V5 and anti-USP5 antibody. Input and IP fractions are shown. 
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As the previous results suggested that USP5 plays a role in the regulation of PQC 
processes, the cellular localization of USP5 in conditions of elevated proteostatic 
stress, causing formation of potentially toxic protein aggregates, was analyzed. 
Accumulation of misfolded proteins, resulting from genetic mutations, ineffective 
refolding by molecular chaperones, defective protein maturation, failure in protein 
catabolic processes, or environmental stress, is known to cause formation of large 
protein aggregates [133]. Once formed, these large protein aggregates often become 
toxic, since they are not removed by proteolytic degradation via the 26S proteasome 
and thus interfere with cellular homeostasis and proteostasis. To induce proteostatic 
stress in mature cardiomyocytes and MEFs, proteasome activity was inhibited by 
administration of MG132 for 4 h, which caused accumulation of protein aggregates 
and formation of large aggresomes that were visualized by the immunofluorescence-
based PROTEOSTAT® aggregation assay (Figure 24 A, B). The PROTEOSTAT® 
aggregation assay is based on a fluorophore coupled dye that binds covalently and 
irreversibly to hydrophobic surfaces of misfolded proteins, causing emission of a red 
fluorescent signal that can be detected by immunofluorescence-based microscopy 
[126]. 
 
Figure 24 USP5 co-localizes with aggresomes in response to proteostatic stress.  
A, B. Immunofluorescence staining of USP5 (green), aggresomes (magenta), and nuclei (DAPI, blue) in 
isolated mature cardiomyocytes (A) and MEFs (B). Cells were treated with 0.2 % DMSO or 10 µmol L-1 
MG132 for 4 h to induce aberrant protein aggregation and aggresome formation. 
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Remarkably, USP5 co-localized with protein aggregates and aggresomes in mature 
cardiomyocytes and MEFs, concomitant with enhanced USP5 staining intensity in 
response to proteostatic stress (Figure 24 A, B). Collectively, these data emphasize an 
important role of USP5 in the regulation of cellular PQC processes to maintain 
proteostasis, probably by handling of free, unanchored polyubiquitin chains provided 
by PSMD14-mediated deubiquitination. 
Isoform- and cell-type specific role of USP5 in the maintenance of 
ubiquitin pools  
As the physiological role of USP5, especially in the cardiovascular system, had not 
been studied, the aim of the study was to recapitulate possible consequences arising 
from loss of USP5 in a cell-type and isoform specific manner. For this purpose, Usp5 
flox/flox mice, carrying a conditionally inactive allele of Usp5, were generated. 
Infection of MEFs derived from homozygous Usp5 flox/flox mice with an adenovirus 
expressing a codon improved cre-recombinase (hereafter called: Ad-Cre) for 6 h 
resulted in efficient recombination reducing USP5 protein levels by approximately 90 
% six days after virus transduction. Homozygous Usp5 flox/flox infected with an 
empty adenovirus (hereafter called: Ad-Null) served as controls (Figure 25 A-D). 
Immunoblot analysis of Ad-Cre infected MEFs did not show dramatic changes in the 
ubiquitin levels compared to MEFs transfected with Ad-Null (Figure 26 A, B), despite 
a moderate accumulation of polyubiquitin chains and polyubiquitinated proteins 
(Figure 26 C).  
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Figure 25 Inactivation of Usp5 in MEFs via adenoviral transduction.  
A. Strategy for Usp5 gene inactivation in MEFs via adenoviral transduction. MEFs were isolated from 
pregnant Usp 5flox/flox mice at E13.5 and after several passages; MEFs were infected with a recombinant 
adenovirus expressing an empty adenovirus (Ad-Null) or a codon improved cre-recombinase (Ad-Cre) 
for 6h. Analysis was performed six days after virus transduction. B. Quantification of Usp5 mRNA levels 
in Usp5 flox/flox MEFs six days after virus transduction. Values were normalized to gapdh mRNA levels. n 
= 6 for each group. Two-tailed unpaired Wilcoxon-rank sum test. ** P < 0.0021. C, D. USP5 protein levels 
(D) and quantification (C) in Ad-Null- or Ad-Cre transduced MEFs. Values were normalized to GAPDH 
protein levels. n = 6 for each group. Two-tailed unpaired Wilcoxon-rank sum test. ** P < 0.0021. 
 
Figure 26 Depletion of USP5 in MEFs via adenoviral transduction does not affect the 
ubiquitin pool.  
A. Immunoblot analysis of ubiquitin in MEFs six days after adenoviral transduction with a recombinant 
adenovirus expressing a codon improved cre-recombinase (Ad-Cre) or an empty adenovirus (Ad-Null) 
for 6h. B, C. Quantification of ubiquitin levels (B) and ubiquitin chains (C) in Ad-Cre and Ad-Null infected 
MEFs. Values were normalized to GAPDH protein expression. n = 6 per group.  
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I also generated homozygous Rosa26-CreERT2//Usp5 flox/flox mice to delete Usp5 in 
MEFs after treatment with 4-hydroxytamoxifen (hereafter called Usp5iKO) (Figure 27 
A). 48 h after treatment with 10 µmol L-1 4-hydroxytamoxifen (4-OHT), USP5 
protein levels in Usp5iKO MEFs were reduced by approximately 50-65 % in 
comparison to 4-OHT-treated Usp5 flox/flox MEFs (Figure 27 B-D).  
 
Figure 27 4-Hydroxytamoxifen (4-OHT) induced inactivation of Usp5 in MEFs. 
A. Strategy for depletion of Usp5 in MEFs. Usp5flox/flox mice were crossbred with mice harboring a 
conditional Rosa26-CreERT2 (Cre recombinase – estrogen receptor T2) transgene, by which the ERT2 
moiety retains the cre recombinase until 4-hydroxytamoxifen (4-OHT) administration releases this 
inhibiting effect. MEFs were isolated from pregnant mice at E13.5 and after several passages, cells were 
treated with 4-OHT for 48 h to induce recombination and depletion of Usp5. B. Quantification of Usp5 
mRNA levels in MEFs from Usp5iKO (CreERT2+/-//Usp5flox/flox) and Usp5 flox/flox control littermates 48 h 
after 4-OHT administration. In addition, MEFs were treated with 0.2 % DMSO or 10 µmol L-1 MG132 for 
6 h before RNA was extracted. Values were normalized to gapdh mRNA levels. n = 4 for each genotype. 
C, D. USP5 protein levels (D) and quantification (C) in MEFs with or without MG132 treatment after 4-
OHT-induced depletion of Usp5. Values were normalized to GAPDH protein levels. n = 4 for each 
genotype. One-way ANOVA followed by Dunn’s post-test. * P < 0.05. 
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Although recombination efficacy was lower compared to Ad-Cre infected Usp5 
flox/flox MEFs, I detected the same moderate increase in polyubiquitin levels and 
levels of polyubiquitinated proteins, even in MG132-treated Usp5 flox/flox MEFs after 
4-OHT administration (Figure 28 A-C). USP5 protein levels were not affected by 
MG132-mediated inactivation of the 20S proteasome activity (Figure 28 C, D). These 
data show that already a moderate reduction of USP5 in MEFs impacts ubiquitin 
levels, particularly in the high molecular weight range.  
 
Figure 28 4-OHT-induced inactivation of Usp5 in MEFs does not change the ubiquitin pool.  
A. Immunoblot analysis of ubiquitin levels in Usp5iKO and Usp5iKO MEFs with or without MG132 
treatment after 4-OHT-induced depletion of Usp5. B, C. Quantification of ubiquitin levels (B) and ubiquitin 
chains (C) relative to GAPDH expression. n = 4 for each group.  
In a second approach, Usp5 flox/flox mice were crossbred with the Myh6-MerCreMer 
transgenic mouse strain to generate homozygous Myh6-MerCreMer//Usp5 flox/flox 
mice (hereafter called Usp5cKO), which enabled conditional inactivation of Usp5 in 
postmitotic, protein aggregation prone mature cardiomyocytes by administration of 
tamoxifen. Administration of 100 mg kg-1 tamoxifen intraperitoneal (i.p.) to P56 old 
male mice for seven consecutive days and subsequent isolation of cardiomyocytes 15 
days after the last tamoxifen doses at P78 resulted in reduction of USP5 protein levels 
by approximately 95 % (Figure 29 A-D).  
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Figure 29 Tamoxifen-induced inactivation of Usp5 in mature cardiomyocytes.  
A. Strategy for ablation of Usp5 in postmitotic, mature cardiomyocytes. Usp5 flox/flox mice were crossbred 
with mice expressing a tamoxifen-inducible Myh6-MerCreMer transgene. P56 old male mice were injected 
with 100 mg kg-1 tamoxifen for seven consecutive days and cardiomyocytes were isolated 15 days post-
infection (= P78). B. Quantification of Usp5 mRNA levels in isolated cardiomyocytes from Usp5cKO (Myh6-
MerCreMer//Usp5 flox/flox) mice and Usp5 flox/flox control littermates at P78. Values were normalized to 
gapdh mRNA levels. n = 8 for each genotype. Unpaired t-test with Welch’s correlation. **** P < 0.0001. 
C, D. USP5 protein levels (D) and quantification (C) in isolated cardiomyocytes from Usp5cKO mice and 
Usp5flox/flox control littermates at P78. Values were normalized to GAPDH protein levels. n = 4 for each 
genotype. Unpaired t-test with Welch’s correlation. * P < 0.05. 
In contrast to MEFs, inactivation of Usp5 in mature cardiomyocytes resulted in 
increased ubiquitin levels (Figure 30 A, B), primarily resulting from elevated poly- but 
also monoubiquitin (Figure 30 C). Treatment of cardiomyocytes from Usp5 flox/flox 
control littermates with MG132 yielded results similar to those observed in MG132-
treated Usp5 flox/flox MEFs, including elevated levels of ubiquitin particularly in the 
high molecular weight range, while the levels of monoubiquitin remained unchanged 
(Figure 30 D-F). Treatment of USP5-deficient cardiomyocytes (Usp5cKO) with 
MG132 did not further increase (poly-) ubiquitin levels in comparison to untreated 
USP5-deficient cardiomyocytes (Figure 30 F). Importantly, effects on ubiquitin levels 
were stronger in Usp5cKO cardiomyocytes compared to ubiquitin levels Usp5iKO 
MEFs. Collectively, these data point towards an instrumental role for USP5 in 
maintaining robust polyubiquitin levels in mature cardiomyocytes, since its 
inactivation affects both mono- and polyubiquitin levels substantially. These findings 
further indicate that inactivation of Usp5 in mature cardiomyocytes may be sufficient 
to completely disrupt proteasome activity.  
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Figure 30 Inactivation of USP5 in mature cardiomyocytes causes accumulation of ubiquitin.  
A. Immunoblot analysis of ubiquitin levels in isolated mature cardiomyocytes from Usp5 flox/flox and 
Usp5cKO mice 15 days after the last tamoxifen administration. B. Quantification of ubiquitin levels relative 
to GAPDH protein expression. n = 6 in Usp5 flox/flox, n = 7 in Usp5cKO. Two-tailed unpaired t-test with 
Welch’s correlation. * P < 0.05. C. Quantification of ubiquitin chains relative to GAPDH protein 
expression. n = 4 for each group. Two-tailed unpaired t-test with Welch’s correlation. * P < 0.05, ** P < 
0.0021. D. Immunoblot analysis of ubiquitin levels in cardiomyocytes from Usp5 flox/flox and Usp5cKO mice 
15 days after the last tamoxifen administration and with (n = 3 for each group) or without (n = 9 for each 
group) MG132 treatment. E. Quantification of ubiquitin levels relative to GAPDH between the groups. 
One-way ANOVA followed by Tukey’s post-test. * P < 0.05. F. Quantification of ubiquitin chains relative 
to GAPDH between the groups. One-way ANOVA followed by Dunn’s and Tukey’s post-test. * P < 0.05; 
** P < 0.0021; *** P < 0.002; **** P < 0.0001. 
Consistent with an active recruitment of USP5 to sites of atypical protein aggregation 
and increased USP5 staining intensity in MG132-treated cardiomyocytes (Figure 24 
A, B), USP5 protein levels were drastically elevated in MG132-treated Usp5 flox/flox 
cardiomyocytes, while USP5 protein levels remained constantly reduced by 95 % in 
cardiomyocytes isolated from Usp5cKO mice (Figure 31 A, B).   
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These data further support a crucial role of USP5 in the cellular PQC response to 
proteotoxic stress, in addition to its already reported role to maintain the ubiquitin 
pool. In this regard, mature cardiomyocytes seem to specifically rely on sufficient 
USP5 levels and USP5-dependent ubiquitin homeostasis.  
 
Figure 31 USP5 protein levels increases in response to proteostatic stress.  
A. USP5 protein levels in isolated cardiomyocytes 15 days after the last tamoxifen administration and with 
(n = 3 for each group) or without (n = 9 for each group) MG132 treatment. B. Quantification of USP5 
protein levels relative to GAPDH protein expression. One-way ANOVA followed by Turkey’s post-test. 
*** P < 0.0002; **** P < 0.0001. 
USP5-deficient cardiomyocytes display reduced 20S proteasome 
activity  
Inactivation of Usp5 in mature cardiomyocytes resulted in elevated ubiquitin levels, 
predominantly in the high molecular weight range, reflecting either polyubiquitin 
chains or polyubiquitinated proteins. Aberrant accumulation of ubiquitin-enriched 
protein aggregates is known to impair proteasome activity both in vitro and in vivo. 
Since accumulation of free, protein unattached ubiquitin chains competitively inhibit 
proteasome activity in vitro in response to loss of USP5 [56, 130, 134], the evident 
question was whether inactivation of Usp5 alone was sufficient to disrupt activity of 
the 20S proteasome. A fluorescence-based kinetic assay [35] was used to specifically 
assess the proteolytic capability of the 20S proteasome in cell extracts of MEFs and 
isolated mature cardiomyocytes. To guarantee robustness of the results and to 
increase the sensibility of the assay, MG132-treated control groups were included.  
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Consistent with the only moderate increase in ubiquitin levels, inactivation of Usp5 in 
MEFs by 4-OHT administration did not impair any of the three peptidase activities 
of the 20S proteasome (Figure 32 A-C). In fact, Usp5iKO MEFs showed slightly 
enhanced caspase- and chymotrypsin-like peptidase activities, while administration of 
MG132 almost completely blocked these two peptidase activities both in MEFs from 
Usp5 flox/flox and Usp5iKO mice (Figure 32 A, C). On the other hand, inactivation of 
Usp5 in Usp5 flox/flox MEFs by adenoviral infection (Ad-Cre) slightly decreased 
caspase- and chymotrypsin-like peptidase activities, while MG132 administration 
resulted in almost complete inhibition (Figure 32 D, F). 
 
Figure 32 Inactivation of Usp5 in MEFs does not affect 20S proteasome activities. 
A-C. Quantification of proteasomal caspase-like activity by Z-Leu-Leu-Glu-AMC digestion (A), 
proteasomal trypsin-like activity by Boc-Leu-Arg-Arg-AMC digestion (B), and chymotrypsin-like activity 
by Suc-Leu-Leu-Val-Tyr-AMC digestion (C) in Usp5 flox/flox and Usp5iKO MEFs treated with (n = 4 for 
Usp5flox/flox, n = 3 Usp5iKO) and without (n = 5 for each group) MG132 after 4-OHT administration. D-
F. Quantification of proteasomal caspase-like activity by Z-Leu-Leu-Glu-AMC digestion (D), proteasomal 
trypsin-like activity by Boc-Leu-Arg-Arg-AMC digestion (E), and chymotrypsin-like activity by Suc-Leu-
Leu-Val-Tyr-AMC digestion (F) in MEFs treated with (n = 6 for each group) and without (n = 6 for each 
group) MG132 after infection with Ad-Null or Ad-Cre. One-way ANOVA followed by Sidak’s post-test. 
* P < 0.005. 
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In stark contrast, inactivation of Usp5 in cardiomyocytes strongly suppressed all three 
peptidase activities of the 20S proteasome, comparable to inactivation of the 20S 
proteasome by MG132 treatment (Figure 33 A-C). These data not only support the 
high sensitivity of the assay, but also argue for defective proteolysis in USP5-deficient 
cardiomyocytes, possibly in response to inappropriate ubiquitin levels. 
 
Figure 33 Impaired proteasome peptidase activities in USP5-deficient cardiomyocytes. 
A-C. Quantification of proteasomal caspase-like activity by Z-Leu-Leu-Glu-AMC digestion (A), 
proteasomal trypsin-like activity by Boc-Leu-Arg-Arg-AMC digestion (B), and chymotrypsin-like activity 
by Suc-Leu-Leu-Val-Tyr-AMC digestion (C) in isolated cardiomyocytes from Usp5 flox/flox and Usp5cKO 
mice 15 days after the last tamoxifen administration. Cardiomyocytes were treated with (n = 4 for each 
group) and without (n = 6 for each group) MG132. One-way ANOVA followed by Dunn’s post-test (B) 
or Tukey’s post-text (C). * P < 0.005; ** P < 0.0021. 
In addition to the total increase in ubiquitin levels in USP5-deficient cardiomyocytes, 
immunoblot analysis revealed elevated levels of Lys48- and Lys63-linkage specific 
ubiquitin, again predominantly in the high molecular weight range (Figure 34 A-D). 
These findings suggest that diminished proteasome activity and consequently 
impaired ubiquitin-dependent proteolysis potentially in combination with failure in 
(selective) autophagy disturbs proteostasis in cardiomyocytes in response to 
inactivation of Usp5. Moreover, the data strengthens the importance of USP5 in 
maintaining normal ubiquitin levels, which are essential for sustained ubiquitin-
dependent proteolysis in cardiomyocytes.  
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Figure 34 Elevated levels of Lys48- and Lys63-linkage specific ubiquitin in cardiomyocytes 
lacking USP5. 
A. Immunoblot analysis of Lys48-linkage specific ubiquitin in isolated cardiomyocytes from Usp5 flox/flox 
and Usp5cKO mice and B. quantification relative to GAPDH expression. n = 3 for each group. Two-tailed 
unpaired t-test with Welch’s correlation. * P < 0.05. C. Immunoblot analysis of Lys63-linkage specific 
ubiquitin in isolated cardiomyocytes from Usp5flox/flox and Usp5cKO mice and D. quantification relative to 
GAPDH expression. n = 3 for Usp5flox/flox, n = 4 for Usp5cKO 
USP5-deficient cardiomyocytes accumulate ubiquitin-enriched 
protein aggregates 
Since forced inactivation of proteasome activity by MG132 resulted in accumulation 
of USP5-containing misfolded proteins to mainly perinuclear aggresomes (Figure 24 
A, B), one might argue that the observed suppression of all three peptidase activities 
of the 20S proteasome in combination with elevated levels of Lys48-linkage specific 
ubiquitin might be sufficient to evoke aberrant protein aggregation in USP5-deficient 
cardiomyocytes but not in USP5-deficient MEFs. To verify this hypothesis, the 
PROTEOSTAT® aggregation assay in combination with immunofluorescence 
staining was used to visualize any ubiquitin-enriched protein aggregates and 
aggresomes. Unexpectedly, Usp5iKO MEFs accumulated large perinuclear 
aggresomes, comparable to Usp5 flox/flox MEFs treated with MG132 (Figure 35 A, 
B). The majority of detected aggresomes in Usp5iKO MEFs contained ubiquitin, 
which argues for accumulation of ubiquitin-conjugated protein aggregates.   
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In contrast, aggresomes in Usp5 flox/flox MEFs were rarely conjugated with ubiquitin 
(Figure 35 C). However, forced inhibition of 20S proteasome activity in Usp5 flox/flox 
MEFs by MG132 treatment also resulted in accumulation of ubiquitin-conjugated 
aggresomes (Figure 35 D). 
 
Figure 35 Accumulation of ubiquitin-conjugated aggresomes in USP5-deficient MEFs.  
A, B. Immunofluorescence staining of aggresomes (magenta) and nuclei (DAPI, blue) in Usp5 flox/flox and 
Usp5iKO MEFs following administration of 4-OHT and treatment with DMSO or MG132 for 6 h. n = 3 for 
each group. Scale bars, 50 µm. C, D. Immunofluorescence staining of ubiquitin (green), aggresomes 
(magenta), and nuclei (DAPI, blue) in Usp5 flox/flox and Usp5iKO MEFs following administration of 4-OHT 
and treatment with DMSO (n = 2 for each group) or MG132 (n = 3 for each group) for 6 h. Scale bars, 
50 µm. 
  
RESULTS 
83 
Consistent with the hypothesis, inactivation of Usp5 in mature cardiomyocytes 
resulted in enhanced load of mainly perinuclear aggresomes (Figure 36 A), which co-
localized with large ubiquitin deposits (Figure 36 B). In summary, these findings 
suggest that accumulation of ubiquitin-conjugated protein aggregates and aggresomes 
in Usp5iKO MEFs might be caused by failure of selective autophagy rather than 
impaired proteasome activity, whereas both branches of cellular PQC – UPS-
dependent proteolysis and clearance of protein aggregates by selective autophagy – 
are impaired in cardiomyocytes in response to inactivation of Usp5.  
 
Figure 36 Accumulation of ubiquitin-containing aggresomes in USP5-deficient 
cardiomyocytes.  
A. Immunofluorescence staining for F-actin (green), aggresomes (magenta), and nuclei (DAPI, blue) in 
isolated cardiomyocytes from Usp5 flox/flox and Usp5cKO mice 15 days after the last tamoxifen 
administration. n = 4 for each group. Scale bars, 50 µm. B. Immunofluorescence staining of ubiquitin 
(green), aggresomes (magenta), and nuclei (DAPI, blue) in isolated cardiomyocytes from Usp5 flox/flox and 
Usp5cKO mice 15 days after the last tamoxifen administration. n = 4 for each group. Scale bars, 50 µm. 
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Profiling of USP5-deficient cardiomyocytes  
To gain deeper insights into the underlying mechanisms, we employed both RNA 
microarray-based transcriptional profiling and whole proteome analysis of USP5-
deficient cardiomyocytes compared to isolated cardiomyocytes from Usp5 flox/flox 
control littermates (Figure 37-41).  
 
Figure 37 Transcriptional profiling of USP5-deficient cardiomyocytes.  
A. Graph bar showing total the total number of up- (yellow, log2 > 1.0, P < 0.05) and down-regulated 
(black, log2 > -1.0, P < 0.05) genes in cardiomyocytes from Usp5 flox/flox and Usp5cKO mice 15 days after 
the last tamoxifen administration. B. Heat map showing differences in expression of ubiquitin-related genes 
based on fold chances (FC). C, D. Box plots showing significantly enriched GO terms of differentially 
expressed genes based on -log10 P-values. GO terms refer to molecular function (C) and cellular 
components (D). 
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Microarray analysis revealed substantial changes in the expression of 229 genes. Half 
of the deregulated genes were either up- or down-regulated in response to Usp5 
inactivation in cardiomyocytes (Figure 37 A). The majority of differentially expressed 
genes encode ubiquitin-related proteins, including various ubiquitin ligases, DUBs, or 
components of the 26S proteasome (Figure 37 B). GO term analysis showed that 
strongest differentially expressed genes are structural components of the cytoskeleton 
or the 19S proteasome. In line with the enrichment analysis, most dysregulated genes 
play important roles in polyubiquitin binding and regulation of the ATPase activity, 
which is crucial for activation of proteasome-dependent catabolic processes (Figure 
37 C, D). Interestingly, microarray analysis also revealed strong changes in the 
expression of the mouse polyUbs Ubb and Ubc (Figure 37 C). RT-qPCR analysis using 
gene-specific TaqMan probes confirmed a 2- to 2.5-fold increase in the mRNA levels 
of Ubb and Ubc in cardiomyocytes of Usp5cKO mice (Figure 38 A). Inhibition of 20S 
proteasome activity by MG132 treatment of isolated cardiomyocytes from Usp5 
flox/flox mice resulted in increased transcription of Ubb and Ubc similar to inactivation 
of Usp5 in cardiomyocytes (Figure 38 A).  
 
Figure 38 Upregulation of polyUbs in USP5-deficient cardiomyocytes.  
A, B. RT-qPCR analysis of polyUbs (A) and Ub-RPs (B) expression in cardiomyocytes from Usp5 flox/flox 
and Usp5cKO mice 15 days after the last tamoxifen administration. Cardiomyocytes were treated with 0.2 
% DMSO (n = 8) or 10 µmol L-1 MG132 (n = 3 for Usp5 flox/flox, n = 4 for Usp5cKO) for 4 h. Values were 
normalized to gapdh expression. One-way ANOVA followed by Dunn’s post-test. * P < 0.05; ** P < 0.0021; 
*** P < 0.0002. 
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MG132 treatment did not further enhance transcription of Ubb and Ubc in USP5-
deficient cardiomyocytes, suggesting that derailed proteasome activity in response to 
inactivation of Usp5 in cardiomyocytes correlates with transcriptional changes in the 
expression of polyUbs, which argues for an enhanced ubiquitin stress response. In 
contrast, no changes in the mRNA levels of the two Ub-RPs Uba52a or Rps27a in 
USP5-deficient cardiomyocytes were detected, even after treatment with MG132 
(Figure 38 B). In addition to the observed transcriptional changes in polyUbs and 
ubiquitin-associated genes, mRNA levels of several cardiac stress-response genes, 
such as Nppa, Myh7, Acta1, Fbxo32, and Uchl1 were substantially upregulated in 
cardiomyocytes from Usp5cKO mice (Figure 39 A). RT-qPCR analysis confirmed 
increased expression of the indicated genes in addition to decreased mRNA levels of 
Myc (Figure 39 B).  
 
Figure 39 Upregulation of cardiac stress response genes in USP5-deficient cardiomyocytes.  
A. Heat map showing most significantly changed transcripts in USP5-deficient cardiomyocytes versus 
cardiomyocytes isolated from Usp5 flox/flox control littermates based on fold chances (FC). B. RT-qPCR 
analysis of differentially expressed genes. Values were normalized to gapdh mRNA expression. n = 8 for 
each group. Two-tailed unpaired t-test with Welch’s correlation or Wilcoxon-rank sum test. * P < 0.05; 
** P < 0.0021; *** P < 0.0002; **** P < 0.0001. 
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Comprehensive whole proteome analysis by LFQ mass spectroscopy of USP5-
deficient cardiomyocytes identified 186 dysregulated proteins with mostly ubiquitin-
associated proteins (Figure 40 A, B). Enrichment analysis of the altered proteome 
revealed USP5-dependent changes of proteins forming the proteasome or ubiquitin 
ligase complexes (Figure 40 C). The majority of identified proteins with significantly 
different LFQ intensities are important for the regulation of protein catabolic 
processes, including proteolysis (Figure 40 D). 
 
Figure 40 Whole proteome analysis of USP5-deficient cardiomyocytes.  
A. Graph bar showing the total number of up- (yellow, log2 > 1.0, P < 0.05) and down-regulated (black, 
log2 > -1.0, P < 0.05) proteins in isolated cardiomyocytes from Usp5 flox/flox and Usp5cKO mice 15 days 
after the last tamoxifen administration. B. Heat map showing differences in LFQ-intensities of ubiquitin-
related proteins. C, D. Box plots representing enriched GO terms of differentially expressed proteins 
based on the -log10 P-values. GO terms refer to cellular components (C) and biological processes (D). 
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Since whole proteome analysis identified dysregulation of several subunits of the 26S 
proteasome in response to inactivation of Usp5 in cardiomyocytes, immunoblot 
analysis was performed to validate the changes. Indeed, immunoblot analysis revealed 
substantial changes in the expression of subunits mainly forming the accessory 
complex of the 19S proteasome, including PSMD12, PSMD11, PSMC3, and PSMC4 
(Figure 41 A-C). The ‘–omics’ data show that loss of USP5 in cardiomyocytes results 
in enhanced ubiquitin stress response and altered composition of mainly the 19S 
regulatory particle of the proteasome, both affecting proteolysis of proteins involved 
in catabolic processes.  
 
Figure 41 Altered proteasome composition in USP5-deficient cardiomyocytes.  
A, B. Immunoblot analysis of indicated subunits of the 19S- and 20S proteasome in cardiomyocytes from 
Usp5 flox/flox and Usp5cKO mice 15 days after the last tamoxifen administration. C. Quantification of 
proteins levels relative to GAPDH protein levels. n = 3 for reach group. Two-tailed unpaired t-test with 
Welch’s correlation or Wilcoxon-rank sum test. * P < 0.05.  
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Cardiac-restricted inactivation of USP5 causes DCM and early 
lethality  
Since mature cardiomyocytes display a very limited self-renewal capacity, I explored 
potential consequences arising from altered ubiquitin pools, impaired UPS-dependent 
catabolic processes, altered proteasome composition, and accumulation of mainly 
ubiquitin-containing protein aggregates for cardiac function after inactivation of Usp5 
in cardiomyocytes. To this end, 100 mg kg-1 tamoxifen was administered for seven 
consecutive days to P56 male Usp5cKO and Usp5 flox/flox mice. Kaplan-Meier survival 
analysis showed that all Usp5cKO mice but none of the Usp5 flox/flox control 
littermates died within 28 days post-tamoxifen injection, with the first Usp5cKO mice 
dying 23 days after the last tamoxifen administration (Figure 42 A).  
 
Figure 42 Increased lethality of Usp5cKO mice.  
A. Kaplan-Meier survival analysis of USp5cKO mice in comparison to Usp5 flox/flox mice after tamoxifen 
administration. The P-value of the Log-rank (Mental-Cox) test is depicted in the graph. B. Timeline for 
analysis of cardiomyocyte-specific knockout of Usp5. Usp5 flox/flox and Usp5cKO mice were injected with 
100 mg kg-1 tamoxifen for seven consecutive days at postnatal day (P) 56. Hearts and cardiomyocytes 
were isolated and analyzed 24-days after the last tamoxifen injection (= P87). C. Effects of cardiomyocyte-
restricted loss of Usp5 on body weight (BW), heart weight (HW), tibia length (TL), and heart weight to 
body weight (HW:BW), body weight to tibia length (BW:TL), or heart weight to tibia length ratios 
(HW:TL). n = 5 for each group. Two-tailed unpaired t-test with Welch’s correlation. * P < 0.05; **** P < 
0.0001. 
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Usp5cKO mice were subjected to a comprehensive phenotype analysis at P87 (25 days 
post-tamoxifen injection), which represents the median of the survival time (Figure 
42 B). Long-term inactivation of Usp5 in cardiomyocytes resulted in prominent weight 
loss, massive gain in heart weight, and consequently elevated heart weight to body 
weight (HW:BW) and heart weight to tibia length (HW:TL) ratios (Figure 42 C). 
Corresponding tibia lengths did not differ between the two groups, which indicate 
that changes in body weight and heart weight are not caused by growth problems of 
Usp5cKO mice (Figure 42 C). 
 
Figure 43 Loss of USP5 causes DCM.  
A, B. Images of dissected hearts (A) and H&E stained cross sections (B) from Usp5 flox/flox and Usp5cKO 
mice 24 days after the last tamoxifen administration. n = 4 for each group. Scale bars, 1000 µm. C. Analysis 
of myocardial wall thickness between the two groups. n = 4 for each group. Two-tailed unpaired 
Wilcoxon-rank sum test. **** P < 0.0001. D, E. Images showing H&E stained (D) and Masson’s trichrome 
stained (E) cross sections of the left ventricle from Usp5 flox/flox and Usp5cKO mice 24 days after the last 
tamoxifen administration. n = 4 for each group. Scale bars, 50 µm. Analysis of fibrotic collagen deposition 
in hearts from Usp5 flox/flox and Usp5cKO mice 24 days after the last tamoxifen administration. n = 4 for 
each group. Two-tailed unpaired t-test with Welch’s correlation. * P < 0.05. 
RESULTS 
91 
Consistent with the observed increase in heart weight, dissected hearts of Usp5cKO 
mice were larger in size. Macroscopic examination revealed immense enlargement of 
Usp5cKO ventricles and dilated atria with increased incidence of thrombus formation. 
H&E stained histological cross sections confirmed pathomorphological changes of 
Usp5cKO hearts in comparison to dissected hearts from Usp5 flox/flox control 
littermates (Figure 43 A, B), including substantial reduction of myocardial wall 
thickness in the left and right ventricle (Figure 43 C). H&E stained histological cross 
sections of Usp5cKO hearts uncovered changes in cardiomyocyte morphology and 
integrity (Figure 43 D), in addition to interstitial collagen deposition (Figure 43 E, F). 
Analysis by electron microscopy confirmed pathomorphological alterations in the 
majority of Usp5cKO cardiomyocytes, including disruption of sarcomere integrity 
(Figure 44 A, B), changes in the size and shape of nuclei and nucleoli (Figure 44 C), 
in addition to changes in the structure of intercalated discs (Figure 44 D).  
 
Figure 44 Pathomorphological alterations in the left ventricle of Usp5cKO mice.  
A-D. Electron microscopy images showing sarcomeres (A, B), nucleus (C), and intercalated discs (D) in 
the left ventricle of Usp5 flox/flox and Usp5cKO mice 24 days after the last tamoxifen administration. n = 3 
for each group. Scale bars, 2500 nm (A, B) and 1000 nm (C, D). ID, intercalated disks; M, mitochondria; 
N, nucleus; S, sarcomeres. 
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All listed pathomorphological changes are indicative of severely compromised cell-
to-cell connection and cell-to-cell communication. Moreover, these findings are 
symptomatic for cardiac remodeling and progression of DCM, potentially 
contributing to the observed lethal phenotype. Since Usp5cKO mice did not show any 
classical symptoms of heart failure such as ascites or pulmonary edema, one might 
speculate that the sudden death of Usp5cKO mice within a narrow time window of 3-
4 days post-tamoxifen inducible inactivation of Usp5 causes acute contractile 
dysfunction or electric conductive defects due to severe disruption of intercalated 
discs.  
Cardiac-restricted inactivation of USP5 causes accumulation of 
ubiquitin-enriched aggresomes  
In addition to disease-related pathomorphological changes of cardiomyocytes from 
Usp5cKO mice, electron microscopy further identified electron-dense aggregates in 
regions with disrupted sarcomeres or otherwise damaged organelles (Figure 45 A, B).  
 
Figure 45 Perinuclear protein deposits in Usp5cKO mice.  
A, B. Electron microscopy showing perinuclear protein-dense aggregates surrounded by cell debris in the 
left ventricle of Usp5 flox/flox and Usp5cKO mice 24-days after the last tamoxifen administration. n = 3 for 
each group. Scale bars, 1000 nm (A) and 2500 nm (B). M, mitochondria; N, nucleus; P, protein-dense 
aggregates; S, sarcomeres. 
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Since USP5 was actively recruited to aggregated proteins after MG132-induced 
inactivation of proteasome activity in cardiomyocytes (Figure 24 A), the questions 
arose whether such electron-dense aggregates may represent misfolded proteins that 
accumulated as a result of strongly impaired proteostasis in Usp5cKO cardiomyocytes.  
Immunofluorescence staining using the PROTEOSTAT® aggregation assay in 
combination with a ubiquitin antibody corroborated enhanced load of mainly 
perinuclear aggresomes containing ubiquitin-enriched aggresomes in Usp5cKO 
cardiomyocytes (Figure 46 A-C), while the majority of aggresomes detected in 
cardiomyocytes from Usp5 flox/flox control littermates showed no co-localization 
with ubiquitin (Figure 46 A, C). Quantitative assessment of aggresome formation 
uncovered increase in the number of cardiomyocytes containing perinuclear 
aggresome in Usp5cKO mice compared to Usp5 flox/flox control littermates (Figure 46 
D). Moreover, Usp5cKO cardiomyocytes contained significantly more aggresomes per 
view field (Figure 46 E). To summarize, immunohistological analysis of aggresome 
formation substantiates the hypothesis that accumulation of ubiquitin-enriched 
protein aggregates is linked to disturbed UPS-dependent proteolysis and dysregulated 
ubiquitin pools in Usp5cKO cardiomyocytes.  
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Figure 46 Accumulation of perinuclear ubiquitin-enriched aggresomes in hearts of UspcKO 
mice.  
A. Immunofluorescence staining of F-actin (green), ubiquitin (magenta), and nuclei (DAPI, blue) in cross-
sectioned hearts of Usp5 flox/flox and Usp5cKO mice 24-days after the last tamoxifen administration. n = 
4 for each group. Scale bars, 50 µm. B. Immunofluorescence staining of F-actin (green), aggresomes 
(magenta), and nuclei (DAPI, blue) in cross-sectioned hearts of Usp5 flox/flox and Usp5cKO mice 24-days 
after the last tamoxifen administration. n = 4 for each group. Scale bars, 50 µm. C. Immunofluorescence 
staining of ubiquitin (green), aggresomes (magenta), and nuclei (DAPI, blue) in cross-sectioned hearts of 
Usp5 flox/flox and Usp5cKO mice 24-days after the last tamoxifen administration. n = 4 for each group. 
Scale bars, 50 µm. D, E. Quantification of cardiomyocytes containing aggresomes (D) and number of 
aggresomes counted per view field (E) in cross-sectioned hearts of Usp5 flox/flox and Usp5cKO mice. n = 
4 for each group. Two-tailed unpaired Wilcoxon-rank sum test. ** P < 0.0021, *** P < 0.0002.  
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Impaired clearance of protein aggregates by selective autophagy 
contributes to persistent protein aggregation in USP5-deficient 
cardiomyocytes 
So far, my data demonstrated that cardiac-specific loss of USP5 induced DCM due 
to altered ubiquitin pools, block of 20S proteasome activity, accompanied by altered 
proteasome composition, and formation of ubiquitin-enriched aggresomes. In 
contrast, inactivation of Usp5 in MEFs caused formation of ubiquitin-enriched 
aggresomes despite the absence of major effects on ubiquitin pools or 20S 
proteasome activity, indicating that USP5 possesses a dual role for proteasomal and 
(selective) autophagy-mediated PQC. To test whether inactivation of Usp5 in 
cardiomyocytes causes defects in selective clearance of protein aggregates, which may 
account for persistent aggresome formation and continuous impairment of cardiac 
homeostasis, expression of key components of selective autophagy were examined by 
immunoblot analysis (Figure 47 A-D). Immunoblot analysis uncovered elevated levels 
of Lys63-linkage specific ubiquitin in Usp5cKO cardiomyocytes (Figure 34 C, D), 
which suggests potential defects in the autophagic machinery in addition to impaired 
UPS-dependent proteolysis (Figure 47 C, D). In addition, immunoblot analysis of the 
early selective autophagy markers p62 and LC3 revealed elevated p62 levels in 
Usp5cKO cardiomyocytes, while the LC3-II/LC3-I ratio remained unchanged when 
compared to cardiomyocytes from Usp5 flox/flox control littermates (Figure 47 A-C). 
These data suggest arrest of autophagic flux in Usp5cKO cardiomyocytes. In addition, 
immunoblot analysis of late selective autophagy markers disclosed compromised 
autophagolysosome formation in Usp5cKO cardiomyocytes, since cortactin (CTTN) 
remained mainly in its acetylated state regardless of enhanced HDAC6 protein levels 
(Figure 47 D-F).  
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Figure 47 Impaired clearance of aggresomes by selective autophagy in USP5-deficient 
cardiomyocytes. 
A. Immunoblot analysis of the early autophagy markers p62 and LC3 in isolated cardiomyocytes from 
Usp5 flox/flox and Usp5cKO mice 15 days after the last tamoxifen administration. B, C. Quantification of 
protein levels relative to GAPDH expression. n = 3 for Usp5 flox/flox, n = 4 for Usp5cKO. D. Immunoblot 
analysis of the late autophagy markers HDAC6 and CTTN in isolated cardiomyocytes from Usp5 flox/flox 
and Usp5cKO mice 15 days after the last tamoxifen administration. E, F. Quantification of protein levels 
relative to GAPDH expression. n = 3 for Usp5flox/flox, n = 4 for Usp5cKO.  
Immunohistochemistry confirmed higher abundance of p62 and HDAC6 in Usp5cKO 
cardiomyocytes (Figure 48 A, B). However, aggresomes completely co-localized with 
p62 and HDAC6 (Figure 48 A, B), which indicated that recruitment and binding of 
p62 and HDAC6 to ubiquitin-enriched aggresomes during early steps of (selective) 
autophagy were not impaired. These results confirmed that defects in the selective 
clearance of ubiquitin-enriched protein aggregates cause persistent aggresome 
formation, which augments cytotoxic effects arising from disturbed UPS function. 
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Figure 48 Selective autophagy markers co-localize with aggresomes in USP5-deficient 
cardiomyocytes. 
A. Immunofluorescence staining of p62 (green), aggresomes (magenta) and nuclei (DAPI, blue) in cross-
sectioned hearts of Usp5 flox/flox and Usp5cKO mice 24 days after the last tamoxifen administration. n = 4 
for each group. Scale bars, 50 µm. B. Immunofluorescence staining of HDAC6 (yellow), aggresomes 
(magenta) and nuclei (DAPI, blue) in cross-sectioned hearts of Usp5 flox/flox and Usp5cKO mice 24 days 
after the last tamoxifen administration. n = 4 for each group. Scale bars, 50 µm. 
As a consequence, elevated cytotoxic stress levels resulted in apoptotic cell death of 
Usp5cKO cardiomyocytes, as indicated by Caspase-3 activation and subsequent 
induction of PARP cleavage (Figure 49 A). Importantly, atypical protein aggregation 
caused by MG132-mediated impairment of UPS function was not sufficient to induce 
a similar degree of apoptotic cell death in cardiomyocytes from Usp5 flox/flox control 
littermates. Most likely, impairment of both branches of PQC in response to 
inactivation of Usp5 is required to induce apoptosis of cardiomyocytes.  
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Figure 49 Enhanced apoptotic cell death of 
USP5-deficient cardiomyocytes.  
A. Immunoblot analysis of Caspase-3, cleaved Caspase-
3, PARP, and cleaved PARP in isolated cardiomyocytes 
of Usp5 flox/flox and Usp5cKO mice 15 days post-
tamoxifen administration. n = 4 for each group. 
USP5 is instrumental for cardiac development and survival 
Since cardiomyocytes isolated at earlier developmental time points expressed both 
Usp5 exon 15 isoforms (Figure 21 A), the next step was to investigate possible 
consequences arising from inactivation of Usp5 both in embryonic and juvenile 
cardiomyocytes. To achieve inactivation of Usp5 at embryonic stage, homozygous 
Usp5 flox/flox mice were crossbred with transgenic mice having the cre-recombinase 
gene driven by Xenopus laevis light chain 2 (XMLC2) promoter (Figure 12 A; Figure 50 
A). Inactivation of Usp5 in cardiac crescent cells at E7.5 was not compatible with life 
as no XMLC2//Usp5 flox/flox mice were born. Isolation of embryos at different time 
points uncovered that homozygous XMLC2//Usp5 flox/flox embryos die around 
E11.5 (Figure 50 A). Homozygous XMLC2//Usp5 flox/flox embryos were smaller in 
body size (Figure 50 B) and showed arrest of cardiac development (Figure 50 C), 
including reduced trabeculation and compaction (Figure 50 C-E), in addition to 
enlarged atria and substantially thinner left ventricular walls (Figure 50 D, F).  
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Figure 50 USP5 is essential for cardiac development and survival.  
A. Timeline for analysis of cardiac-restricted inactivation of Usp5 at embryonic stage. Usp5 flox/flox mice 
were crossbred with transgenic mice harboring the XMLC2-cre recombinase to drive cre-mediated 
recombination in cardiac crescent cells at E7.5. B, C. Images of Usp5 flox/flox and XMLC2//Usp5 flox/flox 
embryos (B) and hearts at E11.5 n = 4 for each group. Scale bars, 1000 µm (B) and 200 µm (C). D, E. H&E 
stained cross sections of Usp5 flox/flox and XMLC2//Usp5 flox/flox embryos as E11.5. n = 4 for each group. 
Scale bars, 50 mm (D) and 25 µm (E). F. Analysis of myocardial wall thickness between the two genotypes. 
n = 4 for each group. Two-tailed unpaired t-test with Welch’s correlation. **** P < 0.0001. 
In addition, inactivation of Usp5 in cardiac- and skeletal muscle at juvenile stage was 
achieved by crossbreeding homozygous Usp5 flox/flox mice with transgenic mice 
having the cre-recombinase gene driven by muscle creatine kinase promoter (MCK) 
(Figure 12 A; Figure 51 A). In accordance with previous results, inactivation of Usp5 
by MCK-cre around E13.5 (Figure 51 A) resulted in 100 % lethality before P30 (Figure 
51 B). Similar to Usp5cKO mice, homozygous MCK//Usp5 flox/flox died within a 
short time window of six days, starting at P21 (Figure 51 B). Notably, homozygous 
MCK//Usp5 flox/flox developed normally within the first three weeks after birth 
without showing any signs of incipient deterioration of their health status in 
comparison to Usp5 flox/flox littermate controls (Figure 51 C).  
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Figure 51 Cardiomyocyte-restricted deletion of USP5 at juvenile stage causes sudden death.  
A. Timeline for analysis of cardiomyocyte-restricted inactivation of Usp5 at juvenile stage. Usp5flox/flox 
mice were crossbred with a transgenic mouse strain by which a muscle creatine kinase promoter drives 
cre-recombinase expression (MCK-cre) in striated muscles. Cre-recombinase becomes activated around 
E13.5. Mice were analyzed at postnatal day P25. B. Kaplan-Meier survival curves of Usp5 flox/flox (n = 29) 
and MCK//Usp5 flox/flox (n = 13) mice. P-value is based on the Log-rank (Mental-Cox) test. C. Body weight 
curves of Usp5 flox/flox and MCK//Usp5flox/flox mice. 
Usp5 flox/flox and MCK//Usp5 flox/flox mice were subjected to a comprehensive 
phenotype analysis at P25, which represents the median of survival (Figure 51 A, B). 
Homozygous MCK//Usp5 flox/flox mice showed dramatic weight loss accompanied 
by a decline in heart weight, which accounted for the elevated heart weight to body 
weight ratio (HW:BW). The observed effects were not caused by growth defects, since 
the corresponding tibia lengths did not differ between the two genotypes (Figure 52 
A).  
 
Figure 52 Effects of striated muscle-restricted knockout of USP5 on body weight, heart 
weight, and tibia length.  
A. Effects of striated-muscle restricted inactivation of Usp5 on body weight (BW), heart weight (HW), 
tibia length (TL), and ratios of heart weight to body weight (HW:BW), body weight to tibia length 
(BW:TL), and heart weight to tibia length (HW:TL). n = 10 for Usp5 flox/flox, n = 7 for MCK//Usp5 flox/flox. 
Unpaired t test with Welch's correction. *** P < 0.0002.  
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Similar to inactivation of Usp5 in cardiac crescent cells and mature cardiomyocytes, 
inactivation of Usp5 at juvenile stage resulted in progression of DCM as indicated by 
increased heart size despite reduction in heart weight (Figure 53 A). Histological 
analysis of H&E stained myocardial sections revealed massively enlarged atria, 
dilation of both ventricles, corresponding to tremendously thinner ventricular walls 
(Figure 53 B, C), severely impaired integrity of cardiomyocytes, and disruptive 
alterations in the formation of proper cell-to-cell contacts (Figure 53 D). In general, 
inactivation of Usp5 during cardiac development caused a stronger DCM phenotype 
as observed in adult hearts, although the principle pathomorphological alterations 
seem to be identical. The data clearly illustrate that USP5 is instrumental for cardiac 
development and survival, as loss of USP5 correlates with rapid progression of DCM 
and a poor survival prognosis. 
 
Figure 53 Cardiomyocyte-restricted deletion of USP5 at juvenile stage causes DCM.  
A, B, D. Images of hearts (A) and H&E stained cross sections (B, D) of Usp5 flox/flox and MCK//Usp5 
flox/flox mice at postnatal day (P) 25. n = 4 for each group. Scale bars, 1000 µm (A, B) and 50 µm (D). C. 
Analysis of myocardial wall thickness in Usp5flox/flox and MCK//Usp5 flox/flox mice at P25. n = 4 for each 
group. Two-tailed unpaired t-test with Welch’s correlation or two-tailed unpaired t-test with Wilcoxon-
rank sum test, respectively. * P < 0.05; **** P < 0.0001.  
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Cardiomyocytes from human DCM patients with late end-stage 
DCM display enhanced load of ubiquitin-containing aggresomes 
lacking USP5  
To illustrate the importance of the present in-vivo findings, I wondered whether 
development of DCM in human individuals is linked to impairment of USP5-
dependent processes. To directly address this aspect, left ventricular biopsies of 
explanted hearts from a cohort of randomly selected human patients with late-end 
stage DCM undergoing heart transplantation were analyzed. Left ventricular biopsies 
from non-failing individuals with preserved cardiac function and without any signs of 
myocardial damage or heart failure served as an appropriate control cohort. Main 
parameters, such as age and gender-to-female ratio, were nearly identical between the 
two groups, qualifying inclusion of all patients in the current study (Figure 54 A). 
Ultrastructural analysis by electron microscopy uncovered pathomorphological 
alterations in cardiomyocytes from end-stage DCM patients, including abnormally 
shaped nuclei and distortion of mitochondria and myofibrils (Figure 54 B). Most 
importantly, cardiomyocytes contained clusters of protein dense aggregates and 
phospholipids, which were mostly located in the proximity of nuclei. In addition, 
cardiomyocytes of DCM patients were further characterized by a roundish shape and 
increased volume of nuclei (Figure 54 C). In contrast, cardiomyocytes in the non-
failing control cohort showed well-preserved sarcomere structures without deposition 
of phospholipids or protein aggregates (Figure 54 B). PROTEOSTAT® aggregation 
assay confirmed aberrant accumulation of misfolded proteins and formation of 
mainly perinuclear aggresomes in cardiomyocytes from late end-stage DCM patients, 
although a similar number of cardiomyocytes with perinuclear aggresomes were 
detected in non-failing individuals (Figure 54 C, D). Nevertheless, cardiomyocytes of 
late end-stage DCM patients contained more protein aggregates that were also larger 
in size (Figure 54 E, F).  
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Figure 54 Randomly selected patients with late-end stage DCM show atypical accumulation 
of perinuclear protein aggregates.  
A. Clinical characteristics of non-failing and late end-stage DCM patients analyzed in the study. B. Electron 
microscopy of hearts from non-failing (n = 2) and DCM individuals (n = 5). Perinuclear clusters in DCM 
individuals reflect protein aggregates and lipid droplets. ID, intercalated disks; M, mitochondria; Mf, 
myofibrils; Nuc, nucleus; PL, phospholipid droplets. C. Immunofluorescence staining of F-actin (green), 
aggresomes (magenta), and nuclei (DAPI, blue) in cross-sectioned hearts from non-failing (n = 2) and DCM 
individuals (n = 5). Scale bars, 50 µm. D. Quantitation of cardiomyocytes containing aggresomes in cross 
sections hearts from non-failing (n = 2) and DCM individuals (n = 5). E, F. Quantitation of the number of 
aggresomes counted per view field and average size of aggresomes in cross-sectioned hearts from non-
failing (n = 2) and DCM individuals (n = 5). Two-tailed unpaired t-test with Wilcoxon-rank sum test. * P 
< 0.05, ** P < 0.0021.  
Importantly, additional immunofluorescence staining revealed atypical deposition of 
large ubiquitin-containing debris in cardiomyocytes from late end-stage DCM 
patients, which co-localized with perinuclear aggresomes (Figure 55 A, B). Taken 
together, these data indicate that progression of DCM is linked to atypical 
accumulation of ubiquitin-conjugated protein aggregates in cardiomyocytes [135, 
136].  
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Figure 55 Accumulation of ubiquitin-containing aggresomes in cardiomyocytes from 
patients with late-end stage DCM.  
A. Immunofluorescence staining of F-actin (green), ubiquitin (magenta), and nuclei (DAPI, blue) in cross-
sectioned hearts from non-failing (n = 2) and DCM individuals (n = 5). Scale bars, 50 µm. B. 
Immunofluorescence staining of ubiquitin (green), aggresomes (magenta), and nuclei (DAPI, blue) in cross 
sectioned hearts from non-failing (n = 2) and DCM individuals (n = 5). Scale bars, 50 µm. 
Since pathomorphological changes in cardiomyocytes from late end-stage DCM 
patients were similar to those observed in the present in vivo mouse model, 
immunoblot analysis in combination with immunohistochemistry was utilized to 
study the expression of USP5. Remarkably, USP5 protein levels were strongly reduced 
in myocardial cell lysates from late end-stage DCM patients in comparison to non-
failing control patients (Figure 56 A, B). Consistently, immunofluorescence analysis 
revealed that cardiomyocytes from late end-stage DCM patients lack USP5 while 
cardiomyocytes from non-failing control patients showed high abundance in USP5 
staining intensity (Figure 56 C). In line with these observations, ubiquitin-enriched 
aggresomes in cardiomyocytes from late end-stage DCM patients showed almost 
complete lack of USP5 labeling (Figure 56 D, E), while ubiquitin-enriched aggresomes 
in cardiomyocytes from non-failing control patients were mostly positive for USP5 
(Figure 56 D, E).   
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Figure 56 Lack of USP5 in cardiomyocytes from patients with late-end stage DCM.  
A. Immunoblot analysis for USP5 in myocardial lysates from non-failing (n = 2) and late end-stage DCM 
individuals (n = 5). B. Quantification relative to GAPDH levels. Unpaired t-test with Welch’s correlation. 
*** P < 0.0002. C. Immunofluorescence staining of USP5 (cyan), F-actin (red), and nuclei (DAPI, blue) in 
cross sectioned hearts from non-failing (n = 2) and late end-stage DCM individuals (n = 5). Scale bars, 50 
µm. D. Immunofluorescence staining of USP5 (green), aggresomes (magenta), and nuclei (DAPI, blue) in 
cross sectioned hearts from non-failing (n = 2) and late end-stage DCM individuals (n = 5). Scale bars, 50 
µm. E. Quantification of USP5-positive aggresomes in cardiomyocytes from non-failing (n = 2) and late 
end-stage DCM individuals (n = 5). Two-tailed unpaired t-test with Wilcoxon-rank sum test. **** P < 
0.0001. 
In summary, the data demonstrate a striking similarity between pathomorphological 
alterations in the heart from human late end-stage DCM patients and the DCM 
phenotype observed in the cardiomyocyte-restricted USP5 KO mouse model.  
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Overexpression of hsUSP5 in cardiomyocytes is compatible with 
normal cardiac proteostasis  
The importance of USP5 for UPS-dependent catabolic processes and selective 
autophagy of protein aggregates in the murine heart and the downregulation of USP5 
in human end-stage cardiomyocytes raised the possibility that the availability of USP5 
is a rate-limiting step to prevent or resolve protein aggregates caused by impaired 
proteostasis. To get insights into this topic and to examine whether augmented 
expression of USP5 counteracts or prevents disease-related protein aggregation, the 
effects of different USP5 splice variants on ubiquitin turnover and PQC processes 
were analyzed first. Transfection of HEK293 cells with plasmids either encoding the 
human (hs) USP5 exon 15 long or short isoform in combination with immunoblot 
analysis to monitor ubiquitin levels demonstrated that the hsUSP5 exon 15 long 
isoform has more pronounced effects in reducing ubiquitin levels (Figure 57 A, B). I 
observed that hsUSP5 exon 15 long decreased the levels of polyubiquitin chains and 
polyubiquitinated proteins, while monoubiquitin levels, essential for de-novo 
ubiquitin conjugation and protein clearance, were elevated (Figure 57 B, C). 
 
Figure 57 hsUSP5 exon 15 isoform specific differences in the ubiquitin pool.  
A, B. Immunoblot analysis of hsUSP5 and ubiquitin levels in HEK293 cells transiently transfected with eGFP 
and GFP-tagged hsUSP5long or hsUSP5short, respectively. n = 3 for each group. Arrow head, endogenous 
USP5. *, eGFP-tagged hsUSP5. C. Quantification of ubiquitin chains relative to GAPDH levels. n = 3 for 
each group. 
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These in-vitro data suggest that the USP5 exon 15 long isoform has a more prominent 
role in maintaining ubiquitin homeostasis, which is particularly important in 
postmitotic cells, such as mature cardiomyocytes. To investigate whether moderate 
overexpression of hsUSP5 in cardiomyocytes interferes with cellular functions, 
another transgenic mouse strain was generated that harbors the FLAG-HA-tagged 
exon 15 long isoform of hsUSP5 in the Rosa26 genomic locus. Crossbreeding with 
transgenic mice expressing a cre-recombinase under the XMLC2-promoter resulted in 
conditional activation of hsUSP5 due to removal of the floxed stop cassette (Figure 
58 A, B). To avoid side effects, which may arise from excessive overexpression, we 
kept transgenic mice constantly heterozygous. R26-FLAG-HA-hsUSP5long 
(hereafter called hsUSP5 CO/+) robustly expressed FLAG-HA-hsUSP5long during 
cardiac development and in mature cardiomyocytes (Figure 58 A, B). hsUSP5 CO/+ 
mice were healthy and fertile, exert normal cardiac function, and did not show any 
significant changes in body weight, heart weight, or ratios of body weight to heart 
weight (BW:HW) or heart weight to tibia length (HW:TL) (Figure 58 C).  
 
Figure 58 Effects of moderate overexpression of hsUSP5 in mature cardiomyocytes.  
A. Timeline for analysis of cardiomyocyte-specific overexpression of hsUSP5. Heterozygous hsUSP5 +/CO 
mice were crossbred with a transgenic mouse strain harboring the XMLC2-cre recombinase to drive cre-
mediated recombination in cardiac crescent cells around E7.5. B. Immunoblot analysis of USP5 expression 
in isolated cardiomyocytes from hsUSP5 +/+ and hsUSP5 CO/+ mice using antibodies against the flag-tag 
(FLAG) or hsUSP5. C. Effects of cardiomyocyte-specific overexpression of hsUSP5 on body weight (BW), 
heart weight (HW), tibia length (TL), and ratios of heart to body weight (HW:BW), body weight to tibia 
length (BW:TL), and heart weight to tibia length (HW:TL). n = 3 for each group.  
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Immunoblot analysis revealed reduced ubiquitin levels, in low and high molecular 
weight range, in isolated cardiomyocytes of hsUSP5 CO/+ mice, while monoubiquitin 
levels remained unchanged compared to hsUSP5 +/+ control mice (Figure 59 A-C).  
 
Figure 59 Moderate overexpression of hsUSP5 in cardiomyocytes reduces levels of ubiquitin.  
A. Immunoblot analysis of ubiquitin levels in isolated cardiomyocytes from hsUSP5 +/+ and hsUSP5 CO/+ 
mice. n = 3 for each group. B, C. Quantification of ubiquitin levels (B) and ubiquitin chains (C) normalized 
to GAPDH. n = 3 for each group.  
As loss of USP5 in cardiomyocytes caused arrest of autophagic flux, which resulted 
in defective clearance of ubiquitin-enriched protein aggregates, which was monitored 
by immunofluorescence staining of LC3. hsUSP5 CO/+ cardiomyocytes showed 
reduced number of LC3-punctae compared to cardiomyocytes from hsUSP5 +/+ 
control littermates, even in response to treatment with chloroquine (Figure 60 A, B). 
Chloroquine, a lysosomotropic agent, prevents both fusion of autophagosomes with 
lysosomes and lysosomal-dependent protein degradation by raising the lysosomal pH 
[137]. Together, these data demonstrate that moderate overexpression of hsUSP5 in 
cardiomyocytes is compatible with normal development and sustained cardiac 
function.  
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Figure 60 Moderate overexpression of hsUSP5 does not induce autophagy.  
A, B. Immunofluorescence staining of F-actin (red), LC3 (yellow), and nuclei (DAPI, blue) in isolated 
cardiomyocytes from hsUSP5 +/+ and hsUSP5 CO/+ mice without (A) or with (B) chloroquine treatment 
for 4 h. n = 2 for each group. Scale bars, 25 µm. 
USP5 resolves protein aggregates induced by a disease-related 
mutation in titin  
To address the question if cardiomyopathy-related protein aggregation phenotypes, 
mostly caused by mutations in structural proteins, can be reversed by moderate 
overexpression of hsUSP5, cardiomyocytes from hsUSP5 CO/+ and hsUSP5 +/+ 
mice were infected with an adenovirus expressing either GFP-tagged wildtype titin or 
the GFP-tagged C31712R titin variant. 48 h post-infection, impact of elevated 
hsUSP5 protein levels on C31712R titin-induced protein aggregation was examined 
(Figure 61 A). The titin variant C31712R is one of the most frequently occurring 
mutations in the A-band region of titin, A150 (Fn3-119), known to cause protein 
destabilization and aggregation, which contributes to the development of HMERF 
(hereditary myopathy with early respiratory failure) [118, 138]. In addition to a muscle 
phenotype, studies show that HMERF-patients carrying the C31712R titin variant 
also show a cardiac-specific phenotype [139].   
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Transfection of cardiomyocytes with C31712R titin resulted in formation of large 
GFP-labeled titin aggregates in hsUSP5 +/+ mice, which mainly formed in close 
proximity to nuclei or intercalated discs. In contrast, the number of GFP-labeled titin 
aggregates in hsUSP5 CO/+ transfected cardiomyocytes was substantially reduced in 
addition to significantly smaller titin aggregates (Figure 61 B-D).  
 
Figure 61 hsUSP5 clears protein aggregates caused by C31712R titin. 
A. Timeline for analysis of cardiomyocyte-specific overexpression of hsUSP5 in respect to clearance of 
protein aggregates caused by the C31712R titin variant. B. Immunofluorescence staining of eGFP (green, 
representing titin), F-actin (magenta), and nuclei (DAPI, blue) in isolated cardiomyocytes from hsUSP5 +/+ 
and hsUSP5 CO/+ mice 48 h after infection with an adenovirus encoding either GFP-tagged wildtype titin 
or GFP-tagged C31712R titin. n = 4 for each group. Scale bars, 25 µm. D, E. Quantification of the number 
(D) and average size of titin aggregates (E) in pooled isolated cardiomyocytes (n ≥ 140) from hsUSP5 +/+ 
and hsUSP5 CO/+ mice. n = 4 mice per genotype. Two-tailed unpaired t-test with Wilcoxon-rank sum test. 
* P < 0.05; *** P < 0.0002. 
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To now elucidate the mechanism underlying the reduced presence of GFP-tagged 
C31712R titin aggregates in hsUSP5 CO/+ cardiomyocytes, 20S proteasome activity 
in non-adenoviral and adenoviral infected cardiomyocytes was examined. At baseline, 
hsUSP5 CO/+ cardiomyocytes showed an overall increase in 20S proteasome activity 
in comparison to isolated cardiomyocytes from hsUSP5 +/+ mice, even though only 
trypsin-like peptidase activity reached statistical significance (Figure 62 A-C). 
Importantly, 20S proteasome activity measurement revealed substantially higher 
trypsin-and chymotrypsin-like peptidase activities in hsUSP5 CO/+ cardiomyocytes 
expressing GFP-C31712R titin in comparison to hsUSP5 +/+ cardiomyocytes 
(Figure 62 A-C). Moreover, 20S proteasome activity remained constant in 
cardiomyocytes of hsUSP5 CO/+ mice infected with either GFP-tagged wildtype or 
GFP-C31712R titin. Overexpression of hsUSP5 further prevented decline of trypsin- 
and chymotrypsin-like peptidase activities in response to expression of aggregation-
prone C31712R titin (Figure 62 A, C). These findings indicate that USP5 supports 
degradation of GFP-C31712R titin aggregates under conditions of increased 
proteostatic stress. 
 
Figure 62 hsUSP5 clears protein aggregates caused by C31712R titin through sustained 
proteasome activity.  
A-C. Quantification of 20S proteasome peptidase activities in isolated cardiomyocytes from hsUSP5 +/+ 
and hsUSP5 CO/+ mice 48 h after infection with an adenovirus encoding either GFP-tagged wildtype or 
GFP-tagged C31712R titin. n = 5 for each group. One-way ANOVA followed by Sidak’s post-test. * P < 
0.05.  
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Next, immunoblots were performed to investigate the impact of ameliorated hsUSP5 
expression on clearance of GFP-C31712R titin aggregates by selective autophagy. At 
baseline, no changes in protein levels of the early autophagy markers p62 or LC3-II 
were observed, which indicated that overexpression of hsUSP5 in cardiomyocytes 
does not affect the autophagic flux (Figure 63 A-C). Consistent with these findings, 
p62 and LC3-II protein levels remained constant in hsUSP5 CO/+ cardiomyocytes 
expressing GFP-C31712R titin, indicating that increased expression of USP5 in 
cardiomyocytes expressing mutant titin does not stimulate autophagy. In contrast, 
hsUSP5 +/+ cardiomyocytes expressing GFP-C31712R titin showed higher protein 
levels of p62 with reduced levels of LC3-II, indicating severe impairment of 
autophagic flux in response to C31712R induced titin aggregation (Figure 63 A-C).  
 
Figure 63 hsUSP5 clears protein aggregates caused by C31712R titin through sustained 
autophagic flux. 
A. Immunoblot analysis of hsUSP5 (FLAG), p62, and LC3 in isolated cardiomyocytes from hsUSP5 +/+ and 
hsUSP5 CO/+ mice 48 h after infection with an adenovirus encoding either GFP-tagged wildtype or GFP-
tagged C31712R titin. n = 5 for each group. B, C. Quantification of protein levels relative to GAPDH 
expression.  
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Collectively, these data confirm that suppression of proteasome activity in 
combination with impaired autophagic flux is associated with aberrant protein 
aggregation. Notably, the findings emphasize the importance of USP5 for appropriate 
proteasome activity and efficient autophagic flux, mainly in conditions of elevated 
cellular stress, which prevent the accumulation of harmful and toxic protein 
aggregates in the heart. I concluded that USP5 may represent a new target for the 
treatment of protein aggregation-related diseases in the heart.  
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 DISCUSSION 
The present study identified the ubiquitin-specific peptidase USP5 (Isopeptidase T, 
IsoT) as a critical component of cellular PQC in the myocardium. The data presented 
in this study demonstrate that conditional loss of USP5 in cardiomyocytes resulted in 
an imbalance of the cellular ubiquitin pools, caused by disturbed ubiquitin turnover, 
enhanced ubiquitin stress, and profoundly impaired UPS-dependent degradation of 
terminally misfolded proteins. Accumulation of such ubiquitin-ligated proteins to 
large, perinuclear located protein aggresomes, and defective clearance by selective 
autophagy resulted in remodeling of the heart, progression of DCM, and sudden 
death. Similarly, cardiomyocytes from human individuals with late end-stage DCM 
showed extensive accumulation of large ubiquitin-conjugated protein aggregates with 
substantially reduced USP5 protein levels in cardiomyocytes. Moreover, 
overexpression of USP5 in cardiomyocytes expressing the most common p.C31712R 
mutant variant of titin, known to cause protein destabilization and aggregation, 
abrogated excessive protein aggregate formation by sustaining UPS-dependent 
proteolysis. Importantly, all described effects were only observed in postmitotic 
cardiomyocytes expressing the non-spliced exon 15 long isoform of USP5. In 
contrast, conditional inactivation of the alternatively spliced variant of Usp5, USP5 
exon 15 short, which is solely expressed in proliferating cells such as MEFs, resulted 
in moderately increased ubiquitin levels without inhibitory effects on 20S proteasome 
activity, although selective autophagy was impaired. In summary, the present study 
offers genetic evidence for the essential and rate-limiting function of USP5 for 
sustained proteostasis in the myocardium, both in mice and humans. Furthermore, 
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the data highlight the UPS-autophagy network to specifically rely on USP5-dependent 
ubiquitin homeostasis, which is indispensable for cardiomyocyte function. 
Cellular functions rely on proper protein homeostasis, i.e. proteostasis, to maintain a 
healthy proteome [83, 91]. Gradual derailment of cellular PQC processes mainly 
caused by enhanced cellular stress or disease conditions, such as gene mutations or 
reduced efficiency of critical components of the proteostasis network during aging, 
impair acquisition of proper protein conformations, which results in the formation of 
terminally misfolded proteins [9, 13]. As misfolded proteins cannot be salvaged by 
molecular chaperones, they need to be removed by either of the two major protein 
degradation systems – ubiquitin-proteasome system (UPS) and lysosomal-dependent 
(selective) autophagy – to prevent accumulation of unutilized, terminally misfolded, 
mutated, or damaged proteins, which interfere with important cellular functions [2, 
18]. Balanced proteostasis is important in organs containing large amounts of 
postmitotic cells, such as the brain and the heart. The high metabolic demand and 
mechanical stress, but also the nonregenerative capacity of neurons and mature 
cardiomyocytes make these cells particularly susceptible to disturbed PQC [2]. 
Accumulation of terminally misfolded proteins in neurons and cardiomyocytes causes 
an overload of the two proteolytic degradation machineries. Consequently, more and 
more proteins accumulate to form large protein aggregates exerting proteotoxicity 
[140]. Derailed proteostasis will drive multiple diseases, including neurodegenerative 
disorders or cardiac diseases, such as dilated cardiomyopathy (DCM) [85], although 
the exact molecular mechanisms have yet to be determined.  
USP5 and cellular polyubiquitin turnover  
Ubiquitination, the posttranslational modification of proteins with the 76 amino acid 
residue ubiquitin, controls tissue patterning and differentiation during maturation and 
development via various cellular processes. Ubiquitination is carried out by three 
enzymes – E1 ubiquitin-activating, E2 ubiquitin-transferring, and E3 ubiquitin-
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ligating enzymes – which ensure conjugation of a ubiquitin molecule to a specific 
protein. The coordinated action of these three enzymes requires multiple protein 
modifications, ranging from conjugation of a single ubiquitin molecule or multiple 
monoubiquitin molecules to the attachment of one or more polyubiquitin chains to a 
lysine residue of the targeted protein substrate through an isopeptide bond [141]. 
Ubiquitination is a reversible process with specific enzymes – deubiquitinating 
enzymes (DUBs) – to ensure recycling of ubiquitin for its reuse. In this context, 
ubiquitination and recycling of ubiquitin are tightly controlled to determine protein 
levels and to guarantee fine-tuning of cellular processes. Although the human genome 
encodes approximately 100 active DUBs, the cell-specific function of most DUBs 
remains to be uncovered [142, 143].  
Previous research on USP5 is limited to in vivo studies in yeast [56, 144], Arabidopsis 
thaliana [145], or Drosophila melanogaster [58], which disclosed the importance of USP5 
for disassembly of free, unanchored ubiquitin chains to keep the proteasome free of 
inhibitory chains [56, 130, 134]. The in vivo mouse data presented in this study are fully 
compatible with this view but uncover functions of USP5 to be cell type- and USP5 
isoform-specific. Disassembly of free, protein unattached polyubiquitin chains was 
impaired in mature cardiomyocytes lacking USP5 but not in USP5-deficient MEFs. 
Consistently, immunoblot analysis revealed severely disturbed ubiquitin pools, which 
resulted from accumulation of polyubiquitin chains and increased monoubiquitin 
levels in cardiomyocytes lacking USP5, while total ubiquitin levels or the composition 
of the ubiquitin pool were not different in USP5-deficient MEFs. Importantly, the 
observed effects in cardiomyocytes correlate to the expression of the exon 15 long 
isoform of USP5, which is solely expressed in organs containing large amounts of 
postmitotic cells. In contrast, USP5 undergoes alternative splicing in proliferating 
cells, such as MEFs, which results in expression of a shorter variant of Usp5 [131]. 
This shorter isoform of USP5 lacks 23 amino acids at the carboxyl-terminus of exon 
15, which does not encode any conserved or functional domain of USP5.  
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Moreover, the discrepancy in the requirement of USP5 for polyubiquitin turnover in 
MEFs and cardiomyocytes corresponds to general differences in the ubiquitin pool 
in proliferating, self-renewable cells, e.g. MEFs, versus postmitotic cells, such as 
cardiomyocytes. While the ubiquitin pool in MEFs is composed of ~ 65 % ubiquitin 
present as monoubiquitinated substrates, ~ 23 % ubiquitin monomers, and ~ 11 % 
polyubiquitin chains, the mouse brain contains only ~ 5 % polyubiquitin chains but 
three-fold more (~ 59 %) ubiquitin present as ubiquitin monomers, and 35 % as 
monoubiquitin on substrates [146]. These differences are even more pronounced in 
the human frontal cortex, which contains ~ 82 % free ubiquitin monomers but only 
~ 4 % polyubiquitin chains [147]. These data suggest that postmitotic cells do not 
tolerate high polyubiquitin levels but need to sustain physiologically high levels of 
monoubiquitin. Increased levels of polyubiquitin chains might potentially impede 
proteasome function and interfere with ubiquitin-dependent signaling. In fact, 
impaired ubiquitin signaling or altered composition of ubiquitin pools render cells 
more susceptible to stress conditions [148, 149], which is particularly detrimental to 
postmitotic cells in the heart as well as in the brain. Since the limited self-renewal 
capacity hinders postmitotic cells to remove harmful and toxic cell fragments by cell 
division, cardiomyocytes and neurons must be more efficient than proliferating cells 
to eliminate terminally misfolded proteins by degradation. Hence, postmitotic cells 
require high levels of conjugation-competent ubiquitin monomers and low levels of 
polyubiquitin chains to guarantee proteolysis of terminally misfolded proteins. USP5 
seems instrumental to achieve this efficiency.  
Only few studies have attempted to determine shared and distinct features of the 
proteome and ubiquitinome in different cell lines, although cell-type specific clusters 
of protein expression are present in all cells [150]. The list of most abundant DUBs 
included components of the proteasome, the constitutive photomorphogenesis 9 
(COP9) signalosome, and the translation initiation machinery. Importantly, USP5 was 
detected as one of the most abundant DUBs in HeLa, HEK, and Swiss3T3 cells with 
a copy number of >4×105 copies, similar to copy numbers of the proteasomal DUBs 
PSMD14, UCHL5, and USP14, underlying its importance for maintaining ubiquitin 
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homeostasis [142]. Given the importance of ubiquitin to most aspects of eukaryotic 
cell function, it is of particularly important to gain more insights into cell-type specific 
differences in protein copy numbers and the demographics of the ubiquitin pool, 
especially under certain stress conditions.  
Why loss of USP5 in proliferating MEFs had no impact on polyubiquitin turnover or 
ubiquitin homeostasis remains to be studied in more detail. Possibly, other DUBs 
involved in processing of protein-conjugated or unanchored polyubiquitin chains 
compensate for the loss of USP5 in MEFs. Different DUBs may target the same 
ubiquitin chain topology, thereby providing a cell-context dependent regulation of 
homeostatic ubiquitin pools. Since MEFs are proliferating cells, their ability to divide 
might allow MEFs to adapt to altered ubiquitin levels faster and more efficiently and 
therefore loss of USP5 had little or no impact on ubiquitin homeostasis. In this regard, 
more in vivo studies are needed to investigate the role of USP5 in other proliferating 
cells and to demonstrate whether the effects seen in MEFs can be recapitulated.  
USP5 and processing of ubiquitin precursors 
Cellular ubiquitin levels are tightly controlled by DUBs, which are indispensable for 
the generation of conjugation-competent ubiquitin [151]. DUBs fulfill this task by 
removing ubiquitin chains from posttranslationally modified proteins, by editing the 
length and/or type of ubiquitin chains on modified proteins, or by processing of 
ubiquitin precursors to generate ubiquitin [60]. In mammals, ubiquitin is synthesized 
by cytosolic ribosomes in four distinct, inactive precursor forms that must be properly 
processed by individual DUBs to generate active, conjugation-competent ubiquitin 
monomers. Each ubiquitin precursor is encoded by different genes [152, 153]: the 
ubiquitin-ribosomal precursors UBA52 and UBA80 (hereafter referred to as Ub-RPs) 
and the polyubiquitin precursors UBB and UBC (hereafter referred to as polyUbs). 
Ub-RPs are composed of a single ubiquitin that is fused to a ribosomal protein – L40 
for UBA52 and S27A for UBA80 – at its carboxyl-terminus [154, 155]. In contrast, 
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polyUbs are translated as linear fusion proteins comprising multiple copies of 
ubiquitin – 3-4 ubiquitin’s for UBB and 7-10 ubiquitin’s for UBC – linked in a ‘head-
to-tail’ manner, followed by a variable extension at the carboxyl-terminus [27, 156]. 
Early studies limited the number of DUBs involved in processing of ubiquitin 
precursors to three, while referring to USP5 as the only DUB that aids processing of 
polyUbs [55]. Nowadays, five DUBs – UCHL3, USP9X, USP7, USP5, and Otulin – 
are characterized to be active towards ubiquitin precursors, but only USP5 and Otulin 
show high reactivity towards polyUbs [25]. The data presented in this study show that 
the inactivation of Usp5 in cardiomyocytes results in profoundly increased mRNA 
levels of polyUbs but not Ub-RPs, which argues for compensatory mechanisms by 
upregulating transcription of polyUbs to replenish the pool of free, unconjugated 
ubiquitin with ubiquitin monomers. Although Otulin is also involved in processing 
of polyUbs, the “-omics” data showed that loss of USP5 in cardiomyocytes does not 
affect mRNA or protein expression of Otulin. Therefore, Otulin cannot compensate 
for the loss of USP5 in cardiomyocytes, showing that USP5 is essential for processing 
of polyUbs. Otulin, unlike USP5, cleaves randomly anchored and unanchored linear 
ubiquitin chains and is thus an important regulator of signaling cascades controlled 
by the ubiquitin-ligase linear-ubiquitin-assembly complex (LUBAC), such as immune 
homeostasis, responses to infection, and NFĸB signaling [157-159]. Constitutive loss 
of Otulin in mice is similar to USP5 early embryonic lethal (E12.5-E14), which 
indicates both DUBs to be crucial for developmental processes.  
Transcription of polyUbs is known to be highly induced in response to certain stress 
conditions, such as oxidative or proteotoxic stress [26, 160]. The data presented in 
this study are fully consistent with this view, since enhanced proteotoxic stress in 
cardiomyocytes, induced by MG132 treatment, resulted in profound upregulation of 
polyUbs, but not Ub-RPs. Remarkably, wildtype cardiomyocytes treated with MG132 
showed a similar increase in mRNA levels of polyUbs compared to cardiomyocytes 
lacking USP5, indicating that inactivation of Usp5 in postmitotic cells resulted in 
elevated proteotoxic stress. 
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USP5 and PQC processes: function at the 26S proteasome 
The function of the proteasome is critical for proteostasis as it impacts the regulation 
of cellular processes in all organs, including the heart [161]. UPS-dependent 
proteolysis of terminally misfolded, mutated, oxidized, or otherwise damaged proteins 
is carried out as a multi-step process that involves binding of (poly-) ubiquitinated 
proteins, deubiquitination, ATP-dependent unfolding, and translocation into the 20S 
CP of the proteasome for degradation [162]. The lysine residue at which ubiquitin is 
attached to, either at the protein or within a polyubiquitin chain, not only determines 
the functional property of the modified protein, it also imparts the specific outcome 
on the fate of the protein substrate [146]. Lys48-, Lys29-, and Lys11-linkage specific 
ubiquitin chains specifically target proteins for proteasomal degradation, while Lys63-
linkage specific polyubiquitin chains are essential for selective autophagy-mediated 
PQC processes [18, 163]. Deubiquitination of proteins targeted for degradation by 
the 26S proteasome is carried out by three DUBs: Rpn11/POH1/PSMD14, 
UCH37/UCHL5, and USP14 [36, 63, 164-167]. However, other studies report the 
association of several other ubiquitin-specific peptidases (USPs), including USP5, 
with the proteasome in human cells, the rat cortex, and rat skeletal muscle [168-170]. 
The findings in the present study are fully consistent with these reports, showing that 
USP5 forms a complex with PSMD14 that is essential for deubiquitination of proteins 
prior to proteasomal degradation. In addition, the BioID approach uncovered that 
USP5 also associates with other components of the 26S proteasome, which needs to 
be further investigated in more detail. However, a close interaction between USP5 
and PSMD14 clearly makes sense, since USP5 selectively cleaves PSMD14-released 
free, unanchored polyubiquitin chains at the proteasome to replenish the pool of free 
monoubiquitin, which – as I discussed earlier – is especially important in postmitotic 
cells. On the other hand, disassembly of PSMD14-released polyubiquitin chains by 
USP5 guarantees rapid elimination of such polyubiquitin chains and therefore keeps 
the 26S proteasome free of inhibitory polyubiquitin chains, which suppress all three 
peptidase activities of the 20S proteasome in addition to accumulation of ubiquitin-
enriched proteins [56, 144, 161]. Therefore, recruitment of accessory factors such as 
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USP5 enables the 26S proteasome to cope with cell-type specific proteolytic demands 
[171]. The results in this study show that inactivation of Usp5 elevates ubiquitin levels, 
including accumulation of Lys48-linkage specific polyubiquitin chains, accompanied 
by severely impaired 20S enzymatic peptidase activities. Importantly, alteration of 
UPS-dependent processes, resulting either from decreased 20S proteasome activity, 
altered composition of the 26S proteasome, or failure in deubiquitination of proteins 
is described to promote the progression of DCM [172-175]. However, this scenario 
was only observed in cardiomyocytes, while inactivation of Usp5 in MEFs had no 
impact on ubiquitin levels or the proteolytic capability of the 20S proteasome. This 
raised the question if proliferative cells other than MEFs might be also tolerant to 
inactivation of Usp5, or if MEFs alone compensate the loss of USP5 by upregulation 
of other DUBs, involved in processing of ubiquitin precursors and maintaining 
homeostatic ubiquitin pools.  
USP5 and PQC processes: function in (selective) autophagy 
Autophagy is an evolutionarily conserved process that plays an important role for 
cellular homeostasis under normal physiological conditions, ensuring basal turnover 
of long-lived proteins and organelles [176]. Autophagy becomes potently induced in 
response to cellular stress or nutrient deprivation to degrade damaged organelles, 
oxidized lipids, or intracellular pathogens. In addition, selective autophagy serves as a 
compensatory catabolic pathway in PQC whenever the 26S proteasome or other 
UPS-dependent processes are impaired or severely disturbed to relieve cells from 
cytotoxic effects of protein aggregates for which no other cellular pathway can 
compensate [177, 178].  
Before toxic protein aggregates are processed for autophagic clearance, they need to 
be transported by microtubule-dependent dynein motors to be concentrated at the 
microtubule-organizing center (MTOC) to form perinuclear inclusion bodies, called 
aggresomes [133, 179]. The deacetylase HDAC6 plays a crucial role during selective 
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autophagy by regulating the transport, concentration, and autophagic clearance of 
aggresomes by lysosomal digestion [71, 129, 132]. HDAC6 contains a C-terminal 
BUZ ubiquitin binding domain that allows binding to Lys63-linked ubiquitin chains 
on protein aggregates, which are released by the non-canonical deubiquitinating 
activity of PSMD14. Binding to Lys63-linkage specific ubiquitin chains results in the 
retrograde transport of protein aggregates towards the MTOC [71], where HDAC6 
dissociates from the protein aggregates. Since HDAC6 no longer binds Lys63-linked 
ubiquitin chains, it deacetylates its target cortactin, which induces remodeling of the 
actinomyosin network and retrograde transport of autophagosomes and lysosomes to 
the MTOC to promote de-aggregation, formation of autolysosomes, and autophagic 
degradation of newly formed aggresomes [129, 180, 181]. The data presented in this 
study indicates that USP5 plays an additional role for the clearance of aggregated 
proteins and aggresomes by selective autophagy. Although inhibition of all three 
enzymatic peptidase activities of the 20S proteasome due to accumulation misfolded 
proteins and Lys48-linkage specific ubiquitin chains is the major defect of PQC in 
cardiomyocytes in response to inactivation of Usp5, I noticed impairment of the 
autophagic machinery in cardiomyocytes lacking USP5. Adverse effects included 
increased levels of Lys63-linkage specific ubiquitin chains and proteins, formation of 
p62-containing aggresomes, and sequestration of proteins from proteolysis by the 26S 
proteasome. Impairment of clearance of protein aggregates by selective autophagy 
and accumulation of p62- containing aggresomes is caused by defects in the activation 
of HDAC6 to deacetylate its target protein cortactin. Potentially, USP5 controls the 
catalytic activity of HDAC6 or the switch of HDAC6-dependent binding to Lys63-
linkage specific ubiquitin chains and deacetylation of cortactin to promote the 
retrograde transport and de-aggregation of aggresomes. As an alternative, increase in 
Lys63-linkage specific ubiquitin chains and impairment of the UPS blocks the activity 
of PSMD14 and thus permits activation of HDAC6. Prolonged aggregation in USP5-
deficient cardiomyocytes, caused by severe impairment of both protein degradation 
pathways, resulted in progressive cell death, as demonstrated by caspase-3 cleavage 
and PARP activation, which was not observed in MG132-treated cardiomyocytes 
from control littermates.  
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Interestingly, early steps in autophagy-mediated clearance of aggresomes, i.e. binding 
of the cargo and autophagosome formation, were not disturbed, as indicated by co-
localization of ubiquitin-conjugated aggresomes with HDAC6 and the autophagy 
receptor p62. Similar to HDAC6, p62 contains a ubiquitin domain that allows binding 
to Lys48- and Lys63-linkage specific polyubiquitin chains on protein aggregates and 
aggresomes. In addition, p62 possesses a zinc-finger binding domain that facilitates 
direct binding to the microtubule-associated protein 1A/1B-light chain 3 (LC3) that 
promotes autophagosome formation [182, 183]. Therefore, p62 acts as an important 
adaptor molecule for selective autophagy of protein aggregates and aggresomes as it 
binds Lys63-linkage specific polyubiquitin chains on the protein cargo and mediates 
the interaction of protein aggregates and aggresomes with the autophagic machinery 
through binding to LC3 [184, 185]. Moreover, p62 acts as a proteotoxic stress sensor 
that mediates crosstalk between the UPS and selective autophagy. Indeed, a crosstalk 
between the both protein degradation systems is supported by several studies showing 
that activation of autophagy, e.g. in the heart, occurs in response to severely impaired 
UPS-dependent catabolic processes [186, 187]. The present study shows that elevated 
levels of proteotoxic stress in USP5-deficient cardiomyocytes resulted in impaired 
autophagic flux, as indicated by elevated p62 protein levels with faulty conversion of 
LC3-I to generate the active, lipidated form LC3-II [188, 189]. These effects might 
also be caused by impaired activation of HDAC6 and subsequently defects in the 
fusion of autophagosome with lysosomes. Hence, USP5 signaling in cardiomyocytes 
is necessary for continuous autophagic flux and lysosomal degradation of aggresomes 
along with the adapter molecule p62, but does not affect early steps during selective 
autophagy, such as protein cargo recognition or the interaction of the cargo with the 
autophagic phagophore machinery. These finding indicate that impaired selective 
autophagy of aggresomes, in addition to already impaired function of the UPS, further 
exacerbates defects in PQC processes with deleterious consequences respective to 
cardiac proteostasis. Accumulation of p62 in response to inhibition of autophagy 
impairs the proteasomal flux and delays degradation of polyubiquitinated proteins by 
the UPS, which is mainly caused by excessive interaction between p62 and Lys48-
linkage specific polyubiquitin chains on misfolded proteins [190, 191]. This in turn 
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results in elevated levels of short-lived proteins, accumulation of proteins prone for 
aggregation, and formation of 62-containing aggresomes with delirious consequences 
[192]. Defects in clearance of protein aggregates are linked to heart failure [193], aging, 
and the development of certain cardiovascular diseases, including DCM [194]. 
USP5 and disease-related protein aggregation 
Proper function of newly synthesized proteins relies on maturation, correct folding 
into a native 3D state, appropriate transport, posttranslational modification, and 
breakdown by degradation. All these steps are controlled by several distinct 
components of the proteostasis network. To function properly, cells highly depend 
on balanced proteostasis that is mediated by crosstalk between the different PQC 
processes [83]. Gradual derailment of proteostasis due to defective PQC, primarily 
affecting the UPS and selective autophagy, results in continuous accumulation of 
ubiquitin-conjugated protein aggregates. Presence of ubiquitin-conjugated protein 
aggregates is an invariant feature of neurodegenerative diseases, such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), or amyotrophic 
lateral sclerosis (ALS) [92, 195]. Importantly, reports show derailed proteostasis to 
drive the progression and development of several cardiac diseases, including cardiac 
hypertrophy (HCM), dilated cardiomyopathy (DCM), and atrial fibrillation (AF), 
although the exact molecular mechanisms remain to be uncovered [3, 85]. Derailed 
proteostasis constitutes a prominent trigger for cardiomyocyte dysfunction and 
impaired cardiac function. Impaired cardiac function, in turn, results from alterations 
in cardiac performance, loss of cardiomyocytes, cardiac remodeling, and activation of 
systemic or neurohumoral inflammatory pathways [20]. As discussed in the previous 
sections, inactivation of Usp5 in cardiomyocytes at various stages of development 
resulted in perinuclear deposition of ubiquitin-enriched protein aggregates, formation 
of large aggresomes, and profound DCM. Progressive impairment of the two main 
protein degradation systems – the UPS and autophagy – is one of the leading causes 
for the development of DCM [175, 196]. Persistent formation of protein aggregates 
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and perinuclear aggresomes in response to inactivation of Usp5 in cardiomyocytes was 
sufficient to initiate remodeling processes in the heart, including apoptosis, loss of 
cardiomyocytes, oxidative stress, and activation of fibroblasts along with deposition 
of collagen (fibrosis). Fibrosis is a known compensatory mechanism of the heart to 
maintain cardiac mass in response to loss of cardiomyocytes. Overall, derailment of 
cardiac proteostasis in combination with remodeling of the myocardium leads to 
aberrant architecture and increased stiffness, ultimately resulting in development of 
DCM and sudden death. Sudden cardiac death accounts for up to 50 % of all deaths 
and is mostly caused by ventricular tachycardia or ventricular fibrillation and less often 
by bradyarrhythmia or asystole. However, the cause of death in the USP5 transgenic 
mice might either be caused by mechanical or electrical problems, which needs to be 
investigated.  
Furthermore, the findings in this study revealed dramatically reduced USP5 protein 
levels and enhanced load of ubiquitin-enriched aggresomes in cardiomyocytes from 
randomly selected human patients with late end-stage DCM. Previous research to 
measure the protein levels of USP5 in DCM patients have been inconclusive, 
reporting a ~ 2.3-fold reduction in the expression of USP5 by referring to a molecular 
weight of ~ 25 kDa of USP5 that did not match the calculated molecular weight of 
~96 kDa observed in this study [197]. However, in agreement to the molecular data 
obtained from USP5-deficient cardiomyocytes and cardiomyocytes from human end-
stage DCM patients, Kostin et al. reported elevated mRNA levels of ubiquitin and 
UCHL1 in combination with polyubiquitinated proteins in myocardial samples from 
human DCM patients compared to cardiac samples from a control cohort. The 
present study demonstrates almost complete lack of USP5 in ubiquitin-enriched 
aggresomes in cardiomyocytes from human late end-stage DCM patients. In contrast, 
cardiomyocytes from non-failing, control individuals showed presence of USP5-
enriched but ubiquitin-negative aggresomes. The findings that aggresomes in DCM 
patients were conjugated with ubiquitin indicate that these aggresomes were marked 
for degradation but that downregulation of USP5 caused failure of PQC, resulting in 
disturbed cardiac proteostasis and clinical manifestation of DCM. In conclusion, the 
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data in this study demonstrate a striking similarity between the DCM phenotype 
observed in a human cohort with late end-stage DCM and present animal models of 
USP5-deficient mice, as characterized by substantially reduced USP5 protein levels 
and accumulation of USP5-lacking but ubiquitin-conjugated aggresomes in 
cardiomyocytes. Translating these data to pathological relevant cardiac disorders 
demonstrates that USP5 is indispensable for normal cardiac development, cardiac 
function, and survival. 
USP5 as a potential drug to target PQC to maintain cardiac 
proteostasis 
Research has started to uncover the molecular mechanisms driving disease-causing 
derailment of proteostasis, as mainly characterized by atypical protein aggregation 
compromising cellular functions, especially in the brain and the heart. None of these 
so called ‘proteinopathies’ are currently curable. Therefore, approaches to enhance 
PQC in disease condition might improve intracellular or extracellular proteostasis 
pathways, involved in protein folding, trafficking and degradation to prevent or 
reverse detrimental effects of aberrant protein aggregation. Moreover, enhancing 
PQC processes might enhance the interaction between the destabilized disease-
associated, aggregation-prone protein with components of the proteostasis network 
[10, 198, 199]. Enhancing the activity of UPS-dependent processes, e.g. by increasing 
the pool of free ubiquitin pool [200] or overexpression of certain E3 ubiquitin ligating 
enzymes [201, 202], substantially reduces proteotoxicity induced by protein 
aggregates. As an alternative approach, enhancing the proteolytic activity of the 20S 
proteasome by small-molecule compounds exerted beneficial effects on 
neurodegenerative diseases [149, 203]. However, most of these studies were 
performed in vitro and their effectiveness in vivo needs to be uncovered. Enhancement 
of (selective) autophagy to promote clearance of protein aggregates in 
neurodegenerative diseases, such as Huntington’s disease (HD), yielded promising 
results in many cell- and mouse models, by reducing the number of disease-related 
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aggregates, and attenuating disease progression as well as life span of the tested 
transgenic mice [204-206]. Since autophagy also enhances the clearance of many 
infectious agents in addition to its protective effects for apoptosis, its activation might 
improve treatment of various diseases. A combination of molecules that stimulate 
proteasome activity with activators of autophagy would maximize the therapeutic 
efficiency. Boosting of the proteostasis network represents an attractive new strategy 
to prevent and possibly treat proteinopathies [85], including cardiomyopathies. In this 
respect, the requirement of highly efficient PQC processes in the heart is particularly 
evident in human individuals carrying mutations in genes encoding sarcomere, 
cytoskeletal, and nuclear envelope proteins [86, 207].  
The present study highlights USP5 as a molecule with substantial therapeutic potential 
for the treatment of cardiac disorders, such as DCM and potentially other 
proteinopathies, e.g. neurodegenerative diseases, by enhancing PQC processes. 
Enhanced expression of USP5 in cardiomyocytes did not cause any noticeable adverse 
effects on the cardiovascular system, arguing for the safety of USP5 overexpression 
and activation. Importantly, enhanced expression of USP5 in conditions favoring 
aggregation of disease-related, mutated proteins stimulated the crosstalk between the 
UPS and selective autophagy, thereby enhancing the proteolytic capacity of the 20S 
proteasome and potentially autophagic flux. In particular, increased 20S proteasome 
activity and consistent levels of selective autophagy prevented or reversed aberrant 
aggresome formation in cardiomyocytes induced by the most common missense 
C31712R mutation in the sarcomere protein titin. Mutant C31712R titin, which is 
known to cause protein destabilization is also linked to the development of hereditary 
myopathy with early respiratory failure (HMERF) [81, 175]. HMERF is characterized 
by aberrant protein aggregation and the presence of rimmed vacuoles enriched with 
ubiquitin, p62, and LC3 [138]. Furthermore, the clinical manifestation of human 
patients carrying such a C31712R variant is closely associated with a cardiac-specific 
phenotype [139]. Ongoing research will reveal whether forced or induced expression 
of USP5 might prevent or reverse cardiomyopathy-associated protein aggregation in 
animal models and human individuals. 
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Proposed model for the regulation of cardiac PQC by USP5 
The molecular data presented in this study show that USP5 plays an important role 
for two important PQC processes, which also represent the most important cellular 
protein degradation pathways – the UPS and selective autophagy. First, USP5 forms 
a complex with the 19S proteasomal DUB PSMD14, which ensures disassembly and 
processing of free, unanchored ubiquitin chains to generate ubiquitin monomers and 
to guarantee proteolysis of misfolded proteins by the 26S proteasome. Processing of 
PSMD14-released free, unanchored ubiquitin chains prevents such ubiquitin chains 
from competitively overloading or inhibiting the 26S proteasome. In addition to its 
canonical role, PSMD14 is important for lysosomal degradation of protein aggregates, 
which due to their stoichiometry cannot be degraded by the 26S proteasome. By 
providing Lys63-linkage specific ubiquitin chains, PSMD14 activates the autophagic 
adaptor HDAC6, which builds a complex with USP5. However, further studies are 
needed to investigate how USP5 regulates HDAC6 and how the complexes between 
USP5 and HDAC6 is controlled and activated. It is conceivable that USP5 regulates 
the switch between the two catalytic activities of HDAC6 – tubulin binding and 
deacetylation of cortactin – and its ubiquitin-binding property to ensure binding, 
transport, and temporarily concentration of protein aggregates as aggresomes before 
initiating lysosomal degradation.  
In summary, the study shows that loss of USP5 in cardiomyocytes disrupts PQC 
processes by interfering with polyubiquitin turnover. As a consequence, accumulation 
of Lys48- and Lys63-linkage specific polyubiquitin chains competitively inhibit 20S 
proteasome activity, which prevents PSMD14-mediated deubiquitination of proteins 
destined for proteasomal degradation. This in turn favors accumulation of ubiquitin-
conjugated proteins and causes formation of large ubiquitin-enriched aggresomes that 
competitively interfere with binding of ubiquitinated proteins at the 20S proteasome. 
In addition, impaired clearance of aggresomes by selective autophagy further disturbs 
ubiquitin homeostasis, which enhances cellular stress-dependent cardiac remodeling, 
development of DCM, and sudden cardiac death. Overexpression of USP5 prevents 
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formation of ubiquitin-enriched protein aggregates in conditions of disease-related 
protein aggregation by promoting a crosstalk between UPS-dependent proteolysis 
and selective autophagy and thus reverses one of many forms of DCM caused by 
proteotoxicity (Figure 64). I consider this as a ground-breaking new finding, which 
opens numerous perspectives for the treatment of DCM and other disorders 
associated with protein aggregation, e.g. neurodegenerative diseases. Furthermore, 
research on DUBs regulating polyubiquitin turnover were mostly performed in cell 
culture and yeast. The present study is the first to demonstrate a cell type- and 
isoform- specific function of a DUB that exhibits a crucial role in polyubiquitin 
turnover, which is essential for proteostasis in postmitotic cells.  
 
Figure 64 USP5 is crucial to maintain cardiac PQC. 
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FUTURE DIRECTIONS 
The study described in this thesis lays an important foundation for future studies of 
the function of DUBs in the myocardium. Primarily, it defines the ubiquitin-specific 
peptidase USP5 as a DUB regulating PQC processes in the myocardium, which is 
essential for sustained proteostasis and cardiac function. USP5 contributes to 
homeostatic ubiquitin pools, polyubiquitin turnover, and persistent proteasome 
activity in cardiomyocytes. In this context, the data demonstrate the importance of 
USP5 as a critical DUB residing at the proteasome for disassembly of free, protein 
unattached polyubiquitin chains, released by PSMD14-mediated deubiquitination, to 
be particularly relevant in cardiomyocytes. However, the study also shows other 
DUBs belonging to the USP family to potentially contribute to proteasomal PQC by 
building a complex with PSMD14, which functions need to be addressed.  
Although the present study is the first to characterize the in vivo function of USP5 
using transgenic mouse models, more questions seem to be raised than answered from 
such an initial effort. First, more in vivo models are needed to uncover the cell-type 
specific role of USP5 in more detail. Second, such an approach would help to further 
elucidate why alternative spliced variants of USP5 behave differently in maintaining 
ubiquitin homeostasis, polyubiquitin turnover, and PQC, or if the observed effects 
are restricted to MEFs and cardiomyocytes. Third, in vivo models will also help to 
address the question whether all proteinopathies will benefit from USP5 
overexpression, or whether only certain protein aggregation-related diseases are 
sensitive to increased expression of USP5. Unraveling the effects of increased USP5 
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protein levels in other cardiomyopathies will help to get more insights into the 
mechanism by which USP5 reverses or prevents protein aggregation and if the 
beneficial effects are also based on augmented proteasome activity, as already seen in 
the titin model used in this study. Furthermore, sqRT-PCR analysis of brain tissue 
samples revealed expression of both USP5 exon 15 isoforms, which suggest that 
neurons may also escape from alternative splicing as already demonstrated for 
postmitotic cardiomyocytes. In addition, neurons rely on low levels of polyubiquitin 
chains, similar to the observed results in cardiomyocytes. While protein aggregation 
is one of the prominent features of neurodegenerative diseases, very little is known 
about how neurons handle toxic protein aggregates in response to altered ubiquitin 
homeostasis. Although the brain represents only 2 % of the body weight, it receives 
15 % of the cardiac output and consumes approximately 20 % of the total body 
oxygen, mostly by neurons [208]. Therefore, neurons, similar to oxygen demanding 
cardiomyocytes, must have evolved mechanisms to deal with protein oxidation and 
elevated stress conditions. We are just beginning to understand how neurons handle 
misfolded proteins and how alterations in the ubiquitin pool and PQC processes 
contribute to development and progression of various neurodegenerative disorders. 
In this context, it might be very useful to investigate possible consequences arising 
from a neuron-specific loss of USP5, particularly in terms of altered ubiquitin levels, 
impaired proteasome activity, and protein aggregation. Such a conditional knockout 
approach of USP5 in neurons might help answering the question, if other postmitotic 
cells rely on USP5-dependent ubiquitin homeostasis and proteostasis, or whether 
compensating USPs or DUBs may exit in neurons similar to MEFs. However, it is 
possible that loss or altered activity of USP5 may play a significant role in the 
development of neurodegenerative diseases. Enhancing proteasome activity may aid 
in degradation of misfolded proteins in the brain. However, no therapeutical agent 
has been shown to improve proteasome function in the cell. Taking this into account, 
future studies could investigate to what extend – similar to the results presented in 
this study – overexpression of USP5 minimizes, reverses, or prevents protein 
aggregation in the brain and if USP5 also provides opportunities for the development 
of therapies for the treatment of neurodegenerative disorders. 
 ix 
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